sent_id	id1	id2	out1	out2	label	score	prediction	explanation
486	765	690	The Shoulder Pain and Disability Index (SPADI) at 1 year follow-up	"a work status of ""not working"""	0	0.17443794	0	
706	1839	1032	normalization of stool consistency	defecation frequency	0	0.25525805	0	
71	1085	866	the levels of inflammatory cells (neutrophils, eosinophils, macrophages, and lymphocytes) and epithelial cells in induced sputum	symptom control	0	0.3341736	0	
392	1476	611	whether the GP had provided patients with a written asthma action plan (WAAP yes/no)	likely to provide a written asthma action plan	1	0.7684994	1	
141	1198	917	health care costs and utilization rates	number of outpatient visits per patient	0	0.55635387	1	
205	360	86	the prevalence of arm, shoulder and neck symptoms	exposure to adverse postures and movements	0	0.36173844	0	
79	1099	378	body weight	protein intake	0	0.37567785	0	
378	884	261	ACR 50 improvement	patient's and physician's global assessments of disease activity	0	0.25506938	0	
307	1362	97	Self-reported knee-specific stiffness, pain and function	two revisions	0	0.10916345	0	
654	1962	880	trough FEV 1 after 12 weeks of treatment (average of the 23 h 10 min and 23 h 45 min post-dose values assessed on the morning of Day 85)	Standardised AUC measurements for FEV 1	1	0.5811824	1	
657	1962	883	trough FEV 1 after 12 weeks of treatment (average of the 23 h 10 min and 23 h 45 min post-dose values assessed on the morning of Day 85)	died	0	0.16898437	0	
452	707	1068	health-related quality of life (HRQoL)	HRQoL assessed with the Maugeri Respiratory Failure questionnaire	1	0.23481692	0	
598	913	248	initiation of breastfeeding	intervention during labour and delivery	0	0.38783845	0	
241	1313	564	the primary process outcome	Daily inhaled corticosteroid dose	0	0.1074077	0	
121	1150	619	numbers of patients with recorded foot inspections in the previous calendar month	the likelihood of a recorded foot inspection	1	0.7555734	1	
494	1952	20	Kinetic force platform gait analysis (PVF BW )	responsive	0	0.27695918	0	
751	1933	937	abstinence from illicit opiates at final prescription as indicated by a urine sample	visits to professional carers during detoxification	0	0.45557413	1	
328	1402	128	the patient assessment of spinal pain (100-mm VAS)	the NNTs	0	0.5089989	1	
696	1924	789	the anatomical knowledge (MCQ)	the anatomical MC exam	1	0.6940097	1	
159	226	929	Moderate - Vigorous MET minutes of Physical Activity	MET minutes of activity (from the IPAQ)	1	0.5982485	1	
168	237	613	Aberrant Behaviour Checklist-Community (ABC-C)	functional benefits	0	0.093939185	0	
320	528	1016	GHbA1c	insulin sensitivity	0	0.0	0	
605	1717	365	changes in absenteeism, school rule infractions and suspension days during the four-month pretest period prior to randomization compared with the four-month intervention period	suspension rates	0	0.4351506	1	
128	1161	826	The mean decrease in HAM-D score from baseline	dry mouth	0	0.19193666	0	
106	161	854	HbA1c, lipid levels, blood pressure, BMI after 24 months of follow-up	systolic blood pressure (SBP) levels	0	0.6180376	1	
600	917	562	S-GGT	the after-treatment S-AST levels	0	0.0	0	
105	159	67	the mean change from pre-dose FEV 1 at 12 hours post dose	sustained bronchodilator effect	0	0.41130468	1	
728	1882	215	whether or not a survey recipient responded	the response rates (RR)	1	0.4975357	1	
203	360	84	the prevalence of arm, shoulder and neck symptoms	receiving information on healthy computer use	0	0.34775078	0	
115	166	351	the percentage of patients who reached 25(OH)D levels of 30 ng/ml or above on day 7	1,25(OH)D	0	0.0	0	
592	1701	530	intra-operative pain	anesthesia related complications	0	0.37889785	0	
641	1773	709	changes in the mean FEV 1 , PEF, and ACT scores	asthma control	0	0.24268618	0	
194	1983	81	nutrition knowledge	said they 'are currently eating a healthy diet' (39.6%) or 'would try to eat a healthy diet'	0	0.36559987	0	
361	626	295	the intra-individual change in the total score of the Hamilton Rating Scale for Depression (HAM-D, 17-item version) between baseline and the end of the 6-week acute phase	safe	0	0.15686056	0	
494	770	539	the time until shock reversal	IL-10	0	0.0	0	
762	1979	929	an injury surveillance with a missed match injury definition	primary non-contact knee injury	0	0.60419357	1	
390	632	215	WOMAC Pain	Vitality	0	0.32209247	0	
619	932	923	PDSS	therapist time	0	0.05326409	0	
597	913	247	Apgar scores less than 8	likely to have continuous electronic fetal monitoring	0	0.29253766	0	
511	792	414	Involuntary termination of a woman's pregnancy (miscarriage) and other fetal loss (eg stillbirth),	a single risk factor	0	0.27492115	0	
176	257	1082	adherence and participation	adherence	0	0.81315416	1	
65	108	800	rescue NSAIDs	all three scores in the comparative questionnaire (locomotion, every-day situations, and skin & coat)	0	0.14452645	0	
425	1821	204	participation in the Link-Up Study, through attendance at a biospecimen collection site to provide a blood sample and giving written consent to participate, including use of blood samples for genetic and other research	took part in the Link-Up Study	1	0.59754735	1	
412	652	941	systemic haemodynamics	peripheral resistances (PR)	0	0.2904817	0	
164	1227	686	the ratio of expiratory time to reach PTEF to the total expiratory time	25/PT	0	0.0	0	
108	161	856	HbA1c, lipid levels, blood pressure, BMI after 24 months of follow-up	the compliance in all the control criteria, except for LDL cholesterol	0	0.4669741	1	
210	1274	1037	the incidence of predefined GI AEs	msSBP	0	0.0	0	
5	1016	99	blood pressure	90% of all possible pedometer diaries were submitted	0	0.20442122	0	
237	1965	199	to test the effect of TA on the incidence of IR and VS in patients undergoing elective CPB	D-dimer	0	0.0	0	
537	826	502	the p27 antigen analysis of serum samples	persistent FeLV p27 antigenaemia	1	0.32470024	0	
185	1270	550	90-day mortality	costs	0	0.1793044	0	
305	512	627	the reduction in systolic blood pressure defined as the average of 3 office readings with the patient in the sitting position	Minor side-effects	0	0.14030112	0	
664	990	953	the mean number of oocytes retrieved	chemical, clinical and continuing pregnancies	0	0.25072813	0	
366	1441	236	time needed to perform the motor task	time to complete the MT	1	0.68845916	1	
523	1596	149	second-progression-free survival	QALY	0	0.22059068	0	
175	1241	146	the duration of severe neutropenia (DSN) in cycle 1	The mean DSN in cycle 1	1	0.7435521	1	
686	1833	1068	IPV (Composite Abuse Scale CAS) and depression (Edinburgh Postnatal Depression Scale EPDS)	mean abuse scores	0	0.3519338	0	
190	1271	82	change in nutrition knowledge scores, attitudes to healthy eating and acceptability of the intervention by children and teachers	enjoyed playing the game	0	0.400894	1	
273	467	450	reduction in systolic blood pressure, total cholesterol and estimated 10-year CVD risk	risk factor	0	0.494844	1	
230	1291	241	antimalarial drug prescription	Antimalarial prescriptions	1	0.69964993	1	
137	1456	911	VC	%VC	1	0.0	0	
314	1372	821	target vessel revascularization (TVR)	TVR	1	0.1906894	0	
342	1423	358	differences in screening interest and patient test preferences between versions of the decision aid	screening interest	0	0.5530705	1	
16	420	1039	'success'	the proportion of examinations with a diagnosis of perforation during therapy	0	0.0	0	
239	1313	562	Asthma control	Overall monitoring adherence	0	0.34764463	0	
756	1936	58	Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating	sensory/cognitive awareness	0	0.19536144	0	
80	1099	379	body weight	MetS components	0	0.2568742	0	
106	161	854	blood pressure	baseline glycated hemoglobin A1c	0	0.40915754	1	
348	569	92	diarrhoea	hypochlorhydria	0	0.0	0	
169	1912	964	knowledge of labour analgesia, decisional conflict (uncertainty regarding analgesia decision) and anxiety	decisional conflict scores	0	0.6672099	1	
83	128	654	absence of parasites and clinical signs on days 14 and 28, and good clinical and biological tolerability	an efficacy	0	0.5097921	1	
284	1341	743	shoulder mobility	pain	0	0.38684213	0	
312	1770	97	knee-specific patient-reported WOMAC scores	two revisions	0	0.23056306	0	
515	796	617	the proportion of children achieving a well clinical response and time to a well clinical response	Parasitological response	0	0.5170428	1	
223	389	472	comparison of the change from baseline to end of 12 weeks between simvastatin and fenofibrate	apoB	0	0.24668999	0	
594	897	564	improvement of GHbA 1c and the SF-36 quality of life score	SF-36 score	0	0.50627786	1	
764	1979	931	an injury surveillance with a missed match injury definition	lower-limb muscle strains	0	0.28961307	0	
193	1983	80	nutrition knowledge	Total nutrition knowledge score	1	0.74195856	1	
76	1092	767	malaria incidence during the study period	incidence of malaria	1	0.65894914	1	
736	1887	974	decisional conflict 42 47	decisional conflict	1	0.9999998	1	
224	1288	968	mortality	rates of adverse functional outcomes, expressed as the odds of not returning to pre-stroke functioning in their daily life	0	0.26135808	0	
78	1099	377	body weight	components of metabolic syndrome	0	0.3515706	0	
190	288	365	the number of hospital days after surgery	adjusted average cost saving	0	0.2895371	0	
545	830	222	the change in morning peak expiratory flow (PEF) rate from baseline to the end of the treatment period (mean of weeks 23–24)	exacerbation frequency	0	0.3653205	0	
460	1519	661	PASI-75	PSA	0	0.0	0	
244	1314	23	the assessment of treatment toxicity and tumor response as measured according to modified (volumetric) MacDonald's criteria 20	grade 1-3 adverse events	0	0.34418944	0	
42	1072	333	the recruitment rate	the overall recruitment yield	1	0.79060787	1	
196	1983	83	nutrition knowledge	nutrition knowledge	1	1.0	1	
58	1368	938	post-operative morphine consumption in a 24 hour period as self administered using a patient controlled analgesia (PCA) pump	pain relief	0	0.38236967	0	
536	1618	583	crying	frequency of stooling	0	0.19784604	0	
466	1536	395	number of post-CCRT hospital admission days	tube dependency	0	0.16643715	0	
150	221	535	a difference of ≥ 20% in the microvascular flow index of small vessels among groups	other factors (for example, volume status, timing, hemodynamics and progression of the disease)	0	0.714887	1	
577	881	375	the overall discomfort reported during WC versus SC pH-metry	costly	0	0.13658032	0	
69	1085	864	the levels of inflammatory cells (neutrophils, eosinophils, macrophages, and lymphocytes) and epithelial cells in induced sputum	lung function	0	0.4867039	1	
332	721	638	change in body weight and waist circumference	waist circumference	0	0.7333708	1	
241	406	265	a dichotomous measure (occurrence of low back pain)	 whether a Soldier received the physical/USI examination	0	0.25673985	0	
390	632	215	Physical Function	Body Pain	0	0.4430817	1	
243	406	267	a dichotomous measure (occurrence of low back pain)	health status	0	0.19523461	0	
501	852	851	a reduction in depression	the number of exercise sessions completed	0	0.3807154	0	
314	1372	821	target vessel revascularization (TVR)	in-stent restenosis	0	0.4834578	1	
565	1652	170	the proportion of subjects achieving PASI-75, defined as ≥ 75% improvement in PASI score from baseline,	Internal consistency reliability	0	0.29799393	0	
457	1518	544	pain catastrophising	function	0	0.114868306	0	
111	210	856	glycated hemoglobin A1c	glycated hemoglobin A1c	1	0.99999976	1	
450	1512	1051	more frequently interrupted MARS sessions without anticoagulation	Systemic ionized calcium concentrations	0	0.24732955	0	
193	304	120	The median RTDI	overall survival (OS)	0	0.2382151	0	
124	190	185	all-cause mortality over 3 years	post-bronchodilator FEV 1	0	0.41203856	1	
553	854	333	time to achieve haemostasis at the suture line	The mean time to haemostasis	1	0.68347543	1	
192	302	211	u-AQP2 CR	u-ENaC β-CR	0	0.0	0	
65	108	800	force platform variables PVF and impulse, the HCPI and rescue NSAIDs	NSAID use	0	0.3560332	0	
242	406	266	a dichotomous measure (occurrence of low back pain)	The overall web based response rate	0	0.32474384	0	
693	1834	795	The MC exam	advantage concerning anatomical skills	0	0.22692768	0	
361	1436	651	gastric emptying T half	arterial stiffness	0	0.30254662	0	
188	1271	80	change in nutrition knowledge scores, attitudes to healthy eating and acceptability of the intervention by children and teachers	Total nutrition knowledge score	0	0.5524321	1	
717	1862	926	pain severity and knee range of motion (ROM)	this ROM	0	0.22152969	0	
477	739	128	gingival bleeding	follow-up prevalence of plaque and calculus	0	0.3298743	0	
617	1723	512	response rate, survey response bias, item non-response, and cost	The total cost	0	0.42427006	1	
589	1701	527	intra-operative pain	Mean patient cooperation	0	0.24750912	0	
461	712	381	change in urinary HRQOL at 3 months	biochemical control	0	0.29532295	0	
393	634	512	patient intention to visit a psychosocial counselor	agreed with the benefits of the tool	0	0.28213075	0	
384	1463	263	the differences in the levels of iFGF23	the iPTH level	0	0.7159788	1	
250	1320	840	to determine the time from beginning the scenario to correct insertion of the laryngeal airway after the students' opinion	mean time to correct placement	1	0.62893516	1	
282	486	344	recurrence	the minimum	0	0.16369085	0	
522	808	493	time from induction to delivery and incidence of vaginal delivery within 12 and 24 hours	elective inductions of labor beyond 40 weeks of gestation	0	0.6086426	1	
218	383	993	PCR-adjusted 42-day cure rates after starting treatment	Recrudescent parasitaemia	0	0.2214914	0	
456	1518	543	pain catastrophising	pain	0	1.0	1	
621	1731	254	change from baseline in fasting serum total cholesterol	LDL-cholesterol	0	0.0	0	
564	1647	178	serum metal ion concentration	serum metal ion concentrations	1	0.94046164	1	
668	1942	758	patient satisfaction	reported pain	0	0.28668106	0	
226	389	475	comparison of the change from baseline to end of 12 weeks between simvastatin and fenofibrate	small LDLP	0	0.18871646	0	
108	161	856	HbA1c	SBP levels	0	0.28630158	0	
385	627	318	the ovicidal effect of the treatments, defined as no nymphal lice emerging from eggs between treatments	cure rate	0	0.3806972	0	
435	1496	908	sickness absence	SA days	1	0.18770133	0	
33	50	569	IES-R	drop-out rates	0	0.0	0	
454	708	572	The LSAS-SR	social anxiety scales	0	0.064258136	0	
687	1833	1069	IPV (Composite Abuse Scale CAS)	depression (EPDS score ≥13)	0	0.28427726	0	
96	141	192	begin oral intake	Time to regain consciousness	0	0.16235234	0	
96	141	192	begin oral intake	total coma duration	0	0.25094146	0	
694	1834	796	The MC exam	difficult to learn	0	0.059040472	0	
231	1291	242	antimalarial drug prescription	received antimalarial prescriptions	1	0.74690455	1	
93	1845	756	the effect on markers of bone turnover at 24 weeks	serum levels of the bone-formation marker PINP	0	0.605571	1	
279	1337	68	cumulative survival without mechanical ventilation or oxygen dependency at 30 days; mortality at 30 days; therapy failure; crossover rate; and persisting pulmonary problems defined as oxygen dependency or still being on a ventilator at 30 days	treatment effect	0	0.40565115	1	
393	634	512	patient intention to visit a psychosocial counselor	‘unsure’ about possible barriers to interact with the clinicians (mean = 2.8) or to privacy of information	0	0.4253871	1	
564	861	938	changes in lifestyle according to established goals	the proportion of participants with unhealthy diet	0	0.5136703	1	
402	646	208	MCS	Women's mental health scores	0	0.13495791	0	
390	632	215	Physical Function	the SF-36 Physical Function	0	0.8499269	1	
506	1577	818	the average FEV 1 from the first intake of study drug to the measurement at 90 minutes	treatment failure	0	0.30371103	0	
184	277	0	change in score	regarded the disease	0	0.33270407	0	
727	1873	674	change in Treatment Satisfaction (Tables 5 and 6 ), change in Perceived Hyperglycaemia (Tables 7 and 8 ) and change in Perceived Hypoglycaemia (Tables 9 and 10 )	response to change	0	0.41772005	1	
282	486	344	recurrence	The maximum follow-up period	0	0.10847966	0	
687	1833	1069	depression (Edinburgh Postnatal Depression Scale EPDS)	mental wellbeing mean scores (MCS-SF36	0	0.37888107	0	
523	808	494	time from induction to delivery and incidence of vaginal delivery within 12 and 24 hours	abnormal FHR tracings	0	0.29930693	0	
725	1873	672	change in Treatment Satisfaction (Tables 5 and 6 ), change in Perceived Hyperglycaemia (Tables 7 and 8 ) and change in Perceived Hypoglycaemia (Tables 9 and 10 )	Treatment Satisfaction	0	0.36216998	0	
391	632	216	WOMAC Pain	pain	1	0.53796107	1	
381	1454	35	the incidence of oxygen desaturations defined as a decrease in oxygen saturation ≥ 5%, assessed by continuous pulse oxymetry, at any time between the start of the induction sequence and two minutes after the completion of the intubation	extent of oxygen desaturations	0	0.45223197	1	
366	597	245	a decrease in carer burden in the intervention group three months after receiving the DA	burden	1	0.30361286	0	
671	1802	1020	The throughput times length of ED stay (LOS) and time to first physician 1	The average LOS	0	0.52457273	1	
167	237	612	Aberrant Behaviour Checklist-Community (ABC-C)	treatment-related side effects	0	0.075593695	0	
412	652	941	systemic haemodynamics	systolic blood pressure (BP)	0	0.16210747	0	
585	1683	106	the clinical and laboratory adverse event profile	at least one adverse event	1	0.59825236	1	
279	485	844	time to catheter association blood stream infection	CRBSI	1	0.42844653	1	
431	672	487	response rate to treatment	rescue medication use	0	0.41571632	1	
443	695	672	an ASAS40	the Bath AS Functional Index (BASFI) score	0	0.1312355	0	
346	941	308	the Gastrointestinal Symptom Rating Scale-IBS version (GSRS-IBS) 42	the overall treatment effects	0	0.49486795	1	
52	1074	835	the proportion of patients with plasma HIV-1 RNA levels <200 copies/mL at week 24	HIV-1 RNA <50 copies/mL	0	0.34951094	0	
424	1493	208	response rate	average biospecimen yield	0	0.41991022	1	
749	1933	935	abstinence from illicit opiates at final prescription as indicated by a urine sample	Risk of non-completion of detoxification	0	0.3042595	0	
605	1717	365	changes in absenteeism	suspension rates	0	0.3230208	0	
341	1421	164	the rate of renal involvement at one year	the risk of acute gastrointestinal complications	0	0.51725817	1	
107	1588	943	extubated	the proportion of time propofol was required	0	0.35403392	0	
229	1289	862	the rate of success	VAS	0	0.1420855	0	
360	626	294	the intra-individual change in the total score of the Hamilton Rating Scale for Depression (HAM-D, 17-item version) between baseline and the end of the 6-week acute phase	The incidence of adverse events	0	0.43985802	1	
23	33	983	composite death, reinfarction, stroke, or new myocardial ischemia	rate of recurrent ischemia	0	0.5786232	1	
704	1839	1029	no more painful defecation	the presence of an abdominal or rectal mass	0	0.48211905	1	
559	861	932	changes in lifestyle according to established goals	mean body mass index	0	0.306671	0	
329	543	638	body weight (kg) and waist circumference (cm)	waist circumference reductions	0	0.7467448	1	
706	1839	1032	1) defecation frequency > 3/week; 2) normalization of stool consistency; 3) no more painful defecation; 4) absence of abdominal or rectal palpable mass at physical examination	softer stools	0	0.40951303	1	
568	880	255	retention in treatment, which was defined as the number of weeks that patients remained in the study before being discharged	depressive symptoms	0	0.1890059	0	
598	913	248	relative risk	intervention during labour and delivery	0	0.19834583	0	
598	913	248	postpartum haemorrhage	intervention during labour and delivery	0	0.29669672	0	
89	136	790	the hands-on time during the first three minutes of the cardiac arrest	delayed their first defibrillation	0	0.6527358	1	
120	1150	618	the primary care practices' mean levels of HbA1c, cholesterol and BP, and numbers of patients with recorded foot inspections in the previous calendar month	systolic BP	0	0.24431048	0	
154	1220	559	Total costs	IPA subscale autonomy	0	0.15860413	0	
281	486	343	recurrence	the mean time off from work	0	0.12790307	0	
484	1541	597	ETDRS visual acuity recorded in the laboratory, supplemented with a number of secondary lab-based visual function measures	safety	0	0.20223059	0	
752	1936	54	Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	eye contact	0	0.18711244	0	
596	913	246	postpartum haemorrhage	postpartum haemorrhage	1	1.0	1	
109	210	854	glycated hemoglobin A1c, body mass index (BMI), blood pressure, lipids and control criteria during the 2-year follow-up period	baseline glycated hemoglobin A1c	0	0.6823854	1	
116	166	352	the percentage of patients who reached 25(OH)D levels of 30 ng/ml or above on day 7	vitamin D deficiency	0	0.18315338	0	
19	420	1042	detection of bilateral aerated middle ears (confirmed with tympanometry) at two consecutive monthly visits	pneumococcal carriage	0	0.19958854	0	
318	1376	1082	The 6MWT	St. George’s Respiratory Questionnaire score	0	0.30697203	0	
131	200	458	the change in serum methylmalonic acid (MMA) levels after one month of treatment	adherence to treatment	0	0.40684685	1	
573	1659	311	response rate	likely to respond	1	0.428819	1	
170	244	156	a composite endpoint of all-cause mortality or all-cause hospitalization	commonly prescribed oral antihyperglycemic agent	0	0.42249042	1	
361	1436	651	gastric emptying T half	GE	1	0.07886166	0	
659	984	320	improvement in oxygenation (improvement of PaO 2 /FiO 2 (PF) ratio)	tidal volume	0	0.23543595	0	
12	1028	404	the PCR-adjusted parasitological cure rate up to day 42 of the follow-up period	cure rates	1	0.51395917	1	
384	1463	263	the differences in the levels of iFGF23 and iPTH after each treatment period	the iFGF23 level	0	0.7274498	1	
693	1834	795	The MC exam	spatial imagination	0	0.078696504	0	
8	3	250	prescription data of a three-year period (one year before and 2 years after guideline dissemination) and proportion of change according to recommendations	prescribing behaviour	0	0.243886	0	
463	1528	341	the Patient Reported Physician Cultural Competency (PRPCC) Scale	glycosylated hemoglobin	0	0.18815109	0	
121	1150	619	the primary care practices' mean levels of HbA1c, cholesterol and BP, and numbers of patients with recorded foot inspections in the previous calendar month	the likelihood of a recorded foot inspection	0	0.7325713	1	
390	632	215	Physical Function	WOMAC Pain	0	0.4291263	1	
637	954	622	the serum phosphorus at 12 weeks	the proportions of subjects who had hypocalcemia	0	0.503109	1	
717	1862	926	knee range of motion (ROM)	this ROM	1	0.19739704	0	
502	1571	190	HSCL-25	the severity of symptoms of depression and anxiety	1	0.0	0	
725	1873	672	change in Treatment Satisfaction (Tables 5 and 6 )	a Questionnaire × Ceiling interaction	0	0.25861746	0	
329	543	638	waist circumference (cm)	waist circumference reductions	1	0.8656125	1	
605	1717	365	changes in absenteeism, school rule infractions and suspension days during the four-month pretest period prior to randomization compared with the four-month intervention period	rule infractions	0	0.5032724	1	
289	493	405	self-rated overall effect of treatment, measured once; on the day treatment was completed	EQ VAS	0	0.14036731	0	
233	1291	244	antimalarial drug prescription	malaria parasitaemia	0	0.42908227	1	
480	742	232	the duration of fluid fast prior to induction of anaesthesia	fluid fasting	1	0.5350839	1	
756	1936	58	Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating	the ATEC	1	0.44788423	1	
494	770	539	the time until shock reversal	IL-6	0	0.0	0	
349	569	93	diarrhoea	Mild (grade 1) gastric atrophy	0	0.0	0	
118	170	134	The frequency, duration and severity of exacerbations	lung function	0	0.29319352	0	
148	221	533	a difference of ≥ 20% in the microvascular flow index of small vessels among groups	perfused vessel density	0	0.47321358	1	
340	549	591	patient reported pain	easier	0	0.11375222	0	
665	1790	1024	severity of mental health symptoms measured using the Hospital Anxiety and Depression Scale (HADS) 23	Costs	0	0.24391142	0	
44	1072	336	the recruitment rate	The estimated sample size for a full trial	0	0.483326	1	
519	808	490	time from induction to delivery and incidence of vaginal delivery within 12 and 24 hours	abnormal fetal heart rate (FHR) tracings	0	0.43048638	1	
314	1372	821	target vessel revascularization (TVR)	target lesion revascularization	0	0.8177913	1	
84	1103	958	global quality of life change at 6-weeks, measured by EORTC QLQ-C30	progression	0	0.33810195	0	
243	1314	22	the assessment of treatment toxicity and tumor response as measured according to modified (volumetric) MacDonald's criteria 20	progression-free survival	0	0.31923267	0	
277	475	666	the shortened version of the Chedoke Arm & Hand Activity Inventory (CAHAI-7)	the CMSA Arm (p = 0.04) and Hand	0	0.7029691	1	
215	379	1051	day-28 failure rates (uncorrected and PCR corrected)	treatment efficacy	0	0.31151426	0	
681	1812	681	duration of diarrhea (in hours) from onset and from admission until cessation of diarrhea (passage of soft/formed or no stools for two consecutive 8-hour periods), and the total stool weight in grams during hospitalization	intravenous fluids used	0	0.3230722	0	
68	1085	863	the levels of inflammatory cells (neutrophils, eosinophils, macrophages, and lymphocytes)	induced sputum inflammatory cells	1	0.7019212	1	
129	1878	824	the 17-item HAM-D	effective	0	0.07728088	0	
677	999	1037	Chlamydia screening rates	likely to log on	0	0.10777784	0	
517	1584	648	whether or not the ulcer was completely healed within 8 weeks	complete ulcer healing	1	0.49270144	1	
264	1329	349	no missed activities during the previous month 41	the number of days with pain	0	0.6532592	1	
498	1567	557	retention on treatment at 1 year	well tolerated	0	0.15442845	0	
136	1883	194	incidence of adverse effects	local tolerability	0	0.3424318	0	
421	655	105	attitudes	knowledge	0	0.262655	0	
257	440	634	the number of ECT treatments given	ECT effectiveness	0	0.55370224	1	
234	1291	245	antimalarial drug prescription	the specificity	0	0.18513057	0	
144	1200	0	Anthropometry at birth	birth weight	1	0.5939194	1	
390	632	215	Total scores	Vitality	0	0.1389588	0	
419	655	103	attitudes, knowledge and skills in EBM	The knowledge level	0	0.5986578	1	
547	831	142	violent attitudes using the Total MVQ score	self-reported measures of violent attitudes	1	0.565564	1	
612	1723	507	response rate	a response rate	1	0.99999994	1	
175	257	1081	adherence and participation	participation	0	0.8131542	1	
317	526	1074	back-related functional status and symptom bothersomeness	estimates of treatment effectiveness	0	0.3725969	0	
513	1583	983	an overall response that integrated clinical, bacteriological and radiological results, at the end of treatment (month 6) and after 12 additional months of follow-up (month 18)	serum TGF-beta	0	0.13779037	0	
184	1270	549	90-day mortality	days in the ICU	0	0.20515144	0	
260	455	435	the generic instrument EuroQol-5D (EQ5D)	EuroQol-5D	1	0.0	0	
622	1731	255	change from baseline in fasting serum total cholesterol	triglyceride toxicity grades	0	0.4532351	1	
617	1723	512	cost	The total cost	1	0.68214214	1	
582	1671	182	distension	the GSRS abdominal distension subscore	1	0.7707674	1	
759	1938	545	reduction in duration of severe pneumonia and pneumonia	cyanosis	0	0.48955828	1	
191	288	366	the number of hospital days after surgery	hospital length of stay after high-risk major surgery	1	0.811716	1	
68	396	799	force platform variables PVF and impulse, the validated HCPI and the use of rescue NSAIDs	guessing what group their dogs had been in	0	0.50021845	1	
401	645	543	the temperature difference between the CRPS affected and the contralateral limbs	Muscle force	0	0.22811688	0	
513	792	416	Involuntary termination of a woman's pregnancy (miscarriage) and other fetal loss (eg stillbirth),	Specific risk factor content was delivered as prescribed	0	0.38933194	0	
434	1496	906	physical activity	physical activity levels	1	0.8905094	1	
241	406	265	a dichotomous measure (occurrence of low back pain)	BMI	0	0.17623864	0	
444	695	673	an ASAS40	the physician global assessment of disease activity	0	0.29042065	0	
375	1445	810	The AIMS2 walking and bending sub-scale	other clinical outcomes	0	0.103256956	0	
366	597	245	a decrease in carer burden in the intervention group three months after receiving the DA	decisional conflict	0	0.24807803	0	
448	706	136	changes between baseline and nine months of bone mineral density (BMD) of the proximal femur and lumbar spine (dual-energy X-ray absorptiometry) and serum markers of bone resorption and formation	BMD	0	0.3666603	0	
187	277	5	change in score	their knowledge and attitudes and practice	0	0.32710007	0	
299	507	869	the change from baseline to 52 weeks of carotid arterial wall volume, reflecting plaque burden, as measured by carotid cardiovascular magnetic resonance	their HbA1c	0	0.437062	1	
294	501	310	disease-free survival (DFS) at three years	the probability of DFS at three years	1	0.8035851	1	
390	632	215	Physical Function	Total dimensions	0	0.27282688	0	
361	626	295	the intra-individual change in the total score of the Hamilton Rating Scale for Depression (HAM-D, 17-item version) between baseline and the end of the 6-week acute phase	efficacy	0	0.11564874	0	
670	998	336	sRaw	FEV 1	0	0.0	0	
438	1852	631	(1) anti-malarial consumption recorded from routine statistics in ledger books of all HF before and after intervention; (2) anti-malarial prescription recorded during observed consultations in cross-sectional surveys conducted in all HF before and 18 months after m RDT implementation	quinine vials	0	0.18322179	0	
365	1441	235	time needed to perform the motor task	Times to perform the MT	1	0.5481547	1	
103	159	65	the slope of decline in FEV 1 from 2 hours post-dose, the area under the FEV 1 curve (AUC) (0–24 hours) and the mean change from pre-dose FEV 1 at 12 hours post dose	a sustained bronchodilation	0	0.3420366	0	
683	1816	851	pain	pain	1	1.0	1	
84	1103	958	global quality of life change at 6-weeks, measured by EORTC QLQ-C30	Overall response rate	0	0.38443345	0	
138	204	149	percentage aggregation on day 5 (2 hours after drug administration,) expressed as percentage of baseline, using 1.1 μg/ml collagen as an agonist	inhibiting platelet aggregation after coronary surgery	1	0.54479206	1	
214	1276	829	the number of clinical episodes of P. falciparum malaria	the prevalence malaria	0	0.7229997	1	
704	1839	1029	no more painful defecation	painful defecation	1	0.7421425	1	
235	1965	197	to test the effect of TA on the incidence of IR and VS in patients undergoing elective CPB	Incidence of IR	0	0.4132531	1	
314	1372	821	cardiac death	cardiac death	1	1.0	1	
238	1965	200	to test the effect of TA on the incidence of IR and VS in patients undergoing elective CPB	the development of IR	0	0.62085575	1	
288	493	404	self-rated overall effect of treatment, measured once; on the day treatment was completed	Ten metre walk time	0	0.4128688	1	
339	547	59	pain visual analogue scores	pain	1	0.5374378	1	
659	1962	886	trough FEV 1 after 12 weeks of treatment (average of the 23 h 10 min and 23 h 45 min post-dose values assessed on the morning of Day 85)	rescue medication use	0	0.2735116	0	
174	1239	762	the change in test scores for residents and faculty (pre-test vs. post-test), and the difference in score improvement between the residents randomized to undergo proctored ultrasound examinations compared to those who were not	knowledge retention	0	0.28545353	0	
303	512	625	the reduction in systolic blood pressure defined as the average of 3 office readings with the patient in the sitting position	24-h systolic BP	1	0.30796567	0	
676	1811	503	the overall between-patient variability around the mean time to neurological assessment	were extubated	0	0.3951661	0	
671	1802	1020	The throughput times length of ED stay (LOS)	The average LOS	1	0.56064636	1	
134	1883	191	incidence of adverse effects	the mean number of collected oocytes (primary endpoint)	0	0.2682923	0	
464	1532	29	 appropriate osteoporosis management based on the 2002 clinical practice guidelines for osteoporosis in Canada 16	taking calcium (54% [54/101] vs 20% [20/100]; RR 2.67, 95% CI 1.74 to 4.12) and vitamin D	0	0.35809574	0	
366	1441	236	time needed to perform the motor task	minimal assistance to supervision (CG)	0	0.31657678	0	
578	1660	642	The number of destroyed alveolar attachments, expressed as a percentage over the total number of alveolar attachments,	airway stretch	0	0.23322274	0	
259	448	1024	10-percentage point difference between arms in increase in the proportion of participants reaching the target level in five global and two patient-group specific clinical parameters at 12 months	systolic blood pressure	0	0.29576603	0	
554	1631	515	The proportion of recurrent parasitaemia's during the 4-week follow-up	The 28-day PCR-corrected cure rate	0	0.5185916	1	
53	1074	836	the proportion of patients with plasma HIV-1 RNA levels <200 copies/mL at week 24	drug-related oral/perioral paresthesia	0	0.2765745	0	
509	1583	979	an overall response that integrated clinical, bacteriological and radiological results, at the end of treatment (month 6) and after 12 additional months of follow-up (month 18)	pulmonary lesions	0	0.23811644	0	
765	1979	932	an injury surveillance with a missed match injury definition	weeks missed due to non-contact knee injury	0	0.67765784	1	
202	1273	123	the percentage of patients who had a CSTE	Thrombocytopenia-related adjustments in lenalidomide	0	0.42044052	1	
669	998	335	sRaw	oscillometry measurements of resistance and reactance	0	0.0	0	
314	1372	821	myocardial infarction	in-stent restenosis	0	0.5604295	1	
474	736	516	incidence of low back pain resulting in the seeking of health care	low back pain episodes	0	0.63870037	1	
431	672	487	response rate to treatment	Response rates	1	0.6521659	1	
269	464	973	a change in the serum ALT activity or the INR	other measures of liver injury	0	0.36782864	0	
682	1812	682	duration of diarrhea (in hours) from onset and from admission until cessation of diarrhea (passage of soft/formed or no stools for two consecutive 8-hour periods), and the total stool weight in grams during hospitalization	the duration of acute diarrhea	0	0.7361529	1	
344	1423	360	differences in screening interest and patient test preferences between versions of the decision aid	interest in colorectal cancer screening	0	0.6146998	1	
530	814	645	to decrease reintubation rates, defined by the necessity of mechanical positive-pressure ventilation through orotracheal intubation in the first 48 hours after extubation, in the treatment group	mean SAPS II	0	0.29484925	0	
667	1942	757	patient satisfaction	The rate of skin complication	0	0.30085433	0	
289	1342	740	"the percentage change in ""average pain for the past 24 hours"" NPRS scores from baseline to weeks 2 through 8"	safe	0	0.163583	0	
133	200	461	the change in serum methylmalonic acid (MMA) levels after one month of treatment	The number of patients needed to treat to detect a metabolic response in MMA after one month	0	0.78917515	1	
81	1099	380	body weight	body composition	0	0.6805931	1	
40	62	583	weight gain after eight weeks	gain in height	0	0.5778435	1	
688	1833	1070	IPV (Composite Abuse Scale CAS) and depression (Edinburgh Postnatal Depression Scale EPDS)	parenting stress	0	0.43020675	1	
369	607	575	log HbA 1c	geometric mean HbA 1c	1	0.65975857	1	
109	210	854	glycated hemoglobin A1c	systolic blood pressure (SBP) levels	0	0.59585726	1	
372	607	578	HRQL	glycaemic control	0	0.07947868	0	
319	1376	1083	The 6MWT	Total staff costs of the programme per participant	0	0.37196717	0	
353	1434	569	HbA 1c	estimated mean scores of the DSC-R questionnaire	0	0.2011351	0	
198	1272	1067	the difference in FMD between the two blends of supplements and placebo following a 2-hour oral glucose tolerance test (OGTT) after 8 weeks of treatment	glucose	0	0.34761187	0	
106	161	854	blood pressure	SBP	1	0.19915539	0	
316	1373	700	overall success	The agreement between the participants and their instructors in terms of LMA placement success rates	0	0.4863702	1	
419	1492	999	the differences between groups in changes over time in perceived stress, as measured by the Perceived Stress Scale (PSS) 11	the rate of stress reduction	1	0.65421927	1	
153	1219	671	disease-free survival (DFS)	lipids	0	0.1536527	0	
400	645	542	the temperature difference between the CRPS affected and the contralateral limbs	the temperature asymmetry	1	0.76115555	1	
439	683	686	u-AQP2 and u-ENaC	Atrial-and brain natriuretic peptide	0	0.0	0	
510	1583	980	an overall response that integrated clinical, bacteriological and radiological results, at the end of treatment (month 6) and after 12 additional months of follow-up (month 18)	Disease-related deaths	0	0.1985387	0	
248	408	81	the recovery rate, defined as the percentage of patients who had an adequate clinical and parasitological response (ACPR) after follow-up for 28 days	tolerability	0	0.20851958	0	
133	1163	194	the number of retrieved oocytes	retrieved oocytes	1	0.7235953	1	
755	1936	57	changes compared to baseline observed after 4 weeks (40 sessions) of treatment, in parallel groups, on (1) Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating, (2) Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating, and (3) Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	the ABC total score and subscales	0	0.715481	1	
625	1731	258	change from baseline in fasting serum total cholesterol	waist-to-hip ratios	0	0.24606231	0	
402	646	208	the EPDS (a 10-item scale developed for use in the postnatal period, in which a score ≥ 13 identifies probable depression 33	EPDS ≥ 13 ('probable depression')	1	0.47872812	1	
505	1577	816	the average FEV 1 from the first intake of study drug to the measurement at 90 minutes	FEV 1	1	0.49511588	1	
520	1591	115	ICP control	the incidence of arterial hypotension	0	0.23286113	0	
20	420	1043	detection of bilateral aerated middle ears (confirmed with tympanometry) at two consecutive monthly visits	resistant pneumococci	0	0.19723287	0	
649	1782	884	Trough FEV 1 after 12 weeks of treatment	QTc	0	0.31731763	0	
597	913	247	induction of labour	likely to have continuous electronic fetal monitoring	0	0.17951788	0	
135	1883	192	incidence of adverse effects	The incidence of adverse events	1	0.74070203	1	
295	501	311	disease-free survival (DFS) at three years	Grades 3 and 4 toxicities	0	0.30107194	0	
314	1372	821	major adverse cardiac events (MACE) defined as a composite endpoint of cardiac death, myocardial infarction, and target vessel revascularization (TVR)	TVR	0	0.19549446	0	
120	1150	618	the primary care practices' mean levels of HbA1c, cholesterol and BP, and numbers of patients with recorded foot inspections in the previous calendar month	target BP control	0	0.34793583	0	
692	1834	794	The MC exam	overall performances	0	0.15915154	0	
251	1320	841	to determine the time from beginning the scenario to correct insertion of the laryngeal airway after the students' opinion	time to correct placement	1	0.6233207	1	
668	998	334	sRaw	the geometric mean sRaw at 12 hrs post dose	1	0.0	0	
719	1862	928	pain severity and knee range of motion (ROM)	levels of pain	0	0.57818156	1	
314	1372	821	major adverse cardiac events (MACE) defined as a composite endpoint of cardiac death, myocardial infarction, and target vessel revascularization (TVR)	all cause death	0	0.31724995	0	
523	1596	149	second-progression-free survival	total costs	0	0.030415235	0	
34	1052	15	Correlation between VPW measurements from the portable chest radiograph with the PAOP	CVP	0	0.16049756	0	
293	1346	231	body mass index (BMI) percentile	obesity rates	0	0.32486054	0	
69	396	800	the validated HCPI	NSAID use	0	0.15259549	0	
533	814	648	to decrease reintubation rates, defined by the necessity of mechanical positive-pressure ventilation through orotracheal intubation in the first 48 hours after extubation, in the treatment group	reintubation rate	1	0.46094212	1	
547	831	142	violent attitudes using the Total MVQ score	rational problem-solving	0	0.19492361	0	
680	1812	680	duration of diarrhea (in hours) from onset and from admission until cessation of diarrhea (passage of soft/formed or no stools for two consecutive 8-hour periods)	The mean duration of diarrhea from enrolment	1	0.76289576	1	
284	1341	743	shoulder mobility	shoulder mobility	1	1.0	1	
34	50	570	IES-R	the quality of the online relationship at the end of treatment	0	0.0	0	
137	1456	911	VC	SpO 2	0	0.09208765	0	
482	1541	595	ETDRS visual acuity recorded in the laboratory, supplemented with a number of secondary lab-based visual function measures	visual field	0	0.53135365	1	
513	1583	983	an overall response that integrated clinical, bacteriological and radiological results, at the end of treatment (month 6) and after 12 additional months of follow-up (month 18)	advanced oxidation protein products	0	0.2828504	0	
589	896	408	PK parameters and safety and tolerability	dose	0	0.27582267	0	
142	1198	919	health care costs	A COPD-related cost offset	1	0.40204474	1	
241	406	265	a dichotomous measure (occurrence of low back pain)	Age	0	0.05320328	0	
209	1274	1036	the incidence of predefined GI AEs	a moderate or severe event	0	0.41450542	1	
186	277	2	change in score	the ethnic control group scores	0	0.48823616	1	
353	586	13	the American College of Rheumatology 20% improvement criteria (ACR20) response at week 24 19 20	SF-36 scores	0	0.26471096	0	
535	1618	582	crying	bowel movements	0	0.10025928	0	
213	378	279	the duration of the weaning process	complications	0	0.13314812	0	
644	970	642	Difference in plasma bone marker concentration between treatment groups	bone marker concentrations	1	0.6470785	1	
597	913	247	Apgar scores less than 8	augmentation of labour	0	0.013384073	0	
79	126	834	changes in pain as measured on a verbal rating scale from 0 to 10 during a flexion-extension range of motion evaluation and changes in disc height as measured on CT scans	disc height	0	0.37928674	0	
21	1035	1078	the parasite clearance rate constant K	clearance	1	0.462134	1	
577	1660	641	The number of destroyed alveolar attachments, expressed as a percentage over the total number of alveolar attachments,	the % destroyed attachments	1	0.6355873	1	
622	935	54	global perceived effect (GPE) and the impact of the headache using the Headache Impact Test (HIT-6)	The number of recruited patients	0	0.36621606	0	
371	1444	141	the Premature Infant Pain Profile (PIPP) score in the first minute after skin puncture	Local skin erythema	0	0.3381108	0	
76	428	679	change in BMD between pre-treatment and 16 weeks	bone gap area	0	0.32422134	0	
300	1361	696	i) cognitive functioning, as measured by the ADAS-Cog, a 0–70 point scale with a higher score indicating worse cognition; and ii) quality of life, rated by the participant and their nominated carer, as measured by the QOL-AD, both 13-item scales, scoring between 13 and 52 points with a higher score indicating better quality of life	participant-rated quality of life score	0	0.56548	1	
195	1983	82	nutrition knowledge	enjoyed playing the game	0	0.14247939	0	
136	1883	194	number of oocytes	retrieved oocytes	1	0.56873316	1	
241	406	265	a dichotomous measure (occurrence of low back pain)	military status	0	0.1710564	0	
754	1936	56	Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating	stereotypy	0	0.3108542	0	
504	782	948	the mean time to onset of the first 24-h heartburn-free period after initial dosing	overall quality of pain relief	0	0.37176237	0	
566	867	507	troponin T on POD1	Concentration of troponin T as the most sensitive marker for myocardial injury at POD1	1	0.5955184	1	
157	224	1066	'first-step' pain (measured on a 100 mm Visual Analogue Scale) and the Foot Health Status Questionnaire domains of foot pain, foot function and general foot health	events were mild to moderate and short-lived	0	0.31969857	0	
494	770	539	the time until shock reversal	IL-1ra	0	0.0	0	
50	102	824	pulmonary or cardiac toxicity	The post-radiotherapy physical-, cognitive- and emotional-functioning scores	0	0.105855346	0	
318	528	1014	GHbA1c	quality of life	0	0.0	0	
543	830	220	the change in morning peak expiratory flow (PEF) rate from baseline to the end of the treatment period (mean of weeks 23–24)	forced expiratory volume in 1 second measured at the clinics	0	0.78529394	1	
115	166	351	the percentage of patients who reached 25(OH)D levels of 30 ng/ml or above on day 7	Parathyroid hormone levels	0	0.34600523	0	
454	708	572	The LSAS-SR	quality of life	0	0.03778105	0	
386	631	360	The mean decrease in Young Mania Rating Scale score from baseline	The means Extrapyramidal Symptoms Rating Scale scores	0	0.7421996	1	
629	942	203	the EQ-5D utility	The mean incremental QALY	0	0.2545065	0	
421	655	105	knowledge	knowledge	1	1.0000001	1	
128	1161	826	The mean decrease in HAM-D score from baseline	sedation	0	0.058801636	0	
154	1220	559	Total costs	self-care	0	0.0	0	
429	672	485	response rate to treatment	VAS outcomes	0	0.31697077	0	
285	493	401	self-rated overall effect of treatment, measured once; on the day treatment was completed	were much better or very much better	0	0.48619735	1	
130	1878	826	the 17-item HAM-D	anticholinergic effects	0	0.05081109	0	
105	159	67	the slope of decline in FEV 1 from 2 hours post-dose, the area under the FEV 1 curve (AUC) (0–24 hours) and the mean change from pre-dose FEV 1 at 12 hours post dose	sustained bronchodilator effect	0	0.40096444	1	
596	913	246	Apgar scores less than 8	postpartum haemorrhage	0	0.1212566	0	
6	1016	100	blood pressure	Attendance at the monthly education sessions	0	0.1440912	0	
168	1912	963	knowledge of labour analgesia, decisional conflict (uncertainty regarding analgesia decision) and anxiety	knowledge scores	0	0.43566772	1	
205	1273	126	the percentage of patients who had a CSTE	post-treatment biopsy	0	0.25040755	0	
754	1936	56	changes compared to baseline observed after 4 weeks (40 sessions) of treatment, in parallel groups, on (1) Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating, (2) Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating, and (3) Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	speech	0	0.11518463	0	
648	974	283	the percent of subjects meeting TR during the initial 30 minutes of treatment	often reached TR	1	0.39230204	0	
364	625	387	self-reported withdrawal symptom severity during the detoxification period	Follow up rates	0	0.2872731	0	
597	913	247	relative risk	likely to have continuous electronic fetal monitoring	0	0.33161175	0	
255	437	1079	comet assay	GPx	0	0.35914505	0	
552	1628	376	'TQ total score'	Subjective reports of TQ subscales	0	0.17000754	0	
120	1150	618	BP	systolic BP	1	0.7526329	1	
82	1103	956	global quality of life change at 6-weeks, measured by EORTC QLQ-C30	role functioning	0	0.22161289	0	
210	378	273	the duration of the weaning process	type of surgery	0	0.3132411	0	
512	1583	982	an overall response that integrated clinical, bacteriological and radiological results, at the end of treatment (month 6) and after 12 additional months of follow-up (month 18)	converted again to positive	0	0.4072427	1	
99	1126	827	the reduction in tumour proliferation measured as the change in the biomarker Ki67 by conventional immunohistochemistry	molecular effects	0	0.2873015	0	
215	379	1051	day-28 failure rates (uncorrected and PCR corrected)	sulphadoxine-pyrimethamine failure	1	0.63779265	1	
242	1313	565	the primary process outcome	long-acting β 2 -agonists	0	0.1392002	0	
557	1634	295	the change in YBOCS score from baseline to endpoint	the Yale-Brown Obsessive-Compulsive Scale	1	0.56306887	1	
626	937	817	cure and severity of IAD	skin barrier function	0	0.27023244	0	
31	1052	11	Correlation between VPW measurements from the portable chest radiograph with the PAOP	VPW	0	0.2764366	0	
345	941	307	the Gastrointestinal Symptom Rating Scale-IBS version (GSRS-IBS) 42	clinical effectiveness	0	0.30854252	0	
410	651	683	the PHQ-9	Follow up rates at 3 and 6 months	0	0.35399026	0	
580	1661	748	return of final follow-up questionnaire or reminder by the participant	response rates to postal questionnaires	1	0.36954483	0	
272	1457	355	the proportion of patients who reported being sexually active at six months compared to randomization	the burden of kidney disease on sex life	0	0.5402571	1	
477	1601	399	costs per quality adjusted life years (cost/QALY)	the probability for PREP being cost-effectiv	0	0.38477147	0	
158	224	1067	foot pain	foot pain	1	1.0	1	
163	233	1028	10 MCP Trans PDA	a variety of ultrasound (US) endpoints	0	0.26936084	0	
69	396	800	force platform variables PVF and impulse, the validated HCPI and the use of rescue NSAIDs	HCPI	0	0.30318686	0	
476	1601	398	costs per quality adjusted life years (cost/QALY)	costs per QALY	1	0.7605099	1	
594	897	564	improvement of GHbA 1c and the SF-36 quality of life score	GHbA 1c	0	0.3694574	0	
504	1573	888	the clinical and virological effects of zidovudine in combination with lamivudine	disability score	0	0.262021	0	
691	1834	792	The MC exam	the MC exam	1	0.82408905	1	
754	1936	56	Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating	the ABC	1	0.42688805	1	
610	928	392	child body mass index (BMI) z-score	objectively assessed troop PA	0	0.24243034	0	
289	1342	740	"the percentage change in ""average pain for the past 24 hours"" NPRS scores from baseline to weeks 2 through 8"	efficacy	0	0.086011335	0	
404	646	210	the EPDS (a 10-item scale developed for use in the postnatal period, in which a score ≥ 13 identifies probable depression 33	the physical health of mothers six months after birth	0	0.60528517	1	
185	277	1	change in score	complications	0	0.11856986	0	
322	1391	210	the proportion of delivered compressions within target depth compared over a 2-minute period within the groups and between the groups	were CPR instructors	0	0.31118935	0	
309	1770	93	knee-specific patient-reported WOMAC scores	Knee-specific scores	1	0.80538183	1	
639	1773	707	ACT scores	ACT score	1	0.8645461	1	
118	1145	1056	the number of additional donors deferred by the HQ	self-deferred	0	0.0	0	
58	273	1003	Treatment Alliance Scale (TAS) 40 and Client Satisfaction Questionnaire (CSQ) 44 	motivation for treatment	0	0.2481903	0	
416	1489	1064	PCR-corrected adequate clinical and parasitological response (ACPR) on day 28	the packed cell volume	0	0.43947485	1	
97	1122	89	days alive and off assisted breathing	functional residual capacity	0	0.15627299	0	
518	808	489	incidence of vaginal delivery within 12 and 24 hours	delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05)	1	0.5627595	1	
118	1145	1056	the number of additional donors deferred by the HQ	used the self-exclusion option on the DHAQ but did not indicate that they should not donate blood on the HQ	0	0.7023941	1	
679	1811	506	the overall between-patient variability around the mean time to neurological assessment	effective	0	0.17298278	0	
111	210	856	control criteria during the 2-year follow-up period	the compliance in all the control criteria, except for LDL cholesterol	1	0.6843063	1	
516	796	618	the proportion of children achieving a well clinical response and time to a well clinical response	Mortality	0	0.19131961	0	
596	913	246	relative risk	induction	0	0.03629331	0	
654	980	99	BMD	balance	0	0.07856339	0	
48	82	1056	change in SBP and change in HOMA index, from week 0 (pre-treatment) to week 6	HR	0	0.13924691	0	
53	102	827	pulmonary or cardiac toxicity	global health status	0	0.34627944	0	
623	1731	256	change from baseline in fasting serum total cholesterol	proportion of patients maintaining HIV-1 RNA <400 or <50 copies/mL	0	0.5042246	1	
357	626	289	the intra-individual change in the total score of the Hamilton Rating Scale for Depression (HAM-D, 17-item version) between baseline and the end of the 6-week acute phase	HAM-D total scores	1	0.5151937	1	
440	1852	633	anti-malarial prescription recorded during observed consultations in cross-sectional surveys conducted in all HF before and 18 months after m RDT implementation	anti-malarial prescription	1	0.28330684	0	
106	161	854	HbA1c, lipid levels, blood pressure, BMI after 24 months of follow-up	SBP	0	0.22497232	0	
760	1938	546	reduction in duration of severe pneumonia and pneumonia	oxygen use	0	0.23703434	0	
464	797	378	change in EPIC urinary HRQOL domain summary score at 3 months after the completion of RT (ΔEPIC-U 3mo )	PSA nadir	0	0.33989647	0	
140	1198	916	health care costs and utilization rates	non-study respiratory medications	0	0.3856602	0	
390	632	215	WOMAC Pain, Physical Function and Total scores	the SF-36 Physical Function	0	0.69280666	1	
358	1434	574	HbA 1c	relief in hyper- and hypoglycaemic distress	0	0.13989316	0	
141	1198	917	health care costs	number of outpatient visits per patient	0	0.5079233	1	
471	1536	400	tube dependency at one-year and number of post-CCRT hospital admission days	probability of being cost-effective	0	0.35741314	0	
67	108	802	the HCPI	veterinary assessment	0	0.14804485	0	
597	913	247	caesarean birth	augmentation of labour	0	0.14161423	0	
66	1083	51	changes in the HDRS, ATYP and the SIGH-SAD-SR over the 8-week study period	he number needed to treat (NNT) for light	0	0.5356887	1	
276	1337	65	therapy failure	mortality	0	0.3018924	0	
97	141	193	death	the mortality	1	0.37371552	0	
89	1107	76	treatment preference	the IBS sum score	0	0.23722585	0	
517	808	488	time from induction to delivery and incidence of vaginal delivery within 12 and 24 hours	The induction-delivery interval	0	0.30376872	0	
109	210	854	glycated hemoglobin A1c, body mass index (BMI), blood pressure, lipids and control criteria during the 2-year follow-up period	systolic blood pressure (SBP) levels	0	0.6574674	1	
582	1671	182	the GSRS subscores for abdominal pain	GSRS abdominal pain subscore	1	0.75233465	1	
390	632	215	WOMAC Pain, Physical Function and Total scores	hamstring strength in both legs	0	0.27756184	0	
105	159	67	the slope of decline in FEV 1 from 2 hours post-dose, the area under the FEV 1 curve (AUC) (0–24 hours) and the mean change from pre-dose FEV 1 at 12 hours post dose	change from pre-dose FEV 1 at 12 hours	0	0.8668936	1	
141	1198	917	health care costs and utilization rates	outpatient costs	0	0.7138558	1	
96	141	192	coma recovery time	time to start oral intake	0	0.48301286	1	
96	141	192	coma recovery time	total coma duration	0	0.5279207	1	
323	528	1019	GHbA1c	glycemic control	1	0.0	0	
767	1986	1042	daily physical activities (measured by a validated tri-axial accelerometer)	time spent sitting	0	0.13640107	0	
444	695	673	an ASAS40	erythrocyte sedimentation rate (ESR)	0	0.09286059	0	
553	854	333	time to achieve haemostasis at the suture line	mean blood loss after cross-clamp removal	0	0.4037831	1	
86	1107	73	treatment preference	preferred placebo to L. plantarum MF1298 treatment	1	0.6299566	1	
146	221	531	a difference of ≥ 20% in the microvascular flow index of small vessels among groups	systemic hemodynamics	0	0.4080869	1	
111	210	856	blood pressure	glycated hemoglobin A1c	0	0.39888066	0	
68	396	799	force platform variables PVF and impulse, the validated HCPI and the use of rescue NSAIDs	happier	0	0.07902051	0	
332	1418	260	FEV 1 (% predicted) in the two groups at 1, 5, 15, 30, 60 min after administration of the study drug	MPIS	0	0.0	0	
433	978	485	response rate based on a 20% improvement in WOMAC pain scores	VAS outcomes	0	0.41603965	1	
158	224	1067	foot function	general foot health	0	0.48343992	1	
409	651	682	the PHQ-9	received favourably by participants and facilitators	0	0.32924747	0	
213	378	279	the duration of the weaning process	adaptation	0	0.06278758	0	
626	1731	259	change from baseline in fasting serum total cholesterol	lipid profiles	0	0.40248412	1	
673	1804	145	reversal of metabolic syndrome in the intervention group subjects compared to controls at 12 months follow-up	Median age	0	0.31293333	0	
573	881	370	the overall discomfort reported during WC versus SC pH-metry	Overall failure rate	0	0.44149366	1	
393	1476	612	whether the GP had provided patients with a written asthma action plan (WAAP yes/no)	confident	0	0.19658436	0	
208	368	837	the mean change in modified extrinsic tooth stain index (all sites) from baseline to week 6	mean tooth shade scores	0	0.5548366	1	
550	839	106	the comparison of sensitivity and specificity of perfusion-CMR to detect CAD on CXA vs SPECT based on a single-point threshold reading	The diagnostic performance (= area under ROC = AUC)	0	0.6045013	1	
236	399	1101	biochemically verified 7-day point prevalence smoking abstinence defined as no cigarettes (not even a puff) in the previous 7 days at Week 26, validated using salivary cotinine collected at Week 26	reported using pharmacotherapy in their most recent quit attempt	0	0.64460796	1	
673	1804	145	reversal of metabolic syndrome in the intervention group subjects compared to controls at 12 months follow-up	mean waist size	0	0.29945314	0	
626	1731	259	change from baseline in fasting serum total cholesterol	virologic suppression	0	0.38186884	0	
203	1273	124	the percentage of patients who had a CSTE	numbers of transfusions	0	0.38924736	0	
577	1660	641	The number of destroyed alveolar attachments, expressed as a percentage over the total number of alveolar attachments,	the airway smooth muscle area	0	0.48052496	1	
741	1898	1086	3 types of acute-care services, defined as hospitalizations, partial hospitalizations, and visits to emergency departments (EDs)	hospitalization	0	0.28517273	0	
258	448	1022	10-percentage point difference between arms in increase in the proportion of participants reaching the target level in five global and two patient-group specific clinical parameters at 12 months	The proportion of patients with diastolic blood pressure initially above the target level decreasing to 85 mmHg or lower	0	0.75878567	1	
263	1329	348	the percentage of children who had ≤ 4 days with pain and no missed activities during the previous month 41	the intensity of painful episodes	0	0.58315474	1	
581	1668	768	the Freezing of Gait Questionnaire	gait	0	0.15749364	0	
369	607	575	log HbA 1c and HRQL	geometric mean HbA 1c	0	0.6654409	1	
390	632	215	Physical Function	Social Functioning domains	0	0.3789219	0	
637	954	622	the serum phosphorus at 12 weeks	the proportions of those with hypercalcemia	0	0.5144859	1	
236	399	1101	biochemically verified 7-day point prevalence smoking abstinence defined as no cigarettes (not even a puff) in the previous 7 days at Week 26, validated using salivary cotinine collected at Week 26	The average number of quit attempts in the past year	0	0.6461994	1	
651	974	286	the percent of subjects meeting TR during the initial 30 minutes of treatment	heart rates at all time points	0	0.5756411	1	
216	1276	831	the number of clinical episodes of P. falciparum malaria	Time to first malaria episode	0	0.5838351	1	
369	607	575	log HbA 1c	HbA 1c	1	0.84915173	1	
406	1483	188	the Premature Infant Pain Profile (PIPP ) 48 49	pain response	1	0.30308318	0	
352	569	96	diarrhoea	one marker of bacterial translocation	0	0.0	0	
569	880	256	retention in treatment, which was defined as the number of weeks that patients remained in the study before being discharged	intensity of opioid craving	0	0.20265909	0	
158	224	1067	'first-step' pain (measured on a 100 mm Visual Analogue Scale)	general foot health	0	0.1554249	0	
558	1634	298	(1) the change in YBOCS score from baseline to endpoint and (2) the clinical global impression of improvement (CGI-I) at endpoint	effective	0	0.22139041	0	
420	655	104	knowledge	a knowledge score	1	0.73617	1	
20	420	1043	'success'	resistant pneumococci	0	0.0	0	
669	1942	759	patient satisfaction	patient comfort	0	0.7563081	1	
300	1361	696	cognitive functioning, as measured by the ADAS-Cog, a 0–70 point scale with a higher score indicating worse cognition	participant-rated quality of life score	0	0.44958976	1	
318	1376	1082	The 6MWT	6 minute-walk-distance	1	0.25554547	0	
55	1074	838	the proportion of patients with plasma HIV-1 RNA levels <200 copies/mL at week 24	virologic response	0	0.40714997	1	
568	1656	1013	change in this composite from baseline at four months post-randomization	Intervention attendance rates	0	0.22388399	0	
137	204	146	percentage aggregation on day 5 (2 hours after drug administration,) expressed as percentage of baseline, using 1.1 μg/ml collagen as an agonist	The mean aggregation (using 1.1 μg/ml of collagen)	1	0.4799123	1	
488	768	1090	peak systolic and end-diastolic blood flow velocities in the short posterior ciliary artery (SPCA) under the new therapy	Systolic and diastolic blood flow velocities in the SPCA	1	0.84666497	1	
299	1356	307	the difference (Δ) between the VAS scores after treatment compared to pre-treatment VAS scores	the sensation of pain	0	0.54383963	1	
619	1731	252	change from baseline in fasting serum total cholesterol	high density lipoprotein (HDL)-cholesterol	0	0.4173932	1	
276	1337	65	therapy failure	survival without supplemental oxygen or on ventilator	0	0.37929964	0	
50	1808	339	the mean change in self-reported symptoms of depression as measured on the BDI	This number of centres	0	0.37141687	0	
360	1436	650	gastric emptying T half	GE T half	1	0.61937624	1	
200	332	116	NRS changes	The ODQ score	0	0.10403089	0	
238	1965	200	the incidence of IR	VS	0	0.16105385	0	
71	1085	866	the levels of inflammatory cells (neutrophils, eosinophils, macrophages, and lymphocytes) and epithelial cells in induced sputum	control of eosinophilic airway inflammation	0	0.58508503	1	
531	1610	301	improvement in attention scores for the intervention group	academic skills	0	0.3015813	0	
240	1313	563	Asthma control	ACQ score	1	0.14036418	0	
70	396	801	force platform variables PVF and impulse, the validated HCPI and the use of rescue NSAIDs	the veterinary assessment variables	0	0.62722236	1	
10	1016	105	blood pressure	the primary blood pressure outcomes	1	0.70673215	1	
761	1938	547	reduction in duration of severe pneumonia	duration of severe pneumonia	1	0.86443764	1	
597	1712	273	safety, tolerability and level at which dose limiting toxicity occurred	The overall response	0	0.411803	1	
531	814	646	to decrease reintubation rates, defined by the necessity of mechanical positive-pressure ventilation through orotracheal intubation in the first 48 hours after extubation, in the treatment group	MV time before enrollment	0	0.49908572	1	
1	0	1007	the horizontal VAS according to Jensen	free of complaints	0	0.19219895	0	
646	1782	881	Trough FEV 1 after 12 weeks of treatment	use of rescue medication	0	0.29257807	0	
124	1150	623	the primary care practices' mean levels of HbA1c, cholesterol and BP, and numbers of patients with recorded foot inspections in the previous calendar month	mortality	0	0.31483054	0	
133	1163	194	the number of retrieved oocytes	local tolerability	0	0.23175356	0	
264	1329	349	the percentage of children who had ≤ 4 days with pain and no missed activities during the previous month 41	the number of days with pain	0	0.8151184	1	
226	1288	970	mortality	the hospital diagnostic and therapeutic procedures were performed	0	0.2872925	0	
124	1150	623	BP	mortality	0	0.051603448	0	
581	1668	768	the Freezing of Gait Questionnaire	walking speed	0	0.14485988	0	
51	1074	834	the proportion of patients with plasma HIV-1 RNA levels <200 copies/mL at week 24	HIV-1 RNA <200 copies/mL	1	0.34951094	0	
716	1862	925	knee range of motion (ROM)	ROM	1	0.18435346	0	
401	1481	42	Depressive symptoms	Depressive symptoms	1	1.0	1	
404	646	210	the EPDS (a 10-item scale developed for use in the postnatal period, in which a score ≥ 13 identifies probable depression 33 , and the physical and mental component scores (PCS and MCS) of the Short Form 36 (SF-36), a widely used general health status measure 34	the physical health of mothers six months after birth	0	0.64984155	1	
155	1220	560	Total costs	Average total costs	1	0.7848895	1	
94	1121	781	the patient's death or institutionalization	only one personal contact (33 cases, 34%)	0	0.45168537	1	
507	782	951	the mean time to onset of the first 24-h heartburn-free period after initial dosing	a 24-h heartburn-free period in moderate episodic heartburn	1	0.5982526	1	
160	226	930	the total MET minutes of moderate and vigorous physical activity accrued over the past 7 days	resting heart rate	0	0.36238375	0	
277	1337	66	mortality at 30 days	survival without oxygen or on ventilator	0	0.43349075	1	
108	161	856	HbA1c, lipid levels, blood pressure, BMI after 24 months of follow-up	SBP levels	0	0.3531039	0	
177	1241	148	the duration of severe neutropenia (DSN) in cycle 1	DSN	1	0.11844499	0	
704	1839	1029	absence of abdominal or rectal palpable mass at physical examination	painful defecation	0	0.39001626	0	
151	1219	669	disease-free survival (DFS)	TC	0	0.003966422	0	
273	1506	344	The observed change on the RDQ	functional limitations	0	0.22591588	0	
102	1128	943	time from the commencement of study drug to extubation	the proportion of time propofol was required	0	0.70077485	1	
18	420	1041	detection of bilateral aerated middle ears (confirmed with tympanometry) at two consecutive monthly visits	Beta-lactamase positive non-capsular H. influenzae (NCHi)	0	0.1840037	0	
119	173	182	the 15th percentile point	MLD	0	0.08068276	0	
362	625	385	self-reported withdrawal symptom severity during the detoxification period	proportion of people allocated to buprenorphine provided a urine sample negative for opiates (abstinent)	0	0.50864434	1	
220	383	995	PCR-adjusted 42-day cure rates after starting treatment	well tolerated	0	0.20759946	0	
158	224	1067	foot pain	general foot health	0	0.46261367	1	
421	655	105	attitudes, knowledge and skills in EBM	scores in attitudes	0	0.46630213	1	
95	1122	87	days alive and off assisted breathing	mean ± SD total lung capacity	0	0.20930502	0	
723	1867	608	spontaneous preterm delivery between 34 and 37 weeks' gestation	The neonatal complications	0	0.4656766	1	
767	1986	1042	daily physical activities (measured by a validated tri-axial accelerometer)	standing time	0	0.15720537	0	
422	1493	206	response rate	The response rate	1	0.8650803	1	
269	464	973	a change in the serum ALT activity or the INR	serum transaminase	0	0.37967664	0	
569	880	256	retention in treatment, which was defined as the number of weeks that patients remained in the study before being discharged	self-reported opioid and alcohol use	0	0.26850936	0	
189	288	364	the number of hospital days after surgery	adverse events	0	0.20116101	0	
646	1782	881	Trough FEV 1 after 12 weeks of treatment	the percentage of days of poor control	0	0.43198833	1	
32	1052	12	Correlation between VPW measurements from the portable chest radiograph with the PAOP	PEEP	0	0.17189273	0	
475	736	517	incidence of low back pain resulting in the seeking of health care	threat of low back pain	0	0.69841456	1	
261	455	436	the generic instrument EuroQol-5D (EQ5D)	function	0	0.24133237	0	
71	396	802	force platform variables PVF and impulse, the validated HCPI and the use of rescue NSAIDs	veterinary assessment	0	0.2687068	0	
56	273	1001	Treatment Alliance Scale (TAS)	satisfaction	0	0.12019426	0	
657	981	180	the proportion of patients relapse-free at Week 26	efficacy	0	0.21150933	0	
596	913	246	initiation of breastfeeding	induction	0	0.29401362	0	
344	941	306	the Gastrointestinal Symptom Rating Scale-IBS version (GSRS-IBS) 42	measures of quality of life	0	0.2323449	0	
500	852	850	a reduction in depression	depressive symptoms post program	1	0.47185698	1	
423	660	860	clinical response at the test-of-cure visit (14–35 days after therapy) for the m-mITT and ME populations	Corresponding clinical cure rates	0	0.33650127	0	
254	1322	222	the Glasgow Outcome Scale score 3 months after brain injury	The modified Functional Independence Measure scores	0	0.45776442	1	
579	886	71	Major bleeding	the risk	0	0.16962387	0	
185	1270	550	90-day mortality	blood transfusions	0	0.24631913	0	
59	1078	407	the rate of response to PRGF	effusion	0	0.12539265	0	
144	215	48	The PCR-corrected ACPR rate at follow-up on day 28 after the first malaria episode	ACPR rate	1	0.42524093	1	
497	852	846	a reduction in depression	depressive symptoms (Geriatric Depression Scale, GDS-30 score ≥ 11)	1	0.491247	1	
240	406	264	a dichotomous measure (occurrence of low back pain)	Caucasian	0	0.16621354	0	
182	1250	293	The frequency of acute exacerbation	frequency of acute exacerbation	1	0.90597755	1	
656	1962	882	trough FEV 1 after 12 weeks of treatment (average of the 23 h 10 min and 23 h 45 min post-dose values assessed on the morning of Day 85)	The overall rates of AEs	0	0.45735443	1	
140	1198	916	health care costs	non-study COPD medication costs	1	0.62862206	1	
605	924	821	unexpected ocular or systemic findings, adverse event rate, and temporary and permanent discontinuation	logMAR	0	0.3450259	0	
593	1701	531	intra-operative pain	patient comfort	0	0.38452908	0	
518	1591	113	ICP control	Uncontrollable intracranial pressure	1	0.27802193	0	
705	1839	1031	1) defecation frequency > 3/week; 2) normalization of stool consistency; 3) no more painful defecation; 4) absence of abdominal or rectal palpable mass at physical examination	soft stools	0	0.3763045	0	
252	1321	872	the reduction in the number of tender points at 12 months with respect to baseline	the mean number of tender points (pairs)	1	0.78404623	1	
627	937	818	cure and severity of IAD	efficacious against IAD	0	0.58472794	1	
53	1074	836	the proportion of patients with plasma HIV-1 RNA levels <200 copies/mL at week 24	frequency of discontinuing treatment due to adverse events	0	0.4820092	1	
461	1519	662	PASI-75	QOL	0	0.0	0	
533	814	648	to decrease reintubation rates, defined by the necessity of mechanical positive-pressure ventilation through orotracheal intubation in the first 48 hours after extubation, in the treatment group	time under MV	0	0.44244736	1	
207	368	836	the mean change in modified extrinsic tooth stain index (all sites) from baseline to week 6	mean stain scores	1	0.5442623	1	
385	627	318	the ovicidal effect of the treatments, defined as no nymphal lice emerging from eggs between treatments	intensity of infestation	0	0.2830929	0	
467	1536	396	tube dependency at one-year and number of post-CCRT hospital admission days	Total costs	0	0.2504874	0	
118	1145	1056	the number of additional donors deferred by the HQ	indicated on the HQ that they should not donate blood on that day but did not use the confidential self-exclusion option on the DHAQ	0	0.7092154	1	
767	1986	1042	daily physical activities (measured by a validated tri-axial accelerometer)	time spent walking and standing	0	0.20535487	0	
210	378	273	the duration of the weaning process	gender	0	0.20363875	0	
452	707	1068	health-related quality of life (HRQoL)	the Chronic Respiratory Questionnaire	0	0.14184423	0	
193	304	120	the mean RTDI overall	Median time to disease progression (TTDP)	0	0.36603397	0	
96	1122	88	days alive and off assisted breathing	FEV 1 /FVC	0	0.08810101	0	
578	1660	642	The number of destroyed alveolar attachments, expressed as a percentage over the total number of alveolar attachments,	the bronchodilatory effect of lung inflation	0	0.5494875	1	
49	102	823	pulmonary or cardiac toxicity	fatigue	0	0.28442127	0	
337	1458	752	a significant difference in mean birth weight	adverse outcomes	0	0.3602546	0	
75	428	678	change in BMD between pre-treatment and 16 weeks	BMD	1	0.42944163	1	
314	1372	821	myocardial infarction	TVR	0	0.17607604	0	
109	210	854	glycated hemoglobin A1c	baseline glycated hemoglobin A1c	1	0.94675356	1	
65	108	800	PVF	all three scores in the comparative questionnaire (locomotion, every-day situations, and skin & coat)	0	0.058145065	0	
237	399	1102	biochemically verified 7-day point prevalence smoking abstinence defined as no cigarettes (not even a puff) in the previous 7 days at Week 26, validated using salivary cotinine collected at Week 26	Motivation	0	0.20284186	0	
256	1322	224	the Glasgow Outcome Scale score 3 months after brain injury	The mean intracranial pressure values	0	0.4111066	1	
5	0	1011	the horizontal VAS according to Jensen	be cost-effective	0	0.20074748	0	
290	1342	741	"the percentage change in ""average pain for the past 24 hours"" NPRS scores from baseline to weeks 2 through 8"	pain	1	0.36316234	0	
320	1376	1084	The 6MWT	health-related quality of life	0	0.1545281	0	
267	464	970	a change in the serum ALT activity or the INR	The peak mean ALT activity	0	0.662405	1	
473	1601	395	costs per quality adjusted life years (cost/QALY)	hospital admission days	0	0.34774897	0	
303	512	625	the reduction in systolic blood pressure defined as the average of 3 office readings with the patient in the sitting position	diastolic office BP	0	0.41368005	1	
455	1518	542	pain catastrophising	global function based on the Fibromyalgia Impact Questionnaire	0	0.2533461	0	
622	1731	255	change from baseline in fasting serum total cholesterol	protocol-defined total cholesterol	1	0.67423284	1	
384	1463	263	the differences in the levels of iFGF23	the iFGF23 level	1	0.8178382	1	
596	913	246	induction of labour	Apgar scores	0	0.05903468	0	
109	210	854	glycated hemoglobin A1c, body mass index (BMI), blood pressure, lipids and control criteria during the 2-year follow-up period	Glycated hemoglobin A1c	0	0.54619294	1	
314	1372	821	cardiac death	in-stent restenosis	0	0.35026076	0	
594	1707	533	CR	complete response for delayed nausea and vomiting	1	0.1233413	0	
451	706	139	changes between baseline and nine months of bone mineral density (BMD) of the proximal femur and lumbar spine (dual-energy X-ray absorptiometry) and serum markers of bone resorption and formation	function	0	0.26577976	0	
615	1723	510	survey response bias	evidence of response bias	1	0.78745264	1	
288	1342	739	"the percentage change in ""average pain for the past 24 hours"" NPRS scores from baseline to weeks 2 through 8"	considered themselves much or very much improved	0	0.5020228	1	
277	1337	66	cumulative survival without mechanical ventilation or oxygen dependency at 30 days; mortality at 30 days; therapy failure; crossover rate; and persisting pulmonary problems defined as oxygen dependency or still being on a ventilator at 30 days	survival without oxygen or on ventilator	0	0.79896414	1	
65	108	800	rescue NSAIDs	HCPI	0	0.032533385	0	
118	170	134	The frequency, duration and severity of exacerbations	quality of life	0	0.21481837	0	
109	1588	945	extubated	discontinued	0	0.27986875	0	
70	396	801	impulse	the veterinary assessment variables	0	0.08332786	0	
596	913	246	relative risk	instrumental birth	0	0.09644241	0	
411	651	684	the PHQ-9	feasible	0	0.08446486	0	
314	1372	821	target vessel revascularization (TVR)	all cause death	0	0.15011302	0	
223	1284	693	the volume of blood loss between T1 and T4	blood loss	1	0.63547164	1	
65	108	800	the HCPI	all three scores in the comparative questionnaire (locomotion, every-day situations, and skin & coat)	0	0.48145524	1	
391	632	216	WOMAC Pain, Physical Function and Total scores	function	0	0.31321725	0	
357	1434	573	HbA 1c	self-rated health	0	0.08496679	0	
31	50	567	IES-R	PTSD severity	0	0.0	0	
238	1965	200	VS	VS	1	1.0000002	1	
519	1591	114	ICP control	controlling intracranial pressure	1	0.4831248	1	
351	1434	566	HbA 1c	estimated mean scores of the SF36 questionnaire	0	0.2011351	0	
754	1936	56	changes compared to baseline observed after 4 weeks (40 sessions) of treatment, in parallel groups, on (1) Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating, (2) Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating, and (3) Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	total score	0	0.48020372	1	
441	1852	634	(1) anti-malarial consumption recorded from routine statistics in ledger books of all HF before and after intervention; (2) anti-malarial prescription recorded during observed consultations in cross-sectional surveys conducted in all HF before and 18 months after m RDT implementation	Adherence to test result	0	0.42601	1	
525	813	298	the 11-point NRS in patients' daily pain diaries	MPS	0	0.15745886	0	
284	486	347	recurrence	recurrence rate	1	0.78124547	1	
425	660	862	clinical response at the test-of-cure visit (14–35 days after therapy) for the m-mITT and ME populations	efficacious	0	0.13026538	0	
334	1418	262	FEV 1 (% predicted) in the two groups at 1, 5, 15, 30, 60 min after administration of the study drug	bronchodilatory effects	0	0.29603764	0	
332	721	638	waist circumference	waist circumference reductions	1	0.8656125	1	
564	1647	178	bone densitometry	periprosthetic bone density loss	1	0.728859	1	
57	273	1002	Client Satisfaction Questionnaire (CSQ)	satisfaction	1	0.4809059	1	
385	627	318	the ovicidal effect of the treatments, defined as no nymphal lice emerging from eggs between treatments	the level of community engagement	0	0.48058861	1	
206	1274	1033	the incidence of predefined GI AEs	predefined GI AEs	1	0.86099684	1	
508	1583	978	an overall response that integrated clinical, bacteriological and radiological results, at the end of treatment (month 6) and after 12 additional months of follow-up (month 18)	evaluated as complete responders	1	0.5055655	1	
172	1912	967	knowledge of labour analgesia	informed decision making	0	0.15914084	0	
701	1924	797	the anatomical knowledge (MCQ)	the interest in surgery	0	0.5739462	1	
522	1591	118	ICP control	The incidence of adverse effects	0	0.16280316	0	
743	1898	1088	3 types of acute-care services, defined as hospitalizations, partial hospitalizations, and visits to emergency departments (EDs)	use of acute-care services	1	0.44011882	1	
77	1095	227	change from Baseline in ADAS-Cog scores	response to induced ketosis	0	0.1617212	0	
182	1250	293	The frequency of acute exacerbation	social domain	0	0.20513685	0	
536	814	651	to decrease reintubation rates, defined by the necessity of mechanical positive-pressure ventilation through orotracheal intubation in the first 48 hours after extubation, in the treatment group	the efficacy of NIV	0	0.5571561	1	
641	1773	709	changes in the mean FEV 1 , PEF, and ACT scores	treatment adjustment	0	0.3313639	0	
338	1421	161	the rate of renal involvement at one year	the rate of renal involvement	1	0.8352211	1	
429	1821	208	participation in the Link-Up Study, through attendance at a biospecimen collection site to provide a blood sample and giving written consent to participate, including use of blood samples for genetic and other research	response rates	1	0.3069569	0	
219	383	994	PCR-adjusted 42-day cure rates after starting treatment	fever clearance times	0	0.36552697	0	
453	707	1069	health-related quality of life (HRQoL)	dyspnea	0	0.1522107	0	
236	1965	198	VS	the incidence of VS	1	0.61780524	1	
745	1925	246	glycemic variability, represented as SD (Glu SD )	Glycemic variability measures	1	0.25181222	0	
222	383	997	PCR-adjusted 42-day cure rates after starting treatment	effective	0	0.29539177	0	
109	210	854	glycated hemoglobin A1c	SBP	0	0.2021435	0	
557	1634	295	(1) the change in YBOCS score from baseline to endpoint and (2) the clinical global impression of improvement (CGI-I) at endpoint	the Yale-Brown Obsessive-Compulsive Scale	0	0.5589964	1	
555	1631	517	The proportion of recurrent parasitaemia's during the 4-week follow-up	improvement of anaemia	0	0.15984775	0	
96	141	192	time to sit unsupported	sit unsupported	1	0.85748726	1	
650	1782	886	Trough FEV 1 after 12 weeks of treatment	rescue medication use	0	0.29257804	0	
349	1429	733	the performance of the trial according to the revised CONSORT statement	well-being or bowel symptoms	0	0.17112982	0	
719	1862	928	knee range of motion (ROM)	levels of pain	0	0.29807782	0	
88	1107	75	treatment preference	IBS sum score	0	0.21035117	0	
352	1434	568	HbA 1c	vitality-score	0	0.0	0	
564	1647	178	bone densitometry	serum metal ion concentrations	0	0.4071403	1	
528	1602	62	Changes in MMSE sum score	retained cognitive function during one year follow-up	0	0.42932016	1	
111	210	856	glycated hemoglobin A1c, body mass index (BMI), blood pressure, lipids and control criteria during the 2-year follow-up period	glycated hemoglobin A1c	0	0.6648523	1	
351	569	95	diarrhoea	gastric pH	0	0.0	0	
591	896	410	PK parameters and safety and tolerability	blood glucose	0	0.24835752	0	
633	1760	679	Biopsy proven acute rejection (BPAR) at 24 weeks	tolerated	0	0.26471385	0	
714	1862	923	pain severity	pain	1	0.7960456	1	
304	1362	93	Self-reported knee-specific stiffness, pain and function	Knee-specific scores	1	0.06593168	0	
179	1243	323	the change relative to baseline in the multiple sclerosis functional composite score (MSFC)	MSFC scores	1	0.3812123	0	
271	1457	354	the proportion of patients who reported being sexually active at six months compared to randomization	bothered by the impact of kidney disease on their sex life	0	0.6259088	1	
115	1142	232	percentage of labeled concentration in the bottles at the time of testing	the mean age of latanoprost	0	0.6261666	1	
687	1833	1069	depression (Edinburgh Postnatal Depression Scale EPDS)	physical wellbeing mean scores (PCS-SF36	0	0.3459625	0	
302	1361	698	cognitive functioning, as measured by the ADAS-Cog, a 0–70 point scale with a higher score indicating worse cognition	their cognitive functioning	1	0.53583646	1	
198	1272	1067	the difference in FMD between the two blends of supplements and placebo following a 2-hour oral glucose tolerance test (OGTT) after 8 weeks of treatment	insulin	0	0.33789957	0	
680	1812	680	duration of diarrhea (in hours) from onset and from admission until cessation of diarrhea (passage of soft/formed or no stools for two consecutive 8-hour periods), and the total stool weight in grams during hospitalization	The mean duration of diarrhea from enrolment	0	0.75271803	1	
705	1839	1031	normalization of stool consistency	soft stools	1	0.4525782	1	
392	1476	611	whether the GP had provided patients with a written asthma action plan (WAAP yes/no)	able to identify patients at high risk of severe attack	0	0.565866	1	
295	1350	1011	the maximum change in estimated glomerular filtration rate (eGFR) within 48 hours	MBL levels	0	0.3415436	0	
23	1039	152	intestinal volume	The end-tidal CO 2 level	0	0.20691875	0	
96	141	192	coma recovery time; time to sit unsupported, begin oral intake; duration of hospitalization; death and adverse effects	Time to regain consciousness	0	0.33290523	0	
240	406	264	a dichotomous measure (occurrence of low back pain)	have higher levels of education and income	0	0.4475969	1	
679	1811	506	the overall between-patient variability around the mean time to neurological assessment	adverse event	0	0.3366781	0	
489	768	1091	peak systolic and end-diastolic blood flow velocities in the short posterior ciliary artery (SPCA) under the new therapy	IOP	0	0.36930326	0	
671	998	337	sRaw	airway resistance	0	0.0	0	
80	1099	379	body weight	dietary composition	0	0.3602927	0	
642	965	31	lung function	lung function	1	1.0	1	
276	475	665	the shortened version of the Chedoke Arm & Hand Activity Inventory (CAHAI-7)	stages of motor impairment in the hand	0	0.53737676	1	
150	221	535	a difference of ≥ 20% in the microvascular flow index of small vessels among groups	microcirculatory flow abnormalities	0	0.5371572	1	
217	383	992	PCR-adjusted 42-day cure rates after starting treatment	a recurrence of malaria	0	0.4201256	1	
388	1697	713	"the change in IOP from baseline to week 4 at 8 a.m. and 4 p.m. for the per protocol (PP) population using a ""worse eye"" analysis"	IOP	1	0.254718	0	
166	237	611	the ABC Irritability subtest score	the CGI	0	0.39613885	0	
518	808	489	time from induction to delivery and incidence of vaginal delivery within 12 and 24 hours	need for oxytocin augmentation	0	0.4186398	1	
34	50	570	IES-R	the online working alliance	0	0.0	0	
37	1062	317	the comparison of the scores on the 12-Item Short-Form Health Survey (SF-12) and the Graded Chronic Pain Scale (GCPS) questionnaire for the two survey modes	reported mental status score	0	0.42972973	1	
42	1072	333	the recruitment rate	Recruitment	0	0.45382798	1	
261	455	436	the generic instrument EuroQol-5D (EQ5D)	feasible	0	0.12465782	0	
642	965	31	lung function	quality of life	0	0.21975361	0	
555	1631	517	The proportion of recurrent parasitaemia's during the 4-week follow-up	gametocyte carriage	0	0.13954426	0	
584	1678	640	the time course of the corrected colonisation index	The corrected colonisation index	1	0.6476486	1	
447	695	676	an ASAS40	Treatment effects	0	0.10768874	0	
265	1329	351	the percentage of children who had ≤ 4 days with pain and no missed activities during the previous month 41	met the threshold of ≤ 4 day of pain each month and no missed activities	1	0.8756867	1	
180	262	841	the determination of the perioperative concentration of IL-1β in the patient's peritoneal fluid	the time to relapse	0	0.65741336	1	
501	852	851	a reduction in depression	depressive status	1	0.34979215	0	
399	643	811	time to death from all causes, non-fatal myocardial infarction (MI), non-fatal stroke, or heart failure requiring hospitalization or emergency service intervention	Silent ischemia detection procedure	0	0.46503773	1	
221	383	996	PCR-adjusted 42-day cure rates after starting treatment	efficacious	0	0.24762861	0	
356	586	16	the American College of Rheumatology 20% improvement criteria (ACR20) response at week 24 19 20	days with outside help	0	0.45195138	1	
605	1717	365	changes in absenteeism	rule infractions	0	0.3025403	0	
494	770	539	the time until shock reversal	levels of vascular cell adhesion molecule (VCAM)	0	0.17752469	0	
649	1782	884	Trough FEV 1 after 12 weeks of treatment	blood glucose levels	0	0.3263199	0	
665	990	954	the mean number of oocytes retrieved	The overall incidence of adverse events	0	0.38324305	0	
563	861	936	changes in lifestyle according to established goals	weight loss	0	0.26105297	0	
236	1965	198	to test the effect of TA on the incidence of IR and VS in patients undergoing elective CPB	time on mechanical ventilation	0	0.47645095	1	
597	913	247	instrumental birth	augmentation of labour	0	0.09432385	0	
595	897	566	improvement of GHbA 1c	glycaemic control	1	0.13137712	0	
372	607	578	log HbA 1c and HRQL	mental HRQL	0	0.5275289	1	
186	1270	551	90-day mortality	nursing time	0	0.12362269	0	
308	1770	92	knee-specific patient-reported WOMAC scores	completed the five and 10-year review	0	0.27569738	0	
35	1059	1008	the self-reported benefit or achievement (usefulness)	confidence in their capabilities	0	0.52968496	1	
68	1085	863	the levels of inflammatory cells (neutrophils, eosinophils, macrophages, and lymphocytes) and epithelial cells in induced sputum	induced sputum inflammatory cells	0	0.8658221	1	
444	695	673	an ASAS40	active joint count	0	0.1401523	0	
45	77	797	VC	VC	1	1.0000001	1	
621	932	925	PDSS	panic-and agoraphobic symptoms	0	0.18449609	0	
176	257	1082	adherence	Participation	0	0.23634027	0	
754	1936	56	changes compared to baseline observed after 4 weeks (40 sessions) of treatment, in parallel groups, on (1) Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating, (2) Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating, and (3) Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	the ABC	0	0.5573087	1	
347	1428	537	pedometer step counts (Omron HJ-109E Step-O-Meter)	quality of life	0	0.13896388	0	
565	861	940	changes in lifestyle according to established goals	dropout rates	0	0.21136698	0	
725	1873	672	change in Treatment Satisfaction (Tables 5 and 6 )	DTSQs scores at/near ceiling	0	0.22001994	0	
411	1489	1059	PCR-corrected adequate clinical and parasitological response (ACPR) on day 28	The PCR corrected cure rates	0	0.45825267	1	
90	136	791	the hands-on time during the first three minutes of the cardiac arrest	Hands-on time	1	0.6224689	1	
390	632	215	WOMAC Pain, Physical Function and Total scores	Body Pain	0	0.39213693	0	
542	830	219	the change in morning peak expiratory flow (PEF) rate from baseline to the end of the treatment period (mean of weeks 23–24)	The end-study morning PEF rates	1	0.4833159	1	
553	854	333	time to achieve haemostasis at the suture line	mean drain volume	0	0.31181666	0	
455	1518	542	pain catastrophising	quality of life based on the European Quality of Life Scale	0	0.16438709	0	
314	1372	821	major adverse cardiac events (MACE) defined as a composite endpoint of cardiac death, myocardial infarction, and target vessel revascularization (TVR)	myocardial infarction	0	0.67351276	1	
582	1671	182	the GSRS subscores for abdominal pain	the GSRS total score	0	0.52503544	1	
153	1219	671	disease-free survival (DFS)	the lipid profile	0	0.16296567	0	
330	1402	130	the patient assessment of spinal pain (100-mm VAS), patient global assessment of disease activity (100-mm VAS), and the Bath Ankylosing Spondylitis Functional Index (100-mm VAS)	NNTs	0	0.0	0	
628	1745	1091	the cost of therapy per delivered baby, estimated according to a cost-minimization analysis	delivery rate	0	0.4500834	1	
31	50	567	IES-R	other psychopathological symptoms	0	0.0	0	
228	1289	861	the rate of success	the success rate of LPs	1	0.8951862	1	
560	1646	745	the proportion of subjects who achieved targets for compression depth and compression rate	delay concerning initiation of CPR	0	0.36644343	0	
204	1273	125	the percentage of patients who had a CSTE	two serious treatment-related adverse events	0	0.42670384	1	
640	1773	708	changes in the mean FEV 1 , PEF, and ACT scores	FEV 1	0	0.58704185	1	
160	226	930	Moderate - Vigorous MET minutes of Physical Activity	resting heart rate	0	0.1641178	0	
73	112	1072	claim duration (in days) during 12 months follow-up	pain	0	0.15015122	0	
108	161	856	HbA1c, lipid levels, blood pressure, BMI after 24 months of follow-up	glycated hemoglobin A1c	0	0.56976914	1	
32	50	568	IES-R	anxiety	0	0.0	0	
496	1567	555	retention on treatment at 1 year	retention on treatment	1	0.7854067	1	
390	632	215	WOMAC Pain	the SF-36 Physical Function	0	0.40596607	1	
185	277	1	change in score	scores for Knowledge	0	0.4980355	1	
276	1337	65	mortality at 30 days	survival without supplemental oxygen or on ventilator	0	0.40677336	1	
441	695	670	an ASAS40	ASAS20/PedACR30/70 response rates	0	0.18921027	0	
15	420	1038	'success'	success	1	0.0	0	
210	1274	1037	the incidence of predefined GI AEs	msDBP	0	0.0	0	
169	1912	964	decisional conflict (uncertainty regarding analgesia decision)	anxiety	0	0.32746923	0	
325	1391	214	the proportion of delivered compressions within target depth compared over a 2-minute period within the groups and between the groups	Quality of CPR	0	0.16865934	0	
737	1887	975	decisional conflict 42 47	reported vaccinating their child	0	0.17855966	0	
229	389	478	comparison of the change from baseline to end of 12 weeks between simvastatin and fenofibrate	Pre- and post-therapy LDLP/HDLP ratio	0	0.30104443	0	
643	970	641	Difference in plasma bone marker concentration between treatment groups	Plasma low density lipoprotein-cholesterol concentration	0	0.5450579	1	
124	1150	623	BP	diastolic BP	1	0.75568014	1	
256	440	632	the number of ECT treatments given	responded poorer	0	0.2716666	0	
222	383	997	PCR-adjusted 42-day cure rates after starting treatment	parasite and fever clearance times	0	0.36992806	0	
103	159	65	the mean change from pre-dose FEV 1 at 12 hours post dose	a sustained bronchodilation	0	0.34487593	0	
372	1444	142	the Premature Infant Pain Profile (PIPP) score in the first minute after skin puncture	No serious side effect	0	0.39215806	0	
428	1821	207	participation in the Link-Up Study, through attendance at a biospecimen collection site to provide a blood sample and giving written consent to participate, including use of blood samples for genetic and other research	buffy coat	0	0.19666746	0	
11	10	978	whether or not participants have abstained from smoking (self-reported three months prolonged abstinence)	The probability that participants with missing outcome data are not smoking at the end of the trial	0	0.731556	1	
103	1128	944	time from the commencement of study drug to extubation	reintubated	0	0.0	0	
46	82	1054	change in SBP	SBP	1	0.56368494	1	
738	1896	637	The plaque scores	inhibitory effect of plaque regrowth	0	0.31897175	0	
472	1536	401	tube dependency at one-year and number of post-CCRT hospital admission days	ICERs	0	0.0	0	
84	128	655	absence of parasites and clinical signs on days 14 and 28, and good clinical and biological tolerability	No unexpected side-effect	0	0.25726137	0	
6	0	1012	the horizontal VAS according to Jensen	probability of being cost-effective	0	0.291361	0	
69	396	800	the validated HCPI	Quality of life VAS	0	0.25062338	0	
286	493	402	self-rated overall effect of treatment, measured once; on the day treatment was completed	failed to complete treatment	0	0.5173387	1	
156	1257	559	RDQ	IPA subscale autonomy	0	0.24333847	0	
598	913	248	caesarean birth	safe	0	0.08563615	0	
267	464	970	a change in the serum ALT activity	The peak mean ALT activity	1	0.6849381	1	
229	1289	862	the rate of success	the rate of success	1	1.0	1	
615	1723	510	response rate, survey response bias, item non-response, and cost	evidence of response bias	0	0.57638764	1	
345	941	307	the Gastrointestinal Symptom Rating Scale-IBS version (GSRS-IBS) 42	cost-effective	0	0.0	0	
231	389	480	comparison of the change from baseline to end of 12 weeks between simvastatin and fenofibrate	HDLP	0	0.0	0	
501	1569	894	change in summary lifestyle score (Prudence Score) and individual health behaviours at three months	type of spread used	0	0.2587581	0	
236	1965	198	to test the effect of TA on the incidence of IR and VS in patients undergoing elective CPB	the use of norepinephrine	0	0.5839206	1	
106	161	854	HbA1c	Glycated hemoglobin A1c	1	0.7534866	1	
568	880	255	retention in treatment, which was defined as the number of weeks that patients remained in the study before being discharged	opiate withdrawal syndrome	0	0.21809791	0	
403	646	209	the EPDS (a 10-item scale developed for use in the postnatal period, in which a score ≥ 13 identifies probable depression 33 , and the physical and mental component scores (PCS and MCS) of the Short Form 36 (SF-36), a widely used general health status measure 34	Women's physical health scores	0	0.53622454	1	
448	706	136	changes between baseline and nine months of bone mineral density (BMD) of the proximal femur and lumbar spine (dual-energy X-ray absorptiometry)	femoral neck BMD changes	1	0.66872627	1	
240	406	264	a dichotomous measure (occurrence of low back pain)	lower BMI	0	0.43523425	1	
314	1372	821	cardiac death	definite stent thrombosis	0	0.46741727	1	
321	528	1017	GHbA1c	investigator-rated anxiety	0	0.0	0	
65	1083	50	changes in the HDRS, ATYP and the SIGH-SAD-SR over the 8-week study period	the number of responders, as assessed with the HDRS (X 2 = .02)	0	0.7436814	1	
350	569	94	diarrhoea	Anti-LPS IgM	0	0.0	0	
421	655	105	knowledge	self-reported critical appraisal skills	0	0.42112392	1	
503	782	947	the mean time to onset of the first 24-h heartburn-free period after initial dosing	The mean number of heartburn-free days by D7	0	0.56189	1	
287	493	403	self-rated overall effect of treatment, measured once; on the day treatment was completed	response rates	0	0.31206018	0	
375	624	261	the percentage of responders according to American College of Rheumatology 50 criteria	scores on the Health Assessment Questionnaire	0	0.55620164	1	
309	513	197	Early Treatment Failure (ETF); Late Clinical Failure (LCF); Late Parasitological Failure (LPF); Adequate Clinical and Parasitological Response (ACPR) 18	28-day cure rate	0	0.18656299	0	
453	707	1069	health-related quality of life (HRQoL)	exercise tolerance	0	0.19378906	0	
25	472	981	death from any cause, recurrent infarction and unstable angina within one year (per protocol and adjusted for 2 days PCI delay)	The primary combined endpoint of death, recurrent MI and unstable angina	1	0.6620842	1	
751	1933	937	abstinence from illicit opiates at final prescription as indicated by a urine sample	abstinent	1	0.31440446	0	
557	1634	295	the change in YBOCS score from baseline to endpoint	being classified as responders	0	0.33147565	0	
106	161	854	HbA1c, lipid levels, blood pressure, BMI after 24 months of follow-up	baseline glycated hemoglobin A1c	0	0.5776275	1	
204	360	85	the prevalence of arm, shoulder and neck symptoms	the prevalence of arm, shoulder and neck symptoms	1	1.0	1	
443	695	672	an ASAS40	the back pain score	0	0.20074983	0	
514	1584	644	whether or not the ulcer was completely healed within 8 weeks	Complete healing of ulcers, regardless of location and stage,	1	0.48828542	1	
588	1701	526	intra-operative pain	Patient reported mean intra-operative pain scores by visual analog scale	1	0.45745835	1	
176	257	1082	adherence	adherence	1	1.0	1	
710	1843	667	Weight-for-age Z-score	free of sepsis	0	0.0	0	
117	170	133	The frequency	frequency	1	0.7407705	1	
601	1713	238	the Team Check-up Tool (TCT)	validity	0	0.109821804	0	
355	1434	571	HbA 1c	fatigue distress	0	0.08758609	0	
232	1291	243	antimalarial drug prescription	likely to be prescribed antibiotics	0	0.48183	1	
276	1337	65	cumulative survival without mechanical ventilation or oxygen dependency at 30 days	survival without supplemental oxygen or on ventilator	1	0.7937	1	
418	655	102	attitudes	attitude scores	1	0.54774874	1	
378	884	261	ACR 50 improvement	swollen 28-joint count	0	0.032937475	0	
309	1770	93	knee-specific patient-reported WOMAC scores	overall health	0	0.31568408	0	
46	82	1054	change in SBP and change in HOMA index, from week 0 (pre-treatment) to week 6	SBP	0	0.25644624	0	
418	655	102	attitudes	Critical appraisal skills	0	0.21691747	0	
635	1762	6	time to azoospermia	the speed of achieving azoospermia	1	0.5749342	1	
448	706	136	changes between baseline and nine months of bone mineral density (BMD) of the proximal femur and lumbar spine (dual-energy X-ray absorptiometry)	BMD	1	0.3409568	0	
725	1873	672	change in Treatment Satisfaction (Tables 5 and 6 )	Questionnaire effects	0	0.22731867	0	
267	1333	353	sexual activity	the extent to which people were bothered by the impact of kidney disease on their sex life	0	0.3649142	0	
158	224	1067	'first-step' pain (measured on a 100 mm Visual Analogue Scale)	foot pain	0	0.40811408	1	
328	1402	128	the patient assessment of spinal pain (100-mm VAS)	spine pain	1	0.67200077	1	
625	1731	258	change from baseline in fasting serum total cholesterol	C-peptide	0	0.0	0	
595	1707	535	CR	nausea	0	0.06097091	0	
32	50	568	IES-R	co-morbid depression	0	0.0	0	
236	1965	198	VS	the use of norepinephrine	0	0.14122504	0	
412	1489	1060	PCR-corrected adequate clinical and parasitological response (ACPR) on day 28	The re-infection rate	0	0.30767703	0	
391	632	216	WOMAC Pain	quality of life	0	0.0994862	0	
115	1142	232	percentage of labeled concentration in the bottles at the time of testing	The mean age of bimatoprost	0	0.4510514	1	
521	808	492	time from induction to delivery and incidence of vaginal delivery within 12 and 24 hours	an unexplained stillbirth	0	0.3009914	0	
414	652	943	systemic haemodynamics	the BP gap	0	0.1445892	0	
604	924	820	unexpected ocular or systemic findings, adverse event rate, and temporary and permanent discontinuation	BCVA	0	0.21284479	0	
328	1402	128	the patient assessment of spinal pain (100-mm VAS), patient global assessment of disease activity (100-mm VAS), and the Bath Ankylosing Spondylitis Functional Index (100-mm VAS)	the NNTs	0	0.4774595	1	
442	1852	635	(1) anti-malarial consumption recorded from routine statistics in ledger books of all HF before and after intervention; (2) anti-malarial prescription recorded during observed consultations in cross-sectional surveys conducted in all HF before and 18 months after m RDT implementation	antibiotic prescription	0	0.24838316	0	
97	1122	89	days alive and off assisted breathing	forced expiratory flow from 25% to 75% of FVC	0	0.31419897	0	
19	1035	1076	the parasite clearance rate constant K	Early treatment failure	0	0.28552407	0	
376	1448	729	HbA 1c level	glycaemic control	1	0.14393869	0	
640	965	26	lung function	Peak Expiratory Flow	0	0.09735552	0	
245	1619	948	sucrose/pacifier effect on pain reduction	FLACC score	0	0.08999327	0	
471	728	398	Mobilization status as assessed by the 4-item abbreviation of the Barthel index, focusing on lower extremity motoric function	mobilization status	1	0.46607855	1	
672	998	338	sRaw	changes in pulmonary function in patients with mild asthma are detected	0	0.0	0	
415	652	944	systemic haemodynamics	haemodialysis	0	0.0	0	
96	1122	88	days alive and off assisted breathing	TLC	0	0.051526602	0	
215	1276	830	the number of clinical episodes of P. falciparum malaria	malaria cases	1	0.67277783	1	
760	1938	546	reduction in duration of severe pneumonia and pneumonia	time taken for resolution of severe pneumonia, pneumonia	1	0.7149087	1	
336	1458	751	a significant difference in mean birth weight	the proportion of women having a preterm birth	0	0.61470217	1	
767	1986	1042	daily physical activities (measured by a validated tri-axial accelerometer)	intensity of walking	0	0.26911888	0	
180	262	841	the determination of the perioperative concentration of IL-1β in the patient's peritoneal fluid	the distant metastasis rate	0	0.6393335	1	
126	190	187	all-cause mortality over 3 years	the risk of death	0	0.45754814	1	
667	990	956	the mean number of oocytes retrieved	the nature or number of adverse events	0	0.59082913	1	
360	1436	650	gastric emptying T half	GE T half and 1-day palmitoleic acid	0	0.6348994	1	
311	513	200	Early Treatment Failure (ETF); Late Clinical Failure (LCF); Late Parasitological Failure (LPF); Adequate Clinical and Parasitological Response (ACPR) 18	simplicity of administration	0	0.059955455	0	
30	1051	160	incidence of malaria attacks over 8 weeks of follow up	anaemia	0	0.0	0	
559	1646	744	the proportion of subjects who achieved targets for compression depth and compression rate	practical ECC performance	0	0.3601979	0	
741	1898	1086	3 types of acute-care services, defined as hospitalizations, partial hospitalizations, and visits to emergency departments (EDs)	risk of acute-care services	1	0.3908782	0	
122	1150	620	the primary care practices' mean levels of HbA1c	mean HbA1c	1	0.69930327	1	
687	1833	1069	depression (Edinburgh Postnatal Depression Scale EPDS)	depression (EPDS score ≥13)	1	0.6041452	1	
134	200	462	the change in serum methylmalonic acid (MMA) levels after one month of treatment	hematocrit	0	0.20864919	0	
103	1128	944	time from the commencement of study drug to extubation	underwent tracheostomy	0	0.27746677	0	
112	1988	943	time to extubation	the proportion of time propofol was required	0	0.5896677	1	
119	173	182	the 15th percentile point	VI-910	0	0.0	0	
538	1618	585	crying	the infant's sleep	0	0.28069636	0	
69	396	800	force platform variables PVF and impulse, the validated HCPI and the use of rescue NSAIDs	PVF	0	0.25062403	0	
366	1441	236	time needed to perform the motor task	degree of help needed to perform the task	0	0.83751947	1	
426	661	1048	the incidence of clinically relevant VTE (symptomatic deep venous thrombosis (DVT) of the leg and/or pelvic and/or pulmonary embolism (PE)) within the first 3 months	risk of bleeding	0	0.4492705	1	
21	1035	1078	the parasite clearance rate constant K	P. falciparum parasite clearance	1	0.5208067	1	
182	1250	293	The frequency of acute exacerbation	dyspnea scale	0	0.46734506	1	
705	1839	1031	normalization of stool consistency	hard stools	1	0.47206753	1	
390	1697	716	"the change in IOP from baseline to week 4 at 8 a.m. and 4 p.m. for the per protocol (PP) population using a ""worse eye"" analysis"	Conjunctival hyperemia, the most commonly reported adverse event,	0	0.55561966	1	
67	108	802	the HCPI	the HCPI	1	1.0	1	
405	650	166	trough forced expiratory volume in one second (FEV 1 ) at 24 h post-dose after 14 days	Trough FEV 1 after 14 days	1	0.7368854	1	
71	396	802	force platform variables PVF and impulse, the validated HCPI and the use of rescue NSAIDs	the HCPI	0	0.6538184	1	
713	1862	922	pain severity and knee range of motion (ROM)	the pain scores	0	0.5405994	1	
335	1458	750	a significant difference in mean birth weight	Infant birth weight in the second birth	1	0.69691205	1	
660	984	321	improvement in oxygenation (improvement of PaO 2 /FiO 2 (PF) ratio)	mortality at 28 days	0	0.33093366	0	
433	978	485	response rate based on a 20% improvement in WOMAC pain scores	VAS scores	0	0.5063451	1	
436	1496	909	1) physical activity, 2) work productivity, and 3) sickness absence	body weight	0	0.31969464	0	
70	1085	865	the levels of inflammatory cells (neutrophils, eosinophils, macrophages, and lymphocytes) and epithelial cells in induced sputum	sputum cysteinyl leukotrienes	0	0.59331465	1	
135	1883	192	number of oocytes	The incidence of adverse events	0	0.2516929	0	
454	708	572	The LSAS-SR	general anxiety and depression levels	0	0.089519516	0	
747	1925	248	glycemic variability, represented as SD (Glu SD ), glucose lability index ([∑(Glu n - Glu n+1 (mmol/L)) 2 *(h n+1 - h n ) -1 )*(number of readings) -1 or mean daily delta (difference between minimum and maximum) glucose	Diabetes mellitus	0	0.3706177	0	
326	1395	1006	the time to first SRE, including pathologic fracture, spinal cord compression, and the requirement for surgery or radiation therapy to bone	spinal metastases	0	0.5135408	1	
468	1536	397	tube dependency at one-year and number of post-CCRT hospital admission days	Quality adjusted life years	0	0.37210986	0	
30	1051	160	incidence of malaria attacks over 8 weeks of follow up	preventing clinical episodes of malaria	1	0.44720203	1	
596	913	246	Apgar scores less than 8	induction	0	0.12042845	0	
463	797	377	change in EPIC urinary HRQOL domain summary score at 3 months after the completion of RT (ΔEPIC-U 3mo )	EPIC urinary HRQOL at 3 months	1	0.790618	1	
71	396	802	the validated HCPI	the HCPI	1	0.83923507	1	
458	1519	659	PASI-75	the DLQI	0	0.0	0	
433	978	485	response rate based on a 20% improvement in WOMAC pain scores	WOMAC	1	0.57822603	1	
79	126	834	changes in pain as measured on a verbal rating scale from 0 to 10 during a flexion-extension range of motion evaluation and changes in disc height as measured on CT scans	low back pain	0	0.54306924	1	
85	1103	959	global quality of life change at 6-weeks, measured by EORTC QLQ-C30	quality of life	1	0.58336926	1	
652	1962	878	trough FEV 1 after 12 weeks of treatment (average of the 23 h 10 min and 23 h 45 min post-dose values assessed on the morning of Day 85)	Trough FEV 1 after one dose	1	0.6928425	1	
156	224	1065	'first-step' pain (measured on a 100 mm Visual Analogue Scale) and the Foot Health Status Questionnaire domains of foot pain, foot function and general foot health	foot function	0	0.68128467	1	
235	1965	197	the incidence of IR	Incidence of IR	1	0.7045	1	
450	706	138	changes between baseline and nine months of bone mineral density (BMD) of the proximal femur and lumbar spine (dual-energy X-ray absorptiometry) and serum markers of bone resorption and formation	anterior-posterior sway range	0	0.21120892	0	
74	1092	765	malaria incidence during the study period	The mean (standard deviation) haemoglobin concentration at the end of the malaria transmission season	0	0.68343335	1	
359	1436	649	gastric emptying T half	appetite	0	0.1845983	0	
114	166	350	the percentage of patients who reached 25(OH)D levels of 30 ng/ml or above on day 7	total serum calcium levels	0	0.45520917	1	
333	1418	261	FEV 1 (% predicted) in the two groups at 1, 5, 15, 30, 60 min after administration of the study drug	FEV1 (% predicted)	1	0.26156878	0	
687	1833	1069	IPV (Composite Abuse Scale CAS) and depression (Edinburgh Postnatal Depression Scale EPDS)	proportions of women with CAS scores ≥7	0	0.29252338	0	
602	920	439	change of lower leg volume, determined by water replacement plethysmometry	advanced CVI (Grade II and IIIa)	0	0.17965727	0	
175	257	1081	adherence	participation	0	0.32243946	0	
769	1986	1045	daily physical activities (measured by a validated tri-axial accelerometer)	the daily physical activity pattern	1	0.7238954	1	
191	1271	83	change in nutrition knowledge scores, attitudes to healthy eating and acceptability of the intervention by children and teachers	nutrition knowledge	0	0.6300543	1	
748	1931	636	 attitudes towards EBM; personal application and current use of EBM; EBM knowledge; future use of EBM	effective	0	0.25833213	0	
444	1502	1098	sUA < 6.0 mg/dL at final visit	sUA	1	0.50880635	1	
633	945	779	the proportion of children aged 9-23 months completely vaccinated	The proportion of children in the target age groups who received IPTi with each of the 3 vaccinations DTP2, DTP3 and Measles	0	0.741182	1	
34	1052	15	Correlation between VPW measurements from the portable chest radiograph with the PAOP	PAOP	0	0.0	0	
159	1394	628	the cure-markedly effective rate	adverse events	0	0.22653066	0	
609	928	391	child body mass index (BMI) z-score	parent BMI	0	0.37485608	0	
390	632	215	Physical Function	Physical Function	1	0.99999994	1	
273	1506	344	The observed change on the RDQ	patient's main complaints	0	0.265747	0	
506	782	950	the mean time to onset of the first 24-h heartburn-free period after initial dosing	safety	0	0.16485699	0	
211	378	276	the duration of the weaning process	The mean ± sd (standard deviation) duration of the weaning process	1	0.79489416	1	
634	945	781	the proportion of children aged 9-23 months completely vaccinated	coverage of EPI vaccines	0	0.37888438	0	
582	1671	182	the GSRS subscores for abdominal pain, distension, and flatus; and the SODA subscores for bloating and gas	GSRS abdominal pain subscore	0	0.50530434	1	
387	1697	712	"the change in IOP from baseline to week 4 at 8 a.m. and 4 p.m. for the per protocol (PP) population using a ""worse eye"" analysis"	Mean baseline IOP levels	0	0.39612347	0	
606	1719	704	the occurrence of any surgical-site infection within 30 days of surgery	The overall rate of surgical-site infection	1	0.5279517	1	
442	695	671	an ASAS40	all disease activity parameters	0	0.099355504	0	
759	1938	545	reduction in duration of severe pneumonia and pneumonia	stridor	0	0.4375157	1	
416	1489	1064	PCR-corrected adequate clinical and parasitological response (ACPR) on day 28	liver enzymes	0	0.20402685	0	
403	1483	184	the Premature Infant Pain Profile (PIPP ) 48 49	PIPP scores	1	0.19245017	0	
4	0	1010	the horizontal VAS according to Jensen	the probability of acceptable cost-effectiveness	0	0.5075722	1	
348	1428	539	pedometer step counts (Omron HJ-109E Step-O-Meter)	step counts	1	0.85013276	1	
433	1494	47	Number of headache days over a 12 week period (item A MIDAS questionnaire)	impact on daily life of migraine like headaches	0	0.3853605	0	
733	1886	167	a sub-microscopic parasite carriage of ≥ 30% 28	Three clinical malaria episodes	0	0.3501336	0	
740	1898	1085	3 types of acute-care services, defined as hospitalizations, partial hospitalizations, and visits to emergency departments (EDs)	an average duration of 100 days before such treatment alterations	0	0.58367413	1	
314	1372	821	myocardial infarction	all cause death	0	0.1323703	0	
291	1346	229	body mass index (BMI) percentile	BMI	1	0.40678975	1	
559	861	932	changes in lifestyle according to established goals	drop-out rate	0	0.22942288	0	
471	728	398	Mobilization status as assessed by the 4-item abbreviation of the Barthel index, focusing on lower extremity motoric function	pain as measured using the VAS	0	0.7355915	1	
703	1839	1028	normalization of stool consistency	Improvement of hard stool consistency to soft stool consistency	1	0.7901869	1	
364	1440	657	healing at 3 months	healing rates	1	0.48103955	1	
184	1270	549	90-day mortality	Hemodynamic stability	0	0.26945624	0	
660	984	321	improvement in oxygenation (improvement of PaO 2 /FiO 2 (PF) ratio)	mechanical ventilation	0	0.21459317	0	
395	1479	599	safety climate, measured using the Safety Climate Survey	the mean safety climate scores	1	0.6483374	1	
387	631	361	The mean decrease in Young Mania Rating Scale score from baseline	the frequency of side effects	0	0.49380788	1	
519	1591	114	ICP control	effective	0	0.13250391	0	
234	399	1099	biochemically verified 7-day point prevalence smoking abstinence defined as no cigarettes (not even a puff) in the previous 7 days at Week 26, validated using salivary cotinine collected at Week 26	a mean serum cotinine	0	0.4919542	1	
300	1361	696	i) cognitive functioning, as measured by the ADAS-Cog, a 0–70 point scale with a higher score indicating worse cognition; and ii) quality of life, rated by the participant and their nominated carer, as measured by the QOL-AD, both 13-item scales, scoring between 13 and 52 points with a higher score indicating better quality of life	the ADAS-Cog score	0	0.721657	1	
342	941	304	the Gastrointestinal Symptom Rating Scale-IBS version (GSRS-IBS) 42	the IBS-related outcome scales	0	0.42113486	1	
595	1707	535	CR	fatigue	0	0.09162363	0	
605	1717	365	suspension days during the four-month pretest period prior to randomization compared with the four-month intervention period	suspension rates	1	0.39992255	0	
526	813	299	the 11-point NRS in patients' daily pain diaries	velocity	0	0.17761925	0	
69	396	800	the validated HCPI	HCPI	1	0.5712614	1	
413	652	942	systemic haemodynamics	BP	0	0.09083875	0	
166	237	611	Aberrant Behaviour Checklist-Community (ABC-C)	the CGI	0	-0.016926458	0	
289	493	405	self-rated overall effect of treatment, measured once; on the day treatment was completed	HAQ	0	0.17885475	0	
582	891	496	improved PFS for the maintenance phase	the PFS HR	1	0.63950646	1	
157	224	1066	'first-step' pain (measured on a 100 mm Visual Analogue Scale) and the Foot Health Status Questionnaire domains of foot pain, foot function and general foot health	an adverse event	0	0.29282796	0	
64	108	799	force platform variables PVF and impulse, the HCPI and rescue NSAIDs	happier	0	0.042785335	0	
623	935	55	global perceived effect (GPE) and the impact of the headache using the Headache Impact Test (HIT-6)	headache complaints	0	0.3669521	0	
531	1610	301	improvement in attention scores for the intervention group	behaviour	0	0.0	0	
323	528	1019	GHbA1c	measures of insulin sensitivity	0	0.0	0	
482	763	1059	success at quitting (expired CO ≤ 9 ppm), the dose of NRT used, and the rating of withdrawal symptoms using the Mood and Symptoms Scale	The discomfort caused by the beads	0	0.5495751	1	
753	1936	55	Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	Mean parental CGI scores	1	0.40288496	1	
568	1656	1013	change in this composite from baseline at four months post-randomization	retention rates	0	0.22357383	0	
353	586	13	the American College of Rheumatology 20% improvement criteria (ACR20) response at week 24 19 20	RA-associated losses in productivity within and outside the home	0	0.5303199	1	
404	646	210	the EPDS (a 10-item scale developed for use in the postnatal period, in which a score ≥ 13 identifies probable depression 33 , and the physical and mental component scores (PCS and MCS) of the Short Form 36 (SF-36), a widely used general health status measure 34	depression	0	0.3429838	0	
175	257	1081	participation	participation	1	1.0000001	1	
701	1924	797	the anatomical knowledge (MCQ)	learning joint anatomy	1	0.5642103	1	
612	1723	507	response rate, survey response bias, item non-response, and cost	a response rate	0	0.73902804	1	
391	632	216	Physical Function	quality of life	0	0.0950434	0	
109	210	854	glycated hemoglobin A1c, body mass index (BMI), blood pressure, lipids and control criteria during the 2-year follow-up period	SBP	0	0.20306545	0	
555	859	961	blood pressure control	blood pressure	1	0.8799312	1	
238	1965	200	VS	the development of IR	0	0.10885088	0	
234	399	1099	biochemically verified 7-day point prevalence smoking abstinence defined as no cigarettes (not even a puff) in the previous 7 days at Week 26, validated using salivary cotinine collected at Week 26	a mean exhaled carbon monoxide	0	0.40421304	1	
119	1145	1057	the number of additional donors deferred by the HQ	a blood contact	0	0.24087965	0	
172	1912	967	knowledge of labour analgesia	informed of labour analgesia options	1	0.573808	1	
659	1962	886	trough FEV 1 after 12 weeks of treatment (average of the 23 h 10 min and 23 h 45 min post-dose values assessed on the morning of Day 85)	a safety and tolerability profile	0	0.18093853	0	
596	913	246	Apgar scores less than 8	caesarean birth	0	0.14194715	0	
88	133	161	HbA1c	HbA1c	1	1.0000001	1	
476	739	127	gingival bleeding	Prevalence of gingival bleeding at follow-up	1	0.8128435	1	
669	1942	759	patient satisfaction	satisfaction	1	0.7721184	1	
196	304	126	The median RTDI	long-term outcome	0	0.06532258	0	
500	1569	893	change in summary lifestyle score (Prudence Score) and individual health behaviours at three months	The Prudence Score (10 items)	0	0.28144085	0	
119	1145	1057	the number of additional donors deferred by the HQ	risk factor for HIV/AIDS or sexually transmitted infection	0	0.41837975	1	
356	1434	572	HbA 1c	cardiovascular distress	0	0.17815709	0	
190	288	365	the number of hospital days after surgery	costly	0	0.174643	0	
104	1128	945	time from the commencement of study drug to extubation	discontinued	0	0.23539223	0	
428	672	484	response rate to treatment	The response rates (20% reduction in WOMAC pain)	1	0.6894878	1	
245	1619	948	sucrose/pacifier effect on pain reduction	crying times	0	0.20602284	0	
378	884	261	ACR 50 improvement	the Disease Activity Score 28	0	0.23666161	0	
281	486	343	recurrence	The mean hospital stay	0	0.16274826	0	
706	1839	1032	defecation frequency > 3/week	defecation frequency	1	0.8299655	1	
466	1536	395	tube dependency at one-year	hospital admission days	0	0.2370452	0	
6	0	1012	the horizontal VAS according to Jensen	QALYs	0	0.2173048	0	
180	262	841	the determination of the perioperative concentration of IL-1β in the patient's peritoneal fluid	the local recurrence rate	0	0.63993186	1	
612	929	226	the percentage of days on which the prescribed dose of medication was taken, measured objectively over 12 weeks with an electronic medication-monitoring device (TrackCap, Aardex, Switzerland)	adherent days	1	0.46163142	1	
4	0	1010	the horizontal VAS according to Jensen	cost-effectiveness	0	0.0	0	
563	1827	869	patient outcome	unexpected deaths	0	0.1876512	0	
730	1882	217	whether or not a survey recipient responded	response rate	1	0.37080514	0	
65	108	800	force platform variables PVF and impulse, the HCPI and rescue NSAIDs	HCPI	0	0.41669464	1	
681	1812	681	duration of diarrhea (in hours) from onset and from admission until cessation of diarrhea (passage of soft/formed or no stools for two consecutive 8-hour periods), and the total stool weight in grams during hospitalization	the severity of diarrhea indicated by more than three episodes of some dehydration or any episode of severe dehydration after enrolment	0	0.8042499	1	
529	1610	299	improvement in attention scores for the intervention group	working memory	0	0.19573748	0	
681	1812	681	duration of diarrhea (in hours) from onset and from admission until cessation of diarrhea (passage of soft/formed or no stools for two consecutive 8-hour periods), and the total stool weight in grams during hospitalization	the amount of oral rehydration solution	0	0.597136	1	
137	1456	911	VC	efficacy	0	0.07476951	0	
276	1337	65	mortality at 30 days	crossover	0	0.013740603	0	
62	1082	390	the extent to which the Internet affected the participants' confidence in dealing with their LTC	rated themselves as experienced Internet users	0	0.49818465	1	
655	1962	881	trough FEV 1 after 12 weeks of treatment (average of the 23 h 10 min and 23 h 45 min post-dose values assessed on the morning of Day 85)	the percentage of days of poor control	0	0.56979346	1	
261	455	436	the generic instrument EuroQol-5D (EQ5D)	self-efficacy	0	0.0	0	
277	1337	66	cumulative survival without mechanical ventilation or oxygen dependency at 30 days; mortality at 30 days; therapy failure; crossover rate; and persisting pulmonary problems defined as oxygen dependency or still being on a ventilator at 30 days	mortality	0	0.39979702	0	
283	486	346	recurrence	the overall complication rate	0	0.33173424	0	
582	1671	182	distension	the GSRS total score	0	0.09287915	0	
535	814	650	to decrease reintubation rates, defined by the necessity of mechanical positive-pressure ventilation through orotracheal intubation in the first 48 hours after extubation, in the treatment group	Mean ICU length of stay after extubation	0	0.5670474	1	
320	1376	1084	The 6MWT	physical capabilities	0	0.20420727	0	
69	396	800	the use of rescue NSAIDs	all three scores in the comparative questionnaire (locomotion, every-day situations, and skin & coat)	0	0.45899004	1	
103	159	65	the mean change from pre-dose FEV 1 at 12 hours post dose	FEV 1	1	0.53666544	1	
302	1361	698	i) cognitive functioning, as measured by the ADAS-Cog, a 0–70 point scale with a higher score indicating worse cognition; and ii) quality of life, rated by the participant and their nominated carer, as measured by the QOL-AD, both 13-item scales, scoring between 13 and 52 points with a higher score indicating better quality of life	their cognitive functioning	0	0.46496367	1	
219	1284	689	the volume of blood loss between T1 and T4	bleeding duration	0	0.38319686	0	
241	406	265	a dichotomous measure (occurrence of low back pain)	smoking history	0	0.20934181	0	
130	1878	826	the 17-item HAM-D	sedation	0	-0.01141913	0	
96	141	192	coma recovery time	Time to regain consciousness	1	0.45451397	1	
662	1787	251	the initial rate of temperature decrease, expressed as °C/h and the percentage of time the temperature was out of range during the first 24 hours of treatment (defined as more than 0.2°C above or below target temperature)	efficient	0	0.17746654	0	
255	437	1079	comet assay	SOD	0	0.085589916	0	
97	1122	89	days alive and off assisted breathing	absolute FEV1	0	0.14699893	0	
621	1731	254	change from baseline in fasting serum total cholesterol	total cholesterol	1	0.67423284	1	
314	1372	821	target vessel revascularization (TVR)	cardiac death	0	0.3340873	0	
549	1630	589	the frequency of fussing and crying of the infants	feeding	0	0.29830968	0	
616	931	928	combined renal parameters	Interleukin-6	0	0.0	0	
709	1843	666	Weight-for-age Z-score	appetites	0	0.0	0	
158	224	1067	'first-step' pain (measured on a 100 mm Visual Analogue Scale) and the Foot Health Status Questionnaire domains of foot pain, foot function and general foot health	'first-step' pain	0	0.3293866	0	
647	974	282	the percent of subjects meeting TR during the initial 30 minutes of treatment	Median initial SBP	0	0.4163915	1	
596	913	246	instrumental birth	induction	0	0.19452485	0	
564	1647	178	bone densitometry and serum metal ion concentration	periprosthetic bone density loss	0	0.6505561	1	
376	624	262	the percentage of responders according to American College of Rheumatology 50 criteria	therapeutic responses	1	0.2612139	0	
313	1372	820	major adverse cardiac events (MACE) defined as a composite endpoint of cardiac death, myocardial infarction, and target vessel revascularization (TVR)	MACE rate	1	0.46485323	1	
232	389	481	comparison of the change from baseline to end of 12 weeks between simvastatin and fenofibrate	LDLP number	0	0.29740536	0	
525	1702	785	a difference in timing adherence between groups	Parkinson motor scores	0	0.28524444	0	
479	1601	401	costs per quality adjusted life years (cost/QALY)	ICERs	0	0.0	0	
404	646	210	the EPDS (a 10-item scale developed for use in the postnatal period, in which a score ≥ 13 identifies probable depression 33	depression	1	0.37738124	0	
168	237	613	the ABC Irritability subtest score	well-tolerated	0	0.0	0	
597	913	247	initiation of breastfeeding	likely to have continuous electronic fetal monitoring	0	0.28347677	0	
753	1936	55	changes compared to baseline observed after 4 weeks (40 sessions) of treatment, in parallel groups, on (1) Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating, (2) Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating, and (3) Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	Mean parental CGI scores	0	0.45744306	1	
372	607	578	log HbA 1c	mental HRQL	0	0.25044468	0	
415	652	944	systemic haemodynamics	acid-base status	0	0.013404153	0	
402	646	208	the EPDS (a 10-item scale developed for use in the postnatal period, in which a score ≥ 13 identifies probable depression 33	Women's mental health scores	0	0.36652255	0	
392	634	511	patient intention to visit a psychosocial counselor	intention to visit a psychosocial counselor	1	0.9311059	1	
264	1329	349	the percentage of children who had ≤ 4 days with pain	days with missed activities	0	0.6559292	1	
260	455	435	the generic instrument EuroQol-5D (EQ5D)	standing one leg eyes closed	0	0.2584439	0	
96	141	192	time to sit unsupported	Time to regain consciousness	0	0.23242396	0	
59	273	1004	Treatment Alliance Scale (TAS)	alliance	1	0.27774402	0	
109	210	854	blood pressure	systolic blood pressure (SBP) levels	1	0.8223864	1	
504	1573	888	the clinical and virological effects of zidovudine in combination with lamivudine	proviral load	0	0.369288	0	
634	945	781	the proportion of children aged 9-23 months completely vaccinated	coverage of the IPTi	0	0.48280948	1	
307	513	195	Early Treatment Failure (ETF); Late Clinical Failure (LCF); Late Parasitological Failure (LPF); Adequate Clinical and Parasitological Response (ACPR) 18	The mean parasite clearance time	0	0.23691504	0	
763	1979	930	an injury surveillance with a missed match injury definition	primary lower-limb muscle strains	0	0.31678882	0	
346	1428	536	pedometer step counts (Omron HJ-109E Step-O-Meter)	step-counts	1	0.0	0	
393	1476	612	whether the GP had provided patients with a written asthma action plan (WAAP yes/no)	ongoing management of infrequent episodic asthma	0	0.41346526	1	
594	1707	533	CR	complete response for acute nausea and vomiting	1	0.1379398	0	
19	420	1042	'success'	perforations	0	0.0	0	
193	304	120	the mean RTDI overall	overall survival (OS)	0	0.59289396	1	
390	632	215	WOMAC Pain	Social Functioning domains	0	0.27824432	0	
421	655	105	attitudes	scores in attitudes	1	0.6325314	1	
659	984	320	improvement in oxygenation (improvement of PaO 2 /FiO 2 (PF) ratio)	PEEP	0	0.16353525	0	
752	1936	54	changes compared to baseline observed after 4 weeks (40 sessions) of treatment, in parallel groups, on (1) Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating, (2) Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating, and (3) Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	mean physician CGI scores	0	0.47741354	1	
650	974	285	the percent of subjects meeting TR during the initial 30 minutes of treatment	Rescue medication need	0	0.2679461	0	
601	1713	238	the Team Check-up Tool (TCT)	responsiveness	0	0.12966849	0	
47	1808	333	the mean change in self-reported symptoms of depression as measured on the BDI	the overall recruitment yield	0	0.60185057	1	
423	1493	207	response rate	red cells collected	0	0.15415065	0	
241	1313	564	Asthma control	Daily inhaled corticosteroid dose	0	0.20304903	0	
600	1712	276	level at which dose limiting toxicity occurred	Dose limiting toxicity	1	0.6355559	1	
341	1421	164	the rate of acute gastrointestinal complications	the risk of renal involvement	0	0.62850845	1	
549	831	144	violent attitudes using the Total MVQ score	drop-out rate	0	0.32153583	0	
282	1339	857	improvement compared to baseline	symptoms	0	0.23374264	0	
706	1839	1032	defecation frequency > 3/week	softer stools	0	0.15933494	0	
165	1233	84	the maximum % fall in FEV 1 7 hours after the first AMP challenge	protective effect against AMP-induced bronchoconstriction	0	0.3575613	0	
15	420	1038	detection of bilateral aerated middle ears (confirmed with tympanometry) at two consecutive monthly visits	success	0	0.15740646	0	
721	1867	606	spontaneous preterm delivery between 34 and 37 weeks' gestation	The corresponding actual treatment figures	0	0.320447	0	
149	221	534	a difference of ≥ 20% in the microvascular flow index of small vessels among groups	sublingual microcirculatory blood flow	0	0.4642753	1	
336	546	558	the proportion of patients in each group with cardiovascular risk ≥ 10% over five-years at 12 months follow up	patient outcome	0	0.41252843	1	
449	1512	1050	more frequently interrupted MARS sessions without anticoagulation	bilirubin	0	0.1301639	0	
611	1721	806	the incidence of adverse events	unusual or unexpected adverse events	1	0.69513977	1	
225	1288	969	mortality	30-day mortality	1	1.0	1	
201	1273	122	the percentage of patients who had a CSTE	median platelet counts	0	0.33803886	0	
131	1163	191	the number of retrieved oocytes	the mean number of collected oocytes (primary endpoint)	1	0.8356358	1	
35	1059	1008	the self-reported benefit or achievement (usefulness)	experienced benefits of the cane	1	0.6327918	1	
597	913	247	postpartum haemorrhage	augmentation of labour	0	0.29009092	0	
110	210	855	body mass index (BMI)	BMI	1	0.3262909	0	
760	1938	546	reduction in duration of severe pneumonia and pneumonia	duration of hospital stay	0	0.5688565	1	
25	1039	154	intestinal volume	The VAS score for the occurrence of nausea due to abdominal distension	0	0.45652145	1	
153	223	831	change in weight from randomization (0-M) to 12 months post randomization	interaction between treatment and initial weight loss	0	0.5634847	1	
608	928	390	child body mass index (BMI) z-score	promoted PA (x 2 = 23.46, p < .001) and healthful eating	0	0.17538136	0	
182	1250	293	The frequency of acute exacerbation	environment domain	0	0.16665891	0	
54	105	787	a well-validated outcome measure for upper limb function and disability	the DASH questionnaire	0	0.37467465	0	
297	1356	304	the difference (Δ) between the VAS scores after treatment compared to pre-treatment VAS scores	The minor irritation of the teeth	0	0.5433205	1	
375	624	261	the percentage of responders according to American College of Rheumatology 50 criteria	swollen 28-joint count	0	0.18958905	0	
581	1668	768	the Freezing of Gait Questionnaire	cost effective	0	0.08918879	0	
587	891	501	improved PFS for the maintenance phase	safety profile	0	0.283694	0	
359	1436	649	gastric emptying T half	gastric emptying parameters	1	0.6495691	1	
174	1239	762	the change in test scores for residents and faculty (pre-test vs. post-test), and the difference in score improvement between the residents randomized to undergo proctored ultrasound examinations compared to those who were not	knowledge	0	0.1943141	0	
158	1394	627	the cure-markedly effective rate	the cure-markedly effective rates	1	0.9583453	1	
294	1350	1010	the maximum change in estimated glomerular filtration rate (eGFR) within 48 hours	The incidence of creatinine-based and cystatin C-based CIN	0	0.40899494	1	
166	1233	85	the maximum % fall in FEV 1 7 hours after the first AMP challenge	FEV 1	1	0.54626304	1	
391	632	216	WOMAC Pain	function	0	0.17615211	0	
760	1938	546	reduction in duration of severe pneumonia and pneumonia	treatment requiring 2 nd line of drug and 3 rd line drug	0	0.3415968	0	
202	343	968	change from baseline in body mass index (BMI)	body composition	0	0.50256026	1	
65	108	800	the HCPI	Quality of life VAS	0	0.2190009	0	
469	728	396	Mobilization status as assessed by the 4-item abbreviation of the Barthel index, focusing on lower extremity motoric function	the mobility as measured with the four-item Barthel index	1	0.8002671	1	
648	1782	883	Trough FEV 1 after 12 weeks of treatment	died	0	0.17054111	0	
682	1812	682	duration of diarrhea (in hours) from onset and from admission until cessation of diarrhea (passage of soft/formed or no stools for two consecutive 8-hour periods)	the duration of acute diarrhea	1	0.7161708	1	
546	1630	585	the frequency of fussing and crying of the infants	the infant's sleep	0	0.7018248	1	
453	707	1069	health-related quality of life (HRQoL)	mood	0	0.18666394	0	
73	1092	764	malaria incidence during the study period	a protective efficacy	0	0.31487158	0	
611	1721	806	the incidence of adverse events	safety concerns	0	0.29270205	0	
194	304	121	The median RTDI	Overall higher RTDI	1	0.4078992	1	
116	1142	233	percentage of labeled concentration in the bottles at the time of testing	The mean percentage of labeled concentration	1	0.67316765	1	
27	472	983	death from any cause, recurrent infarction and unstable angina within one year (per protocol and adjusted for 2 days PCI delay)	rate of recurrent ischemia	0	0.5961208	1	
551	1628	375	'TQ total score'	The primary efficacy criterion 'TQ total score'	1	0.5817247	1	
742	1898	1087	3 types of acute-care services, defined as hospitalizations, partial hospitalizations, and visits to emergency departments (EDs)	annual total health care costs per patient	0	0.49131402	1	
90	136	791	the hands-on time during the first three minutes of the cardiac arrest	leadership	0	0.20391089	0	
262	461	322	10-year CVD risk	Average population CVD risk	1	0.7894224	1	
767	1986	1042	daily physical activities (measured by a validated tri-axial accelerometer)	movement intensity	0	0.30368978	0	
316	523	957	morning peak expiratory flow after 4 weeks treatment	asthma quality of life score	0	0.2915644	0	
754	1936	56	changes compared to baseline observed after 4 weeks (40 sessions) of treatment, in parallel groups, on (1) Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating, (2) Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating, and (3) Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	hyperactivity	0	0.2076659	0	
550	1628	374	'TQ total score'	the treatment of chronic tinnitus	0	0.17942151	0	
79	126	834	changes in disc height as measured on CT scans	disc height	1	0.49142113	1	
322	528	1018	GHbA1c	serum cortisol levels	0	0.0	0	
419	655	103	knowledge	The knowledge level	1	0.63352793	1	
449	706	137	changes between baseline and nine months of bone mineral density (BMD) of the proximal femur and lumbar spine (dual-energy X-ray absorptiometry) and serum markers of bone resorption and formation	bone formation markers	0	0.7742754	1	
345	1423	361	differences in screening interest and patient test preferences between versions of the decision aid	test choice	0	0.52832943	1	
136	200	464	the change in serum methylmalonic acid (MMA) levels after one month of treatment	haematological signs of B12 deficiency	0	0.39315265	0	
364	1440	657	healing at 3 months	HRQL	0	0.119088344	0	
240	406	264	a dichotomous measure (occurrence of low back pain)	non smoker	0	0.22216488	0	
15	1034	39	changes in ADHD symptoms following treatment	comorbid problems	0	0.50180334	1	
104	159	66	the slope of decline in FEV 1 from 2 hours post-dose	FEV 1	1	0.6558656	1	
661	1787	250	the percentage of time the temperature was out of range during the first 24 hours of treatment (defined as more than 0.2°C above or below target temperature)	the target temperature	0	0.73107755	1	
219	1284	689	the volume of blood loss between T1 and T4	progression to severe PPH	0	0.33359015	0	
69	396	800	the use of rescue NSAIDs	PVF	0	-0.009379114	0	
741	1898	1086	3 types of acute-care services, defined as hospitalizations, partial hospitalizations, and visits to emergency departments (EDs)	crisis services	0	0.33263937	0	
140	1198	916	health care costs	non-study respiratory medications	0	0.45189044	1	
72	1092	763	malaria incidence during the study period	The incidence of clinical attacks of malaria	1	0.64797896	1	
22	1039	151	intestinal volume	Intestinal CO 2 gas volume before and after ESD	1	0.45880932	1	
274	467	451	reduction in systolic blood pressure, total cholesterol and estimated 10-year CVD risk	simpler	0	0.09923029	0	
35	1059	1008	the self-reported benefit or achievement (usefulness)	the self-reported benefits	1	0.7314612	1	
245	1619	948	sucrose/pacifier effect on pain reduction	heart rate	0	0.3302042	0	
408	1486	201	'total number of sand flies per trap per night' before and 5 months after intervention	sand fly densities	1	0.42289844	1	
557	1634	295	(1) the change in YBOCS score from baseline to endpoint and (2) the clinical global impression of improvement (CGI-I) at endpoint	being classified as responders	0	0.347438	0	
41	62	584	weight gain after eight weeks	the hematological profile	0	0.3124196	0	
596	913	246	induction of labour	caesarean birth	0	0.22531168	0	
276	1337	65	therapy failure	therapy failure	1	0.9999999	1	
87	1107	74	treatment preference	The mean (SD) number of weeks with satisfactory relief of symptoms	0	0.35116187	0	
154	1220	559	Total costs	TSK	0	0.049123723	0	
73	1092	764	malaria incidence during the study period	The incidence rate of malaria	1	0.6947637	1	
429	1821	208	participation in the Link-Up Study, through attendance at a biospecimen collection site to provide a blood sample and giving written consent to participate, including use of blood samples for genetic and other research	average biospecimen yield	0	0.51063764	1	
598	913	248	induction of labour	intervention during labour and delivery	0	0.24706796	0	
172	1912	967	knowledge of labour analgesia, decisional conflict (uncertainty regarding analgesia decision) and anxiety	considered the opinion of their care providers	0	0.39732987	0	
253	1321	873	the reduction in the number of tender points at 12 months with respect to baseline	EQ-VAS scale	0	0.22806817	0	
597	913	247	postpartum haemorrhage	likely to have continuous electronic fetal monitoring	0	0.22267501	0	
554	859	960	blood pressure control	body mass index	0	0.25450686	0	
686	1833	1068	IPV (Composite Abuse Scale CAS)	mean abuse scores	1	0.37882528	0	
599	1712	275	safety, tolerability and level at which dose limiting toxicity occurred	was still alive	0	0.26080996	0	
198	1272	1067	the difference in FMD between the two blends of supplements and placebo following a 2-hour oral glucose tolerance test (OGTT) after 8 weeks of treatment	weight	0	0.2787392	0	
326	1395	1006	the time to first SRE, including pathologic fracture, spinal cord compression, and the requirement for surgery or radiation therapy to bone	chest and pelvic metastases	0	0.4547169	1	
466	1536	395	tube dependency at one-year and number of post-CCRT hospital admission days	tube dependency	0	0.57348573	1	
314	1372	821	myocardial infarction	definite stent thrombosis	0	0.551812	1	
314	1372	821	myocardial infarction	myocardial infarction	1	1.0	1	
400	645	542	the temperature difference between the CRPS affected and the contralateral limbs	pain	0	0.335233	0	
438	682	590	trial feasibility, defined by randomization of >25% of eligible patients, delivery of >75% of the prescribed CRRT dose, and follow-up of >95% of patients to 60 days	Mortality	0	0.285011	0	
269	1333	355	sexual activity	the burden of kidney disease on sex life	0	0.39983493	0	
484	1541	597	ETDRS visual acuity recorded in the laboratory, supplemented with a number of secondary lab-based visual function measures	the efficacy	0	0.5800984	1	
208	368	837	the mean change in modified extrinsic tooth stain index (all sites) from baseline to week 6	lightening	0	0.18565704	0	
300	1361	696	quality of life, rated by the participant and their nominated carer, as measured by the QOL-AD, both 13-item scales, scoring between 13 and 52 points with a higher score indicating better quality of life	the ADAS-Cog score	0	0.72501475	1	
336	1458	751	a significant difference in mean birth weight	an infant with a birth weight <10 th percentile	0	0.60896313	1	
687	1833	1069	IPV (Composite Abuse Scale CAS)	proportions of women with CAS scores ≥7	1	0.27481624	0	
679	1811	506	the overall between-patient variability around the mean time to neurological assessment	well tolerated	0	0.27678758	0	
152	1219	670	disease-free survival (DFS)	HDL levels	0	0.15306038	0	
343	1423	359	patient test preferences between versions of the decision aid	likely to choose colonoscopy	1	0.43857715	1	
596	913	246	caesarean birth	instrumental birth	0	0.61499923	1	
359	1436	649	gastric emptying T half	oxidative stress	0	0.25439766	0	
481	763	1058	success at quitting (expired CO ≤ 9 ppm), the dose of NRT used, and the rating of withdrawal symptoms using the Mood and Symptoms Scale	previous quit attempts	0	0.3988838	0	
14	26	342	the Sum of Pain Intensity Differences (SPID) of the CSTP Intensity scale by the child	pain	1	0.33333233	0	
421	655	105	attitudes	self-reported critical appraisal skills	0	0.24134776	0	
624	937	815	cure and severity of IAD	recovered completely from IAD	0	0.4188965	1	
437	682	589	trial feasibility, defined by randomization of >25% of eligible patients, delivery of >75% of the prescribed CRRT dose, and follow-up of >95% of patients to 60 days	SOFA	0	0.088154085	0	
596	913	246	induction of labour	postpartum haemorrhage	0	0.16905215	0	
672	1802	1021	The throughput times length of ED stay (LOS)	These throughput times	1	0.6768769	1	
734	1886	169	a sub-microscopic parasite carriage of ≥ 30% 28	transmission intensity	0	0.24676521	0	
506	1577	818	the average FEV 1 from the first intake of study drug to the measurement at 90 minutes	patient assessment of medication effectiveness	0	0.39012098	0	
373	613	989	time-to-full recovery	time-to-full recovery	1	0.9999998	1	
577	881	375	the overall discomfort reported during WC versus SC pH-metry	patient and caregiver time costs	0	0.32406643	0	
413	1489	1061	PCR-corrected adequate clinical and parasitological response (ACPR) on day 28	The fever clearance time	0	0.43232504	1	
426	1821	205	participation in the Link-Up Study, through attendance at a biospecimen collection site to provide a blood sample and giving written consent to participate, including use of blood samples for genetic and other research	participation rate ratio	0	0.41287065	1	
533	1617	177	the frequency of decision by the specialist to offer a follow-up outpatient appointment, patient satisfaction (Ware Specific Questionnaire), wellbeing (SF12) and enablement (PEI), numbers of tests, investigations, procedures and treatments	the patient selection criteria	0	0.72332805	1	
205	1273	126	the percentage of patients who had a CSTE	bone marrow blasts	0	0.2397128	0	
160	226	930	Moderate - Vigorous MET minutes of Physical Activity	systolic blood pressure	0	0.2492772	0	
212	1274	1039	the incidence of predefined GI AEs	The tolerability profile	0	0.40409243	1	
122	1150	620	the primary care practices' mean levels of HbA1c	likelihood of HbA1c tests being ordered	0	0.55770624	1	
722	1867	607	spontaneous preterm delivery between 34 and 37 weeks' gestation	spontaneous premature birth at < 37 weeks of gestation	1	0.6859814	1	
641	965	28	lung function	Leicester Cough Questionnaire mean difference	0	0.18288696	0	
180	262	841	the determination of the perioperative concentration of IL-1β in the patient's peritoneal fluid	the cancer-related death rate	0	0.6333081	1	
199	1273	120	the percentage of patients who had a CSTE	Del(5q) abnormalities	0	0.2515471	0	
111	210	856	glycated hemoglobin A1c, body mass index (BMI), blood pressure, lipids and control criteria during the 2-year follow-up period	SBP levels	0	0.4006552	1	
584	891	498	improved PFS for the maintenance phase	The median OS for the maintenance phase	0	0.8246368	1	
383	1454	37	the incidence of oxygen desaturations defined as a decrease in oxygen saturation ≥ 5%, assessed by continuous pulse oxymetry, at any time between the start of the induction sequence and two minutes after the completion of the intubation	failed first intubation attempts	0	0.47683322	1	
622	1731	255	change from baseline in fasting serum total cholesterol	these toxicity grades	0	0.39544156	0	
332	721	638	change in body weight and waist circumference	waist circumference reductions	0	0.71173906	1	
172	252	329	objective functional capacity, assessed using a 25 m walk test, a repeated chair rise test, and a stair climb test	Cross sectional area of the QFM	0	0.3051188	0	
98	1122	90	days alive and off assisted breathing	values for select pulmonary function tests	0	0.25532535	0	
81	1099	380	body weight	diet compositin	0	0.44128177	1	
725	1873	672	change in Treatment Satisfaction (Tables 5 and 6 ), change in Perceived Hyperglycaemia (Tables 7 and 8 ) and change in Perceived Hypoglycaemia (Tables 9 and 10 )	a Questionnaire × Ceiling interaction	0	0.25662503	0	
132	200	460	the change in serum methylmalonic acid (MMA) levels after one month of treatment	serum MMA levels	1	0.45191392	1	
592	896	411	PK parameters and safety and tolerability	tumor response	0	0.31518406	0	
402	646	208	the EPDS (a 10-item scale developed for use in the postnatal period, in which a score ≥ 13 identifies probable depression 33	EPDS score	1	0.50487	1	
609	928	391	child body mass index (BMI) z-score	related behavioral variables	0	0.28991017	0	
695	1834	797	The MC exam	the interest in surgery	0	0.30623117	0	
458	712	378	change in urinary HRQOL at 3 months	PSA nadir	0	0.30149952	0	
634	1762	5	time to azoospermia	time to severe oligozoospermia	0	0.70431715	1	
20	1035	1077	the parasite clearance rate constant K	The PCR-corrected adequate clinical and parasitological response (APCR) rates	0	0.5141658	1	
390	632	215	Physical Function	Role Physical	0	0.7122116	1	
106	1588	942	extubated	ICU length of stay	0	0.41566792	1	
237	1965	199	to test the effect of TA on the incidence of IR and VS in patients undergoing elective CPB	interleukin-6	0	0.0	0	
601	1713	238	the Team Check-up Tool (TCT)	The TCT	1	0.25875905	0	
310	1770	94	knee-specific patient-reported WOMAC scores	All revisions	0	0.17908548	0	
478	1601	400	costs per quality adjusted life years (cost/QALY)	probability of being cost-effective	0	0.25560644	0	
390	632	215	WOMAC Pain	Body Pain	0	0.68289053	1	
685	1816	853	pain and disability	social function	0	0.23421808	0	
761	1938	547	reduction in duration of severe pneumonia	hospital stay	0	0.39202073	0	
475	736	517	incidence of low back pain resulting in the seeking of health care	fear	0	0.3320777	0	
561	1646	746	the proportion of subjects who achieved targets for compression depth and compression rate	agreed that the video provided an adequate introduction to BLS skills	0	0.5671066	1	
759	1938	545	reduction in duration of severe pneumonia and pneumonia	The respiratory rate	0	0.5394228	1	
61	317	1002	the ORS scale	alliance	0	0.034637343	0	
613	929	227	the percentage of days on which the prescribed dose of medication was taken, measured objectively over 12 weeks with an electronic medication-monitoring device (TrackCap, Aardex, Switzerland)	treatment satisfaction	0	0.3700153	0	
180	1243	324	the change relative to baseline in the multiple sclerosis functional composite score (MSFC)	response	0	0.16382113	0	
12	26	340	the Sum of Pain Intensity Differences (SPID) of the CSTP Intensity scale by the child	the SPID of children and parents	1	0.50814044	1	
93	137	62	≥ Grade 2 (G2) toxicity incidence	V38	0	0.0	0	
752	1936	54	Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	receptive language	0	0.23622364	0	
452	707	1068	health-related quality of life (HRQoL)	mood state	0	0.1983613	0	
338	547	58	pain visual analogue scores	Therapy effect in the second period	0	0.3232405	0	
108	1588	944	extubated	underwent tracheostomy	0	0.5815256	1	
78	126	833	changes in pain as measured on a verbal rating scale from 0 to 10 during a flexion-extension range of motion evaluation and changes in disc height as measured on CT scans	an average duration of LBP	0	0.4750677	1	
485	1542	16	PVF	the PVF BW	1	0.6228836	1	
520	1591	115	ICP control	infection	0	0.1224972	0	
638	954	623	the serum phosphorus at 12 weeks	iPTH	0	0.320495	0	
453	707	1069	health-related quality of life (HRQoL)	HRQoL	1	0.32932636	0	
295	1350	1011	the maximum change in estimated glomerular filtration rate (eGFR) within 48 hours	cystatin C	0	0.25224403	0	
704	1839	1029	1) defecation frequency > 3/week; 2) normalization of stool consistency; 3) no more painful defecation; 4) absence of abdominal or rectal palpable mass at physical examination	the presence of an abdominal or rectal mass	0	0.75591755	1	
104	159	66	the slope of decline in FEV 1 from 2 hours post-dose, the area under the FEV 1 curve (AUC) (0–24 hours) and the mean change from pre-dose FEV 1 at 12 hours post dose	FEV 1	0	0.627547	1	
244	1314	23	the assessment of treatment toxicity and tumor response as measured according to modified (volumetric) MacDonald's criteria 20	grade 4 toxicity	0	0.4266776	1	
618	932	920	PDSS	the PDSS	1	0.7420261	1	
121	179	454	the proportion of pregnant women who attended ANC with their partners at the subsequent antenatal visit	tested for HIV	0	0.46705687	1	
55	105	788	a well-validated outcome measure for upper limb function and disability	total extension deficit of operated digits	0	0.3331563	0	
508	783	1094	the onset of relief of dyspnoea, expressed as the change in Borg score 1 minute after study drug administration	Borg score	1	0.36759585	0	
208	1274	1035	the incidence of predefined GI AEs	The incidence of peripheral oedema	0	0.56733185	1	
26	1039	155	intestinal volume	total amount of CO 2 insufflation	0	0.3348932	0	
549	1630	589	the frequency of fussing and crying of the infants	sleep	0	0.34999198	0	
368	600	34	patient-perceived recovery (PPR) 10	the outcome of SCs	0	0.1814539	0	
754	1936	56	Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating	speech	0	0.08354777	0	
372	607	578	log HbA 1c and HRQL	glycaemic control	0	0.13533229	0	
303	1362	92	Self-reported knee-specific stiffness, pain and function	completed the five and 10-year review	0	0.1366068	0	
596	913	246	relative risk	Apgar scores	0	0.28028464	0	
431	1494	45	Number of headache days over a 12 week period (item A MIDAS questionnaire)	the number of migraine like headaches	1	0.4872811	1	
519	808	490	time from induction to delivery and incidence of vaginal delivery within 12 and 24 hours	Caesarean section (CS) rate	0	0.42409176	1	
687	1833	1069	IPV (Composite Abuse Scale CAS)	physical wellbeing mean scores (PCS-SF36	0	0.29116133	0	
158	224	1067	foot pain	'first-step' pain	0	0.7538982	1	
100	1128	941	time from the commencement of study drug to extubation	median time to extubation	1	0.69960266	1	
516	1584	646	whether or not the ulcer was completely healed within 8 weeks	Complete healing of stage II ulcer	0	0.41243413	1	
346	1428	536	pedometer step counts (Omron HJ-109E Step-O-Meter)	steps/day	0	0.0	0	
397	636	469	28-day all-cause mortality	the rate of ICU-acquired infections	0	0.42534736	1	
570	1656	1017	change in this composite from baseline at four months post-randomization	retention	0	0.1624768	0	
77	428	680	change in BMD between pre-treatment and 16 weeks	progress toward bone healing	0	0.34839037	0	
619	1731	252	change from baseline in fasting serum total cholesterol	the mean total cholesterol	1	0.720753	1	
399	1481	40	Depressive symptoms	at least one form of health insurance	0	0.12252079	0	
512	792	415	Involuntary termination of a woman's pregnancy (miscarriage) and other fetal loss (eg stillbirth),	attended at least one session	0	0.2260523	0	
276	1337	65	crossover rate	therapy failure	0	0.22667667	0	
249	1619	952	sucrose/pacifier effect on pain reduction	inexpensive	0	0.11925302	0	
599	917	561	S-GGT	after-treatment serum Mg levels	0	0.0	0	
417	1489	1065	PCR-corrected adequate clinical and parasitological response (ACPR) on day 28	efficacy	0	0.4141876	1	
113	1988	944	time to extubation	successfully extubated	1	0.47606727	1	
233	1291	244	antimalarial drug prescription	reported symptoms	0	0.2329758	0	
18	420	1041	'success'	Beta-lactamase positive non-capsular H. influenzae (NCHi)	0	0.0	0	
432	1494	46	Number of headache days over a 12 week period (item A MIDAS questionnaire)	impact on daily life of migraines	0	0.31421322	0	
524	813	297	the 11-point NRS in patients' daily pain diaries	diabetes	0	0.20367977	0	
740	1898	1085	3 types of acute-care services, defined as hospitalizations, partial hospitalizations, and visits to emergency departments (EDs)	underwent a switch from their initial antipsychotic agent	0	0.43189648	1	
367	1444	134	the Premature Infant Pain Profile (PIPP) score in the first minute after skin puncture	PIPP scores	1	0.27698576	0	
490	1952	16	Kinetic force platform gait analysis (PVF BW )	the MA intensity	0	0.2646258	0	
596	913	246	initiation of breastfeeding	Apgar scores	0	0.09984984	0	
37	62	580	weight gain after eight weeks	the primary endpoint of the trial: weight gain after eight weeks	1	0.8454827	1	
440	695	669	an ASAS40	an ASAS40	1	1.0000001	1	
503	1573	887	the clinical and virological effects of zidovudine in combination with lamivudine	discontinued	0	0.23074678	0	
595	1707	535	CR	social functioning	0	0.053980142	0	
673	999	1032	Chlamydia screening rates	completed at least one module	0	0.15553506	0	
176	257	1082	adherence and participation	Participation	0	0.55907357	1	
149	1205	329	Rate of change in [Na]	[Na]	1	0.0	0	
587	1683	109	the clinical and laboratory adverse event profile and the effect of ferroquine on the cardiovascular system	well-tolerated	0	0.0	0	
162	1227	684	the ratio of expiratory time to reach PTEF to the total expiratory time	PTEF	0	0.0	0	
314	1372	821	major adverse cardiac events (MACE) defined as a composite endpoint of cardiac death, myocardial infarction, and target vessel revascularization (TVR)	definite stent thrombosis	0	0.6162321	1	
375	624	261	the percentage of responders according to American College of Rheumatology 50 criteria	patient's and physician's global assessments of disease activity	0	0.3446787	0	
259	448	1024	10-percentage point difference between arms in increase in the proportion of participants reaching the target level in five global and two patient-group specific clinical parameters at 12 months	waist circumference	0	0.22285412	0	
201	343	967	change from baseline in body mass index (BMI)	BMI	1	0.27573436	0	
527	1602	61	Changes in MMSE sum score	time trend differences	0	0.31325546	0	
150	1205	330	Rate of change in [Na]	serum sodium	0	0.06327204	0	
168	237	613	Aberrant Behaviour Checklist-Community (ABC-C)	well-tolerated	0	0.0	0	
111	210	856	glycated hemoglobin A1c, body mass index (BMI), blood pressure, lipids and control criteria during the 2-year follow-up period	the compliance in all the control criteria, except for LDL cholesterol	0	0.6274337	1	
341	1421	164	the rate of acute gastrointestinal complications	the risk of acute gastrointestinal complications	1	0.9231174	1	
78	1099	377	body weight	HDL	0	0.24728507	0	
759	1938	545	reduction in duration of severe pneumonia and pneumonia	fever	0	0.3855092	0	
565	861	940	changes in lifestyle according to established goals	inclusion	0	0.22546342	0	
315	1373	699	overall success	improved performance	0	0.5853918	1	
238	399	1103	biochemically verified 7-day point prevalence smoking abstinence defined as no cigarettes (not even a puff) in the previous 7 days at Week 26, validated using salivary cotinine collected at Week 26	the feasibility of recruiting and enrolling African American light smokers into a clinical treatment trial involving biological data collection and genetic analyses	0	0.54199994	1	
730	1882	217	whether or not a survey recipient responded	associated costs	0	0.20594077	0	
363	625	386	self-reported withdrawal symptom severity during the detoxification period	urine samples negative for opiates	0	0.44458392	1	
520	808	491	time from induction to delivery and incidence of vaginal delivery within 12 and 24 hours	neonates were admitted to the intensive neonatal unit	0	0.51118845	1	
605	924	821	unexpected ocular or systemic findings, adverse event rate, and temporary and permanent discontinuation	a line of visual acuity (VA)	0	0.29987106	0	
17	420	1040	detection of bilateral aerated middle ears (confirmed with tympanometry) at two consecutive monthly visits	the proportion of examinations with penicillin non-susceptible (MIC > 0.1 microg/ml) pneumococci	0	0.5043202	1	
461	712	381	change in urinary HRQOL at 3 months	urinary HRQOL	1	0.5516366	1	
354	586	14	the American College of Rheumatology 20% improvement criteria (ACR20) response at week 24 19 20	productivity	0	0.16291153	0	
146	221	531	a difference of ≥ 20% in the microvascular flow index of small vessels among groups	acid-base homeostasis	0	0.26397038	0	
252	437	1076	comet assay	Plasma superoxide dismutase (SOD) activity after the 8-week KRG supplementation	0	0.33451757	0	
111	210	856	glycated hemoglobin A1c	the compliance in all the control criteria, except for LDL cholesterol	0	0.25885212	0	
521	1591	116	ICP control	controlling intracranial hypertension refractory to first-tier measures	0	0.4129122	1	
158	224	1067	general foot health	foot function	0	0.48343992	1	
555	1631	517	The proportion of recurrent parasitaemia's during the 4-week follow-up	parasite clearance time	0	0.28037542	0	
576	881	374	the overall discomfort reported during WC versus SC pH-metry	tolerated	0	0.1225842	0	
173	1239	760	the change in test scores for residents and faculty (pre-test vs. post-test)	test scores (out of a 24 point test)	1	0.60652894	1	
705	1839	1031	normalization of stool consistency	stool consistency	1	0.8506285	1	
225	389	474	comparison of the change from baseline to end of 12 weeks between simvastatin and fenofibrate	large LDLP	0	0.17347118	0	
188	1271	80	change in nutrition knowledge scores	Total nutrition knowledge score	1	0.688306	1	
270	1457	353	the proportion of patients who reported being sexually active at six months compared to randomization	the extent to which people were bothered by the impact of kidney disease on their sex life	0	0.6949677	1	
341	1421	164	the rate of renal involvement at one year and the rate of acute gastrointestinal complications	the risk of renal involvement	0	0.7570126	1	
427	1821	206	participation in the Link-Up Study, through attendance at a biospecimen collection site to provide a blood sample and giving written consent to participate, including use of blood samples for genetic and other research	The response rate	1	0.38215014	0	
690	1834	789	The MC exam	the anatomical MC exam	1	0.74009037	1	
139	206	521	OMAS	OMAS	1	1.0000001	1	
303	512	625	the reduction in systolic blood pressure defined as the average of 3 office readings with the patient in the sitting position	24-h diastolic BP	0	0.2953629	0	
634	1762	5	time to azoospermia	failures based on semen analysis	0	0.26179105	0	
298	1356	306	the difference (Δ) between the VAS scores after treatment compared to pre-treatment VAS scores	The number of patients taking analgesics for post-treatment pain	0	0.5916883	1	
117	170	133	The frequency, duration and severity of exacerbations	severity	0	0.7131698	1	
403	646	209	the EPDS (a 10-item scale developed for use in the postnatal period, in which a score ≥ 13 identifies probable depression 33 , and the physical and mental component scores (PCS and MCS) of the Short Form 36 (SF-36), a widely used general health status measure 34	PCS	0	0.23168805	0	
658	1962	884	trough FEV 1 after 12 weeks of treatment (average of the 23 h 10 min and 23 h 45 min post-dose values assessed on the morning of Day 85)	QTc	0	0.33352107	0	
613	1723	508	response rate, survey response bias, item non-response, and cost	response rate	0	0.73902804	1	
99	155	783	fear of falling, avoidance of activity, and daily activity	favourable opinion of this	0	0.23111106	0	
384	627	317	the ovicidal effect of the treatments, defined as no nymphal lice emerging from eggs between treatments	eggs	0	0.33786622	0	
552	839	108	the comparison of sensitivity and specificity of perfusion-CMR to detect CAD on CXA vs SPECT based on a single-point threshold reading	the diagnostic performance	0	0.6250826	1	
255	1322	223	the Glasgow Outcome Scale score 3 months after brain injury	The mortality rate	0	0.38554358	0	
360	1436	650	gastric emptying T half	total omega-3 intake	0	0.3191855	0	
390	632	215	WOMAC Pain, Physical Function and Total scores	Physical Function	0	0.76203555	1	
117	170	133	duration	duration of exacerbations	1	0.7958003	1	
235	399	1100	biochemically verified 7-day point prevalence smoking abstinence defined as no cigarettes (not even a puff) in the previous 7 days at Week 26, validated using salivary cotinine collected at Week 26	smoked within 30 minutes of waking	0	0.5059256	1	
628	942	202	the EQ-5D utility	the mean treatment cost per patient	0	0.47655287	1	
268	464	972	a change in the serum ALT activity or the INR	international normalized ratio	0	0.3639089	0	
375	624	261	the percentage of responders according to American College of Rheumatology 50 criteria	the Disease Activity Score 28	0	0.43481734	1	
596	913	246	induction of labour	instrumental birth	0	0.19452485	0	
194	304	121	The median RTDI	a shorter TTDP	0	0.15231599	0	
596	913	246	caesarean birth	induction	0	0.22531168	0	
329	1402	129	the patient assessment of spinal pain (100-mm VAS), patient global assessment of disease activity (100-mm VAS), and the Bath Ankylosing Spondylitis Functional Index (100-mm VAS)	pain	0	0.4887436	1	
610	928	392	child body mass index (BMI) z-score	moderate	0	0.17950535	0	
596	913	246	caesarean birth	episiotomy	0	0.56663674	1	
449	706	137	serum markers of bone resorption and formation	bone formation markers	1	0.8912266	1	
674	999	1034	Chlamydia screening rates	participation rates	0	0.53528553	1	
666	1790	1025	severity of mental health symptoms measured using the Hospital Anxiety and Depression Scale (HADS) 23	total costs	0	0.26057056	0	
708	1843	665	Weight-for-age Z-score	satisfaction with teeth	0	0.0	0	
3	1001	386	the average efficacy over Seasons 1 and 2 for the prevention of culture-confirmed influenza illness due to influenza A or B virus strains antigenically matching those in the vaccine (ie vaccine-matched, culture-confirmed influenza; VMCCI)	immune response	0	0.28427914	0	
172	1912	967	knowledge of labour analgesia	considered the opinion of their care providers	0	0.2877199	0	
169	1912	964	anxiety	anxiety	1	1.0	1	
553	1631	514	The proportion of recurrent parasitaemia's during the 4-week follow-up	recurrent parasitaemias	1	0.54887897	1	
324	534	863	response rates	responded with identical rates	1	0.5444432	1	
391	632	216	Physical Function	pain	0	0.1270003	0	
480	1541	593	ETDRS visual acuity recorded in the laboratory, supplemented with a number of secondary lab-based visual function measures	VA	1	0.13150942	0	
578	1660	642	The number of destroyed alveolar attachments, expressed as a percentage over the total number of alveolar attachments,	alveolar attachments	1	0.32427585	0	
595	1707	535	CR	global health status	0	0.04345565	0	
341	1421	164	the rate of renal involvement at one year and the rate of acute gastrointestinal complications	the risk of acute gastrointestinal complications	0	0.77665657	1	
724	1867	609	spontaneous preterm delivery between 34 and 37 weeks' gestation	The efficacy of the tested probiotics to prevent preterm delivery among women without a history of preterm delivery	1	0.6534947	1	
692	1834	794	The MC exam	The final examination (OSCE)	0	0.63976675	1	
64	1083	49	changes in the HDRS, ATYP and the SIGH-SAD-SR over the 8-week study period	responders on the HDRS	0	0.6680458	1	
602	1717	362	changes in absenteeism, school rule infractions and suspension days during the four-month pretest period prior to randomization compared with the four-month intervention period	absentee periods	0	0.48571947	1	
51	102	825	pulmonary or cardiac toxicity	long-term recovery from fatigue	0	0.29003498	0	
543	830	220	the change in morning peak expiratory flow (PEF) rate from baseline to the end of the treatment period (mean of weeks 23–24)	PEF	1	0.0554942	0	
277	475	666	the shortened version of the Chedoke Arm & Hand Activity Inventory (CAHAI-7)	all responses	0	0.23887163	0	
345	1423	361	patient test preferences between versions of the decision aid	test choice	1	0.55902964	1	
123	179	456	the proportion of pregnant women who attended ANC with their partners at the subsequent antenatal visit	couple antenatal clinic attendance	1	0.537751	1	
303	512	625	the reduction in systolic blood pressure defined as the average of 3 office readings with the patient in the sitting position	systolic office BP	1	0.42438483	1	
280	485	845	time to catheter association blood stream infection	Flow issues requiring catheter removal	0	0.4832974	1	
276	1337	65	crossover rate	crossover	1	0.74208844	1	
113	166	349	the percentage of patients who reached 25(OH)D levels of 30 ng/ml or above on day 7	25(OH)D level	1	0.49354866	1	
83	1103	957	global quality of life change at 6-weeks, measured by EORTC QLQ-C30	two toxic deaths	0	0.24107702	0	
183	1270	548	90-day mortality	The primary outcome measure, 90-day mortality,	1	0.14434704	0	
264	461	325	10-year CVD risk	Prevalence of central obesity	0	0.3658558	0	
439	1852	632	(1) anti-malarial consumption recorded from routine statistics in ledger books of all HF before and after intervention; (2) anti-malarial prescription recorded during observed consultations in cross-sectional surveys conducted in all HF before and 18 months after m RDT implementation	the proportion of patients receiving anti-malarial treatment	0	0.50031585	1	
415	652	944	systemic haemodynamics	haemodynamics	1	0.0	0	
543	830	220	the change in morning peak expiratory flow (PEF) rate from baseline to the end of the treatment period (mean of weeks 23–24)	the use of rescue medication	0	0.6043118	1	
53	1074	836	the proportion of patients with plasma HIV-1 RNA levels <200 copies/mL at week 24	frequency of drug-related grade 1–4 adverse events	0	0.41276762	1	
302	507	875	the change from baseline to 52 weeks of carotid arterial wall volume, reflecting plaque burden, as measured by carotid cardiovascular magnetic resonance	progression of carotid atheroma	1	0.6552497	1	
69	396	800	the use of rescue NSAIDs	HCPI	0	0.0011067726	0	
251	424	548	The Insomnia Severity Index (ISI) 32	effective	0	0.118676625	0	
2	1001	385	the average efficacy over Seasons 1 and 2 for the prevention of culture-confirmed influenza illness due to influenza A or B virus strains antigenically matching those in the vaccine (ie vaccine-matched, culture-confirmed influenza; VMCCI)	immune responses	0	0.31787342	0	
420	655	104	attitudes, knowledge and skills in EBM	a knowledge score	0	0.59433365	1	
448	1512	1049	more frequently interrupted MARS sessions without anticoagulation	the likelihood of completed MARS treatment	1	0.5379571	1	
388	632	213	WOMAC Pain, Physical Function and Total scores	VAS pain	0	0.33151728	0	
582	1671	182	the GSRS subscores for abdominal pain, distension, and flatus; and the SODA subscores for bloating and gas	the GSRS abdominal distension subscore	0	0.6642359	1	
491	768	1093	peak systolic and end-diastolic blood flow velocities in the short posterior ciliary artery (SPCA) under the new therapy	hemodynamics in the short posterior ciliary arteries	1	0.8718426	1	
761	1938	547	reduction in duration of severe pneumonia and pneumonia	duration of severe pneumonia	0	0.9036038	1	
158	224	1067	general foot health	foot pain	0	0.46261367	1	
160	226	930	Moderate - Vigorous MET minutes of Physical Activity	body mass index	0	0.26509127	0	
390	632	215	Total scores	Total dimensions	1	0.58898336	1	
466	797	380	change in EPIC urinary HRQOL domain summary score at 3 months after the completion of RT (ΔEPIC-U 3mo )	biopsy-proven local failure	0	0.2607494	0	
98	141	194	coma recovery time; time to sit unsupported, begin oral intake; duration of hospitalization; death and adverse effects	clinical outcome of cerebral malaria	0	0.47780776	1	
541	1618	589	crying	sleep	0	0.31505677	0	
219	383	994	PCR-adjusted 42-day cure rates after starting treatment	The median parasite clearance time	0	0.38764217	0	
284	1341	743	shoulder mobility, shoulder and arm function and pain	pain	0	0.5908655	1	
371	607	577	log HbA 1c and HRQL	physical HRQL	0	0.5744586	1	
73	112	1072	claim duration (in days) during 12 months follow-up	pain improvement at 6 months	0	0.46419594	1	
729	1882	216	whether or not a survey recipient responded	likely to respond	1	0.5803335	1	
545	830	222	the change in morning peak expiratory flow (PEF) rate from baseline to the end of the treatment period (mean of weeks 23–24)	adverse events	0	0.27176937	0	
108	161	856	HbA1c	the compliance in all the control criteria, except for LDL cholesterol	0	0.2329583	0	
32	1052	12	Correlation between VPW measurements from the portable chest radiograph with the PAOP	VPW correlated with PAOP	1	0.611562	1	
452	707	1068	health-related quality of life (HRQoL)	forced expiratory volume in 1 second	0	0.1869234	0	
616	931	928	combined renal parameters	the urinary excretion of Kidney Injury Molecule-1 and Interleukin-18	0	0.39142385	0	
390	632	215	WOMAC Pain	WOMAC Pain	1	0.99999994	1	
607	928	389	child body mass index (BMI) z-score	opportunities for healthful eating and PA	0	0.18315105	0	
336	546	558	the proportion of patients in each group with cardiovascular risk ≥ 10% over five-years at 12 months follow up	prescribing intensity	0	0.33709762	0	
243	406	267	a dichotomous measure (occurrence of low back pain)	One year response rate	0	0.25644058	0	
107	161	855	HbA1c, lipid levels, blood pressure, BMI after 24 months of follow-up	BMI	0	0.5066055	1	
531	1610	301	improvement in attention scores for the intervention group	cognitive outcomes	0	0.31357887	0	
182	265	268	the precision of the final result set selected to answer the clinical question	precision scores for each question	1	0.6666449	1	
415	1489	1063	PCR-corrected adequate clinical and parasitological response (ACPR) on day 28	The proportion of children with gametocytes	0	0.42035502	1	
699	1924	795	the anatomical knowledge (MCQ)	spatial imagination	0	0.39980873	0	
321	528	1017	GHbA1c	depression	0	0.0	0	
12	26	340	the Sum of Pain Intensity Differences (SPID) of the CSTP Intensity scale by the child	the SPID reported by investigators	0	0.530067	1	
189	288	364	the number of hospital days after surgery	fluid based complications	0	0.31402045	0	
390	632	215	WOMAC Pain, Physical Function and Total scores	Vitality	0	0.26887125	0	
401	645	543	the temperature difference between the CRPS affected and the contralateral limbs	time spent standing, walking	0	0.35055882	0	
402	646	208	the EPDS (a 10-item scale developed for use in the postnatal period, in which a score ≥ 13 identifies probable depression 33 , and the physical and mental component scores (PCS and MCS) of the Short Form 36 (SF-36), a widely used general health status measure 34	MCS	0	0.21274146	0	
766	1979	933	an injury surveillance with a missed match injury definition	weeks missed due to non-contact knee injuries	0	0.6392275	1	
598	913	248	caesarean birth	intervention during labour and delivery	0	0.27027172	0	
255	437	1079	comet assay	DNA tail length	0	0.27417243	0	
752	1936	54	Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	social interaction	0	0.29045135	0	
460	1519	661	PASI-75	PGPA	0	0.0	0	
435	978	487	response rate based on a 20% improvement in WOMAC pain scores	Response rates	1	0.46805993	1	
445	1502	1099	sUA < 6.0 mg/dL at final visit	AE rates	0	0.18815938	0	
281	486	343	recurrence	the mean time to return work	0	0.1814195	0	
443	695	672	an ASAS40	the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score	0	0.13320924	0	
130	192	356	progression-free survival (PFS) per central radiology review, according to RECIST 15	an antitumor effect	0	0.3476404	0	
434	1496	906	1) physical activity, 2) work productivity, and 3) sickness absence	physical activity levels	0	0.50398874	1	
369	1444	137	the Premature Infant Pain Profile (PIPP) score in the first minute after skin puncture	Duration of cry	0	0.30333832	0	
590	896	409	PK parameters and safety and tolerability	Steady-state levels	0	0.23821704	0	
243	406	267	a dichotomous measure (occurrence of low back pain)	demographic characteristics	0	0.27382618	0	
158	224	1067	general foot health	'first-step' pain	0	0.1555748	0	
414	1489	1062	PCR-corrected adequate clinical and parasitological response (ACPR) on day 28	The parasite clearance time	0	0.45476574	1	
120	1150	618	the primary care practices' mean levels of HbA1c, cholesterol and BP, and numbers of patients with recorded foot inspections in the previous calendar month	diastolic BP	0	0.2562278	0	
247	408	80	the recovery rate, defined as the percentage of patients who had an adequate clinical and parasitological response (ACPR) after follow-up for 28 days	a parasite clearance time	0	0.458807	1	
680	1812	680	the total stool weight in grams during hospitalization	The mean duration of diarrhea from enrolment	0	0.5768788	1	
68	1085	863	the levels of inflammatory cells (neutrophils, eosinophils, macrophages, and lymphocytes) and epithelial cells in induced sputum	sputum eosinophils	0	0.62272966	1	
408	650	171	trough forced expiratory volume in one second (FEV 1 ) at 24 h post-dose after 14 days	onset of action (within 5 min) on the first day of dosing	0	0.7481732	1	
359	626	293	the intra-individual change in the total score of the Hamilton Rating Scale for Depression (HAM-D, 17-item version) between baseline and the end of the 6-week acute phase	The number of patients who experienced remission	0	0.4769124	1	
629	1745	1092	the cost of therapy per delivered baby, estimated according to a cost-minimization analysis	the delivery rate	0	0.6098665	1	
545	1630	584	the frequency of fussing and crying of the infants	large bowel movements	0	0.32497025	0	
320	528	1016	GHbA1c	sex-hormone-binding-globuline (SHBG) levels	0	0.0	0	
429	672	485	response rate to treatment	VAS scores	0	0.22348996	0	
439	1852	632	anti-malarial consumption recorded from routine statistics in ledger books of all HF before and after intervention	the proportion of patients receiving anti-malarial treatment	1	0.47661927	1	
445	695	674	an ASAS40	AEs	0	0.0030020026	0	
684	1816	852	disability	pain	0	0.28216222	0	
175	257	1081	participation	adherence	0	0.32243946	0	
161	1227	683	the ratio of expiratory time to reach PTEF to the total expiratory time	t PTEF / t E	1	0.16829905	0	
569	1656	1014	change in this composite from baseline at four months post-randomization	composite scores of cognitive, executive, and episodic memory function	0	0.37418148	0	
402	646	208	MCS	MCS	1	1.0	1	
641	965	28	lung function	Asthma Control Questionnaire mean difference	0	0.2653695	0	
342	1423	358	differences in screening interest	screening interest	1	0.7692609	1	
659	984	320	improvement in oxygenation (improvement of PaO 2 /FiO 2 (PF) ratio)	dynamic compliance	0	0.17395197	0	
35	1059	1008	1) the population reached (usefulness), 2) the self-reported benefit or achievement (usefulness), 3) experienced barriers and potential solutions the (usefulness), 4) the extent to which the intervention was performed according to protocol (acceptability), 5) participants’ exposure to and engagement in the training (acceptability), and 6) the opinion about the training (acceptability)	confidence in their capabilities	0	0.6404785	1	
70	396	801	impulse	force platform impulse	1	0.6598867	1	
36	1062	316	the comparison of the scores on the 12-Item Short-Form Health Survey (SF-12) and the Graded Chronic Pain Scale (GCPS) questionnaire for the two survey modes	missing data	0	0.32541862	0	
314	1372	821	cardiac death	all cause death	0	0.58069116	1	
493	1952	19	Kinetic force platform gait analysis (PVF BW )	technical validity	0	0.24157618	0	
161	226	931	Moderate - Vigorous MET minutes of Physical Activity	cost-effective	0	0.0	0	
457	712	377	change in urinary HRQOL at 3 months	EPIC urinary HRQOL at 3 months	1	0.8470932	1	
63	1082	391	the extent to which the Internet affected the participants' confidence in dealing with their LTC	Attrition	0	0.123699635	0	
159	226	929	the total MET minutes of moderate and vigorous physical activity accrued over the past 7 days	MET minutes of activity (from the IPAQ)	1	0.7674243	1	
199	332	115	NRS changes	acetaminophen	0	0.08784346	0	
492	1952	18	Kinetic force platform gait analysis (PVF BW )	MA duration	0	0.1881581	0	
321	1391	209	the proportion of delivered compressions within target depth compared over a 2-minute period within the groups and between the groups	CPR experience	0	0.2379644	0	
102	158	808	the mean number of detected polyps	the rate of patients with at least one adenoma	0	0.6602303	1	
610	928	392	child body mass index (BMI) z-score	sedentary	0	0.21554165	0	
101	1128	942	time from the commencement of study drug to extubation	ICU length of stay	0	0.37829813	0	
82	1103	956	global quality of life change at 6-weeks, measured by EORTC QLQ-C30	financial scores	0	0.35375586	0	
638	1762	9	time to azoospermia	These failure rates	0	0.2797847	0	
494	770	539	the time until shock reversal	IL-8	0	0.0	0	
276	1337	65	crossover rate	mortality	0	0.24819167	0	
19	1035	1076	the parasite clearance rate constant K	late clinical failure	0	0.3321326	0	
611	928	393	child body mass index (BMI) z-score	feasible	0	0.095022954	0	
274	1506	345	The observed change on the RDQ	satisfaction	0	0.23476686	0	
679	1811	506	the overall between-patient variability around the mean time to neurological assessment	haemodynamic profile	0	0.3090291	0	
355	586	15	the American College of Rheumatology 20% improvement criteria (ACR20) response at week 24 19 20	productivity changes	0	0.28598312	0	
750	1933	936	abstinence from illicit opiates at final prescription as indicated by a urine sample	provided a clean urine sample	1	0.55377907	1	
436	1496	909	1) physical activity, 2) work productivity, and 3) sickness absence	percentage of body fat	0	0.20696881	0	
182	1250	293	The frequency of acute exacerbation	duration of acute exacerbation	0	0.78636193	1	
487	765	691	The Shoulder Pain and Disability Index (SPADI) at 1 year follow-up	consistent predictor of pain and disability, and work status at 1 year follow-up	0	0.6388058	1	
640	1773	708	changes in the mean FEV 1	FEV 1	1	0.6282068	1	
396	636	468	28-day all-cause mortality	The ICU mortality	0	0.7098695	1	
141	1198	917	health care costs	utilization (89.7% of patients) with COPD visits	0	0.44102448	1	
585	1683	106	the clinical and laboratory adverse event profile and the effect of ferroquine on the cardiovascular system	at least one adverse event	0	0.6181077	1	
89	136	790	the hands-on time during the first three minutes of the cardiac arrest	hands-on time during the first 180 seconds of the arrest	1	0.95675933	1	
603	920	442	change of lower leg volume, determined by water replacement plethysmometry	quality of life	0	0.24143776	0	
689	1833	1071	IPV (Composite Abuse Scale CAS) and depression (Edinburgh Postnatal Depression Scale EPDS)	recommend mentors to friends	0	0.17658032	0	
684	1816	852	pain and disability	pain	0	0.80067545	1	
306	1362	96	Self-reported knee-specific stiffness, pain and function	knee-specific results	1	0.09253393	0	
598	913	248	induction of labour	safe	0	-0.025323892	0	
390	632	215	WOMAC Pain, Physical Function and Total scores	Total dimensions	0	0.5195916	1	
459	1519	660	PASI-75	DLQI	0	0.0	0	
537	1618	584	crying	large bowel movements	0	0.1061066	0	
466	1536	395	tube dependency at one-year and number of post-CCRT hospital admission days	hospital admission days	0	0.76572806	1	
96	1122	88	days alive and off assisted breathing	forced expiratory volume in 1 second (FEV 1	0	0.31372777	0	
561	861	934	changes in lifestyle according to established goals	aerobic capacity	0	0.20103972	0	
179	1243	323	the change relative to baseline in the multiple sclerosis functional composite score (MSFC)	MSFC score	1	0.38530424	0	
650	1782	886	Trough FEV 1 after 12 weeks of treatment	bronchodilation	0	0.37618497	0	
660	1787	249	the initial rate of temperature decrease, expressed as °C/h and the percentage of time the temperature was out of range during the first 24 hours of treatment (defined as more than 0.2°C above or below target temperature)	Temperature decline	0	0.33636197	0	
472	728	399	Mobilization status as assessed by the 4-item abbreviation of the Barthel index, focusing on lower extremity motoric function	implant position	0	0.2787105	0	
259	1328	269	DFS	the relapse risk	0	0.22392151	0	
24	1039	153	intestinal volume	blood ΔpH	0	0.26787382	0	
438	682	590	trial feasibility, defined by randomization of >25% of eligible patients, delivery of >75% of the prescribed CRRT dose, and follow-up of >95% of patients to 60 days	dialysis dependence in survivors	0	0.44916013	1	
623	935	55	the impact of the headache using the Headache Impact Test (HIT-6)	headache complaints	1	0.35951123	0	
139	1198	915	health care costs	COPD-related costs	1	0.61865276	1	
102	158	808	the mean number of detected polyps	the mean number of adenomas	0	0.88141185	1	
264	1329	349	the percentage of children who had ≤ 4 days with pain	the number of days with pain	1	0.82177514	1	
292	494	631	the disclosure rate of abuse by women who were identified by the VAWS tool during the three screening sessions compared to those in the interview group	IPV	0	0.15800188	0	
356	586	16	the American College of Rheumatology 20% improvement criteria (ACR20) response at week 24 19 20	work absenteeism	0	0.27143085	0	
239	1313	562	the primary process outcome	Overall monitoring adherence	0	0.2888747	0	
504	1573	888	the clinical and virological effects of zidovudine in combination with lamivudine	bladder function	0	0.217604	0	
278	1337	67	cumulative survival without mechanical ventilation or oxygen dependency at 30 days; mortality at 30 days; therapy failure; crossover rate; and persisting pulmonary problems defined as oxygen dependency or still being on a ventilator at 30 days	the OI response	0	0.37525022	0	
546	830	223	the change in morning peak expiratory flow (PEF) rate from baseline to the end of the treatment period (mean of weeks 23–24)	asthma control	0	0.29809827	0	
767	1986	1042	daily physical activities (measured by a validated tri-axial accelerometer)	sitting time	0	0.11472318	0	
4	1001	387	the average efficacy over Seasons 1 and 2 for the prevention of culture-confirmed influenza illness due to influenza A or B virus strains antigenically matching those in the vaccine (ie vaccine-matched, culture-confirmed influenza; VMCCI)	influenza seasons	0	0.5201893	1	
197	1272	1066	the difference in FMD between the two blends of supplements and placebo following a 2-hour oral glucose tolerance test (OGTT) after 8 weeks of treatment	endothelial function	0	0.2441773	0	
621	1731	254	change from baseline in fasting serum total cholesterol	HDL-cholesterol	0	0.0	0	
315	522	434	the QTcF interval (QT interval corrected for heart rate using Fridericia's formula, QT/RR 0.33 )	the QT interval	1	0.7321549	1	
114	166	350	the percentage of patients who reached 25(OH)D levels of 30 ng/ml or above on day 7	ionized calcium levels	0	0.3042919	0	
616	1723	511	item non-response	rate of item non-response	1	0.7447004	1	
257	1322	225	the Glasgow Outcome Scale score 3 months after brain injury	neurologic outcomes	0	0.4185831	1	
494	770	539	the time until shock reversal	E-selectin	0	0.0	0	
11	1028	403	the PCR-adjusted parasitological cure rate up to day 42 of the follow-up period	late clinical or parasitological failure	0	0.54121727	1	
181	1243	325	the change relative to baseline in the multiple sclerosis functional composite score (MSFC)	reported clinical response	0	0.32266295	0	
134	200	462	the change in serum methylmalonic acid (MMA) levels after one month of treatment	the B12 serum level	0	0.72321105	1	
526	813	299	the 11-point NRS in patients' daily pain diaries	amplitude	0	0.1564176	0	
427	985	1048	death from causes at study end (follow-up until at least 46 weeks after randomization)	risk of bleeding	0	0.29565474	0	
253	1321	873	the reduction in the number of tender points at 12 months with respect to baseline	FIQ score	0	0.2757651	0	
398	636	470	28-day all-cause mortality	The rate of hypoglycaemia (≤ 40 mg/dl)	0	0.38158	0	
596	913	246	Apgar scores less than 8	breastfeeding initiation	0	0.12002422	0	
2	1001	385	the average efficacy over Seasons 1 and 2 for the prevention of culture-confirmed influenza illness due to influenza A or B virus strains antigenically matching those in the vaccine (ie vaccine-matched, culture-confirmed influenza; VMCCI)	immunogenic	0	0.25106317	0	
423	1493	207	response rate	the median number of aliquots of plasma	0	0.3760955	0	
501	1569	894	change in summary lifestyle score (Prudence Score) and individual health behaviours at three months	fish intake	0	0.25475684	0	
478	739	129	gingival bleeding	the amount (millimetres) of calculus	0	0.1789064	0	
146	221	531	a difference of ≥ 20% in the microvascular flow index of small vessels among groups	sublingual microcirculatory variables	0	0.4350109	1	
119	173	182	the 15th percentile point	VI-950	0	0.0	0	
314	1372	821	major adverse cardiac events (MACE) defined as a composite endpoint of cardiac death, myocardial infarction, and target vessel revascularization (TVR)	cardiac death	0	0.5866949	1	
26	1039	155	intestinal volume	reduction of post-ESD intestinal CO 2 gas volume	1	0.6520995	1	
392	1476	611	whether the GP had provided patients with a written asthma action plan (WAAP yes/no)	able to assess the severity of asthma attack	0	0.6305072	1	
96	141	192	time to sit unsupported	time to start oral intake	0	0.5408662	1	
494	770	539	the time until shock reversal	TNF-α	0	0.0	0	
332	721	638	waist circumference	waist circumference	1	1.0	1	
184	277	0	change in score	less knowledge about diabetes	0	0.29213098	0	
111	210	856	control criteria during the 2-year follow-up period	glycated hemoglobin A1c	0	0.09345635	0	
528	813	301	the 11-point NRS in patients' daily pain diaries	responders	0	0.10575439	0	
609	928	391	child body mass index (BMI) z-score	child BMI z-score	1	0.5955193	1	
349	569	93	diarrhoea	HIV status	0	0.0	0	
453	707	1069	health-related quality of life (HRQoL)	lung function decline	0	0.23379862	0	
69	396	800	the validated HCPI	PVF	0	0.09477757	0	
596	913	246	Apgar scores less than 8	episiotomy	0	0.15944977	0	
643	1782	878	Trough FEV 1 after 12 weeks of treatment	Trough FEV 1 after one dose	1	0.8244801	1	
79	126	834	changes in pain as measured on a verbal rating scale from 0 to 10 during a flexion-extension range of motion evaluation	low back pain	1	0.5438984	1	
144	1200	0	Anthropometry at birth	birth length	1	0.564399	1	
248	408	81	the recovery rate, defined as the percentage of patients who had an adequate clinical and parasitological response (ACPR) after follow-up for 28 days	The overall efficacy	0	0.4905673	1	
48	82	1056	change in SBP and change in HOMA index, from week 0 (pre-treatment) to week 6	blood glucose	0	0.114872195	0	
603	1717	363	school rule infractions	infractions	1	0.6567727	1	
158	224	1067	'first-step' pain (measured on a 100 mm Visual Analogue Scale) and the Foot Health Status Questionnaire domains of foot pain, foot function and general foot health	foot pain	0	0.6099943	1	
744	1910	524	information satisfaction, anxiety during the screening process	desired more supportive information	0	0.4769332	1	
274	1506	345	The observed change on the RDQ	the self-rated treatment effectiveness	0	0.5583204	1	
663	990	952	the mean number of oocytes retrieved	efficacy responses	0	0.24895498	0	
35	1059	1008	1) the population reached (usefulness), 2) the self-reported benefit or achievement (usefulness), 3) experienced barriers and potential solutions the (usefulness), 4) the extent to which the intervention was performed according to protocol (acceptability), 5) participants’ exposure to and engagement in the training (acceptability), and 6) the opinion about the training (acceptability)	the self-reported benefits	0	0.7607075	1	
236	1965	198	to test the effect of TA on the incidence of IR and VS in patients undergoing elective CPB	the incidence of VS	0	0.71916217	1	
489	1542	20	PVF	responsive	0	0.029996749	0	
574	1659	312	response rate	cost-effective	0	0.0	0	
78	1099	377	body weight	body weight	1	1.0000002	1	
762	1979	929	an injury surveillance with a missed match injury definition	the incidence of hamstring injury	0	0.7035521	1	
402	646	208	the EPDS (a 10-item scale developed for use in the postnatal period, in which a score ≥ 13 identifies probable depression 33 , and the physical and mental component scores (PCS and MCS) of the Short Form 36 (SF-36), a widely used general health status measure 34	EPDS ≥ 13 ('probable depression')	0	0.4071468	1	
579	1661	747	return of final follow-up questionnaire or reminder by the participant	The response rates	1	0.37436876	0	
447	1512	1047	more frequently interrupted MARS sessions without anticoagulation	had to be terminated prematurely	1	0.33188036	0	
468	797	382	change in EPIC urinary HRQOL domain summary score at 3 months after the completion of RT (ΔEPIC-U 3mo )	contralateral local failures	0	0.36717772	0	
13	1028	405	the PCR-adjusted parasitological cure rate up to day 42 of the follow-up period	Kaplan-Meier PCR-adjusted cure rates	1	0.51395917	1	
288	493	404	self-rated overall effect of treatment, measured once; on the day treatment was completed	time	0	0.4467274	1	
594	1707	533	CR	complete response for the whole period of nausea and vomiting	1	0.1215666	0	
453	707	1069	health-related quality of life (HRQoL)	gas exchange	0	0.10291995	0	
524	1702	784	a difference in timing adherence between groups	The intervention effect (difference in timing adherence pre- to post-intervention between the 2 groups)	1	0.790869	1	
69	396	800	the use of rescue NSAIDs	NSAID use	1	0.65978605	1	
344	1423	360	differences in screening interest	interest in colorectal cancer screening	1	0.76017594	1	
130	192	356	progression-free survival (PFS) per central radiology review, according to RECIST 15	effectively shrinks target lesions in mRCC	0	0.4745253	1	
760	1938	546	reduction in duration of severe pneumonia and pneumonia	pneumonia	0	0.7126489	1	
341	1421	164	the rate of renal involvement at one year	the risk of renal involvement	1	0.7244272	1	
645	1782	880	Trough FEV 1 after 12 weeks of treatment	Standardised AUC measurements for FEV 1	1	0.57331085	1	
111	210	856	control criteria during the 2-year follow-up period	SBP levels	0	0.2670252	0	
463	1528	341	the Patient Reported Physician Cultural Competency (PRPCC) Scale	PRPCC	1	0.0	0	
258	1328	268	DFS	Ki67-positivity	0	0.0	0	
238	1965	200	the incidence of IR	the development of IR	1	0.726924	1	
69	1085	864	the levels of inflammatory cells (neutrophils, eosinophils, macrophages, and lymphocytes) and epithelial cells in induced sputum	airway responsiveness	0	0.38053277	0	
384	627	317	the ovicidal effect of the treatments, defined as no nymphal lice emerging from eggs between treatments	lice	1	0.3506594	0	
753	1936	55	Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	overall functioning	1	0.50992227	1	
754	1936	56	changes compared to baseline observed after 4 weeks (40 sessions) of treatment, in parallel groups, on (1) Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating, (2) Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating, and (3) Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	stereotypy	0	0.29880375	0	
484	763	1062	success at quitting (expired CO ≤ 9 ppm), the dose of NRT used, and the rating of withdrawal symptoms using the Mood and Symptoms Scale	smoking withdrawal	0	0.4016423	1	
74	112	1073	claim duration (in days) during 12 months follow-up	functional status	0	0.1602749	0	
662	987	987	CRF as measured by the BFI	cognitive dysfunction	0	0.21288905	0	
277	475	666	the shortened version of the Chedoke Arm & Hand Activity Inventory (CAHAI-7)	effective	0	0.12479757	0	
467	797	381	change in EPIC urinary HRQOL domain summary score at 3 months after the completion of RT (ΔEPIC-U 3mo )	urinary HRQOL	1	0.45593885	1	
402	1481	43	Depressive symptoms	risk of developing severe depressive symptoms	1	0.6110425	1	
572	881	369	the overall discomfort reported during WC versus SC pH-metry	Overall discomfort score	1	0.519719	1	
608	1721	803	the incidence of adverse events	The incidence of adverse events	1	0.90813804	1	
114	1988	945	time to extubation	discontinued	0	0.18587992	0	
483	1541	596	ETDRS visual acuity recorded in the laboratory, supplemented with a number of secondary lab-based visual function measures	CS	0	0.1462281	0	
117	170	133	The frequency	duration of exacerbations	0	0.27168524	0	
8	1016	102	blood pressure	diastolic BP	0	0.27045044	0	
601	920	438	change of lower leg volume, determined by water replacement plethysmometry	lower leg volume	1	0.59984297	1	
243	406	267	a dichotomous measure (occurrence of low back pain)	individualized attention via additional testing	0	0.2812204	0	
768	1986	1043	daily physical activities (measured by a validated tri-axial accelerometer)	6MWD	0	0.34284335	0	
143	215	47	The PCR-corrected ACPR rate at follow-up on day 28 after the first malaria episode	PCR-corrected ACPRs at day 28 for the first episode	1	0.87705654	1	
658	1962	884	trough FEV 1 after 12 weeks of treatment (average of the 23 h 10 min and 23 h 45 min post-dose values assessed on the morning of Day 85)	blood glucose levels	0	0.3515315	0	
117	1145	1055	the number of additional donors deferred by the HQ	deferred as a result of responses to the questionnaires	0	0.6678701	1	
435	1496	908	1) physical activity, 2) work productivity, and 3) sickness absence	the QQ index	0	0.19466819	0	
598	1712	274	safety, tolerability and level at which dose limiting toxicity occurred	Median overall survival	0	0.39366353	0	
122	1150	620	the primary care practices' mean levels of HbA1c, cholesterol and BP, and numbers of patients with recorded foot inspections in the previous calendar month	mean HbA1c	0	0.4625722	1	
134	200	462	the change in serum methylmalonic acid (MMA) levels after one month of treatment	mean corpuscular volume	0	0.32008788	0	
110	210	855	glycated hemoglobin A1c, body mass index (BMI), blood pressure, lipids and control criteria during the 2-year follow-up period	BMI	0	0.33196065	0	
172	1912	967	knowledge of labour analgesia, decisional conflict (uncertainty regarding analgesia decision) and anxiety	informed decision making	0	0.26481655	0	
96	141	192	time to sit unsupported	total coma duration	0	0.25049263	0	
256	440	632	the number of ECT treatments given	their MMSE scores	0	0.4012845	1	
656	981	179	the proportion of patients relapse-free at Week 26	Adverse events (AEs)	0	0.1920352	0	
154	1220	559	Total costs	RDQ	0	0.19414228	0	
105	1588	941	extubated	median time to extubation	1	0.5592219	1	
193	304	120	The median RTDI	Median time to disease progression (TTDP)	0	0.40908277	1	
585	891	499	improved PFS for the maintenance phase	The one-year survival probabilities	0	0.32694203	0	
603	1717	363	changes in absenteeism, school rule infractions and suspension days during the four-month pretest period prior to randomization compared with the four-month intervention period	infractions	0	0.33836615	0	
97	1122	89	days alive and off assisted breathing	CO diffusion	0	0.05317855	0	
44	77	796	VC	their clinical outcomes including mortality	0	0.020825518	0	
122	1150	620	the primary care practices' mean levels of HbA1c, cholesterol and BP, and numbers of patients with recorded foot inspections in the previous calendar month	likelihood of HbA1c tests being ordered	0	0.5138535	1	
596	913	246	postpartum haemorrhage	caesarean birth	0	0.55495876	1	
462	712	382	change in urinary HRQOL at 3 months	PSA failure	0	0.2800922	0	
518	808	489	incidence of vaginal delivery within 12 and 24 hours	spontaneous rupture of the membranes occurred	0	0.50070655	1	
675	1811	502	the overall between-patient variability around the mean time to neurological assessment	mean neurological assessment times	1	0.69206315	1	
254	437	1078	comet assay	plasma oxidized low-density lipoprotein (LDL) levels	0	0.48986554	1	
245	408	78	the recovery rate, defined as the percentage of patients who had an adequate clinical and parasitological response (ACPR) after follow-up for 28 days	The recovery rate at D28	1	0.60080695	1	
596	913	246	caesarean birth	caesarean birth	1	0.9999998	1	
757	1936	59	changes compared to baseline observed after 4 weeks (40 sessions) of treatment, in parallel groups, on (1) Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating, (2) Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating, and (3) Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	initial autism severity	0	0.4317935	1	
502	1571	190	HSCL-25	anxiety	0	0.0	0	
596	913	246	instrumental birth	postpartum haemorrhage	0	0.27564168	0	
673	1804	145	reversal of metabolic syndrome in the intervention group subjects compared to controls at 12 months follow-up	prescribing of statins and anti-hypertensives	0	0.27283883	0	
70	396	801	force platform variables PVF and impulse, the validated HCPI and the use of rescue NSAIDs	force platform impulse	0	0.5158396	1	
207	1274	1034	the incidence of predefined GI AEs	The incidence and severity of individual predefined GI AEs	1	0.88603616	1	
80	126	835	changes in pain as measured on a verbal rating scale from 0 to 10 during a flexion-extension range of motion evaluation	disc height	0	0.2710303	0	
518	808	489	incidence of vaginal delivery within 12 and 24 hours	need for oxytocin augmentation	0	0.34678608	0	
19	420	1042	detection of bilateral aerated middle ears (confirmed with tympanometry) at two consecutive monthly visits	normal ears	1	0.44282767	1	
598	913	248	instrumental birth	safe	0	0.08781895	0	
194	304	121	the mean RTDI overall	Overall higher RTDI	1	0.43517753	1	
497	1567	556	retention on treatment at 1 year	Kaplan-Meier curves for the probability of premature discontinuation from the study for any reason	0	0.5735176	1	
530	1610	300	improvement in attention scores for the intervention group	any of the academic or behavioural measures	0	0.5614408	1	
428	1821	207	participation in the Link-Up Study, through attendance at a biospecimen collection site to provide a blood sample and giving written consent to participate, including use of blood samples for genetic and other research	red cells collected	0	0.40677398	1	
263	461	324	10-year CVD risk	Prevalence of high blood pressure	0	0.3707409	0	
633	1760	679	Biopsy proven acute rejection (BPAR) at 24 weeks	efficacy	0	0.32713068	0	
450	706	138	changes between baseline and nine months of bone mineral density (BMD) of the proximal femur and lumbar spine (dual-energy X-ray absorptiometry) and serum markers of bone resorption and formation	sway parameters	0	0.32124907	0	
59	273	1004	Client Satisfaction Questionnaire (CSQ)	alliance	0	-0.0010822066	0	
211	1274	1038	the incidence of predefined GI AEs	target joint pain	0	0.34312293	0	
452	707	1068	health-related quality of life (HRQoL)	daytime arterial blood gases	0	0.22890864	0	
289	493	405	self-rated overall effect of treatment, measured once; on the day treatment was completed	pain VAS	0	0.25100183	0	
242	1313	565	the primary process outcome	daily inhaled corticosteroid use	0	0.19112884	0	
27	1051	157	incidence of malaria attacks over 8 weeks of follow up	The incidence of malaria episodes	1	0.5796612	1	
675	999	1035	Chlamydia screening rates	baseline screening rates	1	0.7706513	1	
381	627	314	the ovicidal effect of the treatments, defined as no nymphal lice emerging from eggs between treatments	treatment success	0	0.3054283	0	
253	437	1077	comet assay	Plasma glutathione peroxidase (GPx) and catalase activities	0	0.36213505	0	
524	813	297	the 11-point NRS in patients' daily pain diaries	painful DPN	0	0.30815917	0	
416	1489	1064	PCR-corrected adequate clinical and parasitological response (ACPR) on day 28	laboratory values	0	0.3168042	0	
506	1577	818	the average FEV 1 from the first intake of study drug to the measurement at 90 minutes	treatment success	0	0.29120612	0	
156	1257	559	RDQ	RDQ	1	1.0000004	1	
164	1227	686	the ratio of expiratory time to reach PTEF to the total expiratory time	V PTEF / V E	0	0.12152483	0	
359	1436	649	gastric emptying T half	arterial function	0	0.24767117	0	
113	1988	944	time to extubation	underwent tracheostomy	0	0.38075358	0	
725	1873	672	change in Treatment Satisfaction (Tables 5 and 6 )	Treatment Satisfaction	1	0.5383655	1	
335	546	557	the proportion of patients in each group with cardiovascular risk ≥ 10% over five-years at 12 months follow up	Intensity of prescribing of blood pressure lowering drugs	0	0.40691942	1	
158	224	1067	foot pain	foot function	0	0.5809594	1	
111	1988	942	time to extubation	ICU length of stay	0	0.44666237	1	
547	831	142	violent attitudes using the Total MVQ score	anger cognitions	0	0.3650487	0	
197	332	113	NRS changes	the NRS score for pain	1	0.43985313	1	
156	1257	559	RDQ	self-care	0	0.0	0	
153	223	831	change in weight from randomization (0-M) to 12 months post randomization	initial weight loss	1	0.49868777	1	
333	546	555	the proportion of patients in each group with cardiovascular risk ≥ 10% over five-years at 12 months follow up	cardiovascular risk	1	0.49848777	1	
357	1434	573	HbA 1c	health-related quality of life	0	0.10113375	0	
594	897	564	the SF-36 quality of life score	GHbA 1c	0	0.005406175	0	
421	655	105	knowledge	scores in attitudes	0	0.22241636	0	
358	626	291	the intra-individual change in the total score of the Hamilton Rating Scale for Depression (HAM-D, 17-item version) between baseline and the end of the 6-week acute phase	remission	0	0.119125985	0	
86	128	657	absence of parasites and clinical signs on days 14 and 28, and good clinical and biological tolerability	well-tolerated	0	0.0	0	
605	1717	365	changes in absenteeism	absenteeism	1	0.5953361	1	
382	627	315	the ovicidal effect of the treatments, defined as no nymphal lice emerging from eggs between treatments	The cure rates per-protocol	0	0.46755198	1	
582	891	496	improved PFS for the maintenance phase	the median PFS time for maintenance phase	1	0.88614184	1	
594	897	564	improvement of GHbA 1c	SF-36 score	0	0.11240397	0	
675	999	1035	Chlamydia screening rates	likely to log on to the course	0	0.113049075	0	
100	158	806	the mean number of detected polyps	The overall rate of polyp detection	0	0.61187136	1	
214	379	1050	day-28 failure rates (uncorrected and PCR corrected)	Treatment failure (PCR corrected)	1	0.5708742	1	
198	332	114	NRS changes	the PPI scores	0	0.24562189	0	
205	360	86	the prevalence of arm, shoulder and neck symptoms	receiving education	0	0.21472642	0	
151	223	829	change in weight from randomization (0-M) to 12 months post randomization	mean initial weight loss	1	0.5473233	1	
300	1361	696	quality of life, rated by the participant and their nominated carer, as measured by the QOL-AD, both 13-item scales, scoring between 13 and 52 points with a higher score indicating better quality of life	participant-rated quality of life score	1	0.61212915	1	
523	808	494	time from induction to delivery and incidence of vaginal delivery within 12 and 24 hours	admissions to the neonatal unit	0	0.45262155	1	
271	467	446	reduction in systolic blood pressure, total cholesterol and estimated 10-year CVD risk	rate of patient acceptability	0	0.46855536	1	
440	1852	633	(1) anti-malarial consumption recorded from routine statistics in ledger books of all HF before and after intervention; (2) anti-malarial prescription recorded during observed consultations in cross-sectional surveys conducted in all HF before and 18 months after m RDT implementation	anti-malarial prescription	0	0.26300222	0	
631	945	777	the proportion of children aged 9-23 months completely vaccinated	the proportion of children of 9-23 months who were completely vaccinated (defined as children who received BGG, 3 doses of DTP/Polio, measles and yellow fever vaccines)	1	0.848122	1	
178	262	839	the determination of the perioperative concentration of IL-1β in the patient's peritoneal fluid	Cytokine values	0	0.2287498	0	
314	1372	821	target vessel revascularization (TVR)	definite stent thrombosis	0	0.4807262	1	
61	317	1002	the ORS scale	satisfaction	0	0.1768138	0	
99	155	783	fear of falling, avoidance of activity, and daily activity	their adherence	0	0.3867899	0	
295	501	311	disease-free survival (DFS) at three years	leucopenia	0	0.22136986	0	
370	1444	140	the Premature Infant Pain Profile (PIPP) score in the first minute after skin puncture	the PIPP score	1	0.6266147	1	
117	170	133	The frequency, duration and severity of exacerbations	duration of exacerbations	0	0.82107073	1	
29	1051	159	incidence of malaria attacks over 8 weeks of follow up	protective effect against anaemia	0	0.3698958	0	
759	1938	545	reduction in duration of severe pneumonia and pneumonia	chest indrawing	0	0.3020747	0	
48	82	1056	change in SBP and change in HOMA index, from week 0 (pre-treatment) to week 6	HbA1c	0	0.16250573	0	
418	655	102	attitudes, knowledge and skills in EBM	Critical appraisal skills	0	0.5474509	1	
518	808	489	time from induction to delivery and incidence of vaginal delivery within 12 and 24 hours	additional doses were required	0	0.44494647	1	
629	1745	1092	the cost of therapy per delivered baby, estimated according to a cost-minimization analysis	the overall therapy cost per born baby	1	0.711528	1	
236	1965	198	VS	time on mechanical ventilation	0	0.040705282	0	
544	830	221	the change in morning peak expiratory flow (PEF) rate from baseline to the end of the treatment period (mean of weeks 23–24)	Asthma control	0	0.2888728	0	
498	852	848	a reduction in depression	the GDS	1	0.30506483	0	
277	1337	66	cumulative survival without mechanical ventilation or oxygen dependency at 30 days	survival without oxygen or on ventilator	1	0.8159646	1	
198	1272	1067	the difference in FMD between the two blends of supplements and placebo following a 2-hour oral glucose tolerance test (OGTT) after 8 weeks of treatment	lipids	0	0.23066945	0	
266	1329	352	the percentage of children who had ≤ 4 days with pain and no missed activities during the previous month 41	The therapeutic efficacy	0	0.2734022	0	
434	978	486	response rate based on a 20% improvement in WOMAC pain scores	Rescue medication use	0	0.32905006	0	
165	233	1030	10 MCP Trans PDA	The parallel scan inter-reader reliability of summated 10 MCPJ scores	0	0.20564619	0	
625	1731	258	change from baseline in fasting serum total cholesterol	insulin	0	0.36694574	0	
457	1518	544	pain catastrophising	quality of life	0	0.17310551	0	
562	1637	869	the functional status of the patient at hospital discharge as measured by a Modified Rankin Score (MRS) and Functional Independence Measure (FIM)	unexpected deaths	0	0.20489478	0	
449	706	137	changes between baseline and nine months of bone mineral density (BMD) of the proximal femur and lumbar spine (dual-energy X-ray absorptiometry) and serum markers of bone resorption and formation	physical domains of quality of life	0	0.36855173	0	
416	654	118	SHBG	SHBG	1	1.0000001	1	
450	706	138	changes between baseline and nine months of bone mineral density (BMD) of the proximal femur and lumbar spine (dual-energy X-ray absorptiometry) and serum markers of bone resorption and formation	sway velocity	0	0.28591052	0	
32	1052	12	Correlation between VPW measurements from the portable chest radiograph with the PAOP	cumulative fluid balance	0	0.41842568	1	
163	1227	685	the ratio of expiratory time to reach PTEF to the total expiratory time	TEF10	0	0.0	0	
324	1391	213	the proportion of delivered compressions within target depth compared over a 2-minute period within the groups and between the groups	the proportion of delivered compressions below target depth	0	0.7675722	1	
463	1528	341	the Patient Reported Physician Cultural Competency (PRPCC) Scale	systolic blood pressure	0	0.2256626	0	
169	1912	964	decisional conflict (uncertainty regarding analgesia decision)	decisional conflict scores	1	0.69544977	1	
284	1341	743	pain	shoulder mobility	0	0.38684213	0	
541	1618	589	crying	feeding	0	0.17402962	0	
174	252	331	objective functional capacity, assessed using a 25 m walk test, a repeated chair rise test, and a stair climb test	functional capacity	1	0.42208332	1	
596	913	246	relative risk	postpartum haemorrhage	0	0.169301	0	
390	632	215	WOMAC Pain	Total dimensions	0	0.18664229	0	
313	522	432	the QTcF interval (QT interval corrected for heart rate using Fridericia's formula, QT/RR 0.33 )	QTcF change	1	0.6211787	1	
483	1541	596	ETDRS visual acuity recorded in the laboratory, supplemented with a number of secondary lab-based visual function measures	normal illumination VA	1	0.40364143	1	
556	1631	518	The proportion of recurrent parasitaemia's during the 4-week follow-up	proportion of cases with re-infections	0	0.5643762	1	
353	586	13	the American College of Rheumatology 20% improvement criteria (ACR20) response at week 24 19 20	HAQ-DI	0	0.0	0	
263	461	324	10-year CVD risk	high cholesterol	0	0.32396027	0	
687	1833	1069	IPV (Composite Abuse Scale CAS) and depression (Edinburgh Postnatal Depression Scale EPDS)	depression (EPDS score ≥13)	0	0.5231052	1	
539	1618	587	crying	colic	0	0.24289457	0	
716	1862	925	pain severity and knee range of motion (ROM)	ROM	0	0.17358838	0	
593	896	412	tolerability	well tolerated	1	0.2823093	0	
317	1373	701	overall success	poor at mimicking reality	0	0.25205284	0	
83	1103	957	global quality of life change at 6-weeks, measured by EORTC QLQ-C30	Neutropenia	0	0.2178213	0	
390	632	215	Physical Function	hamstring strength in both legs	0	0.15330908	0	
428	1821	207	participation in the Link-Up Study, through attendance at a biospecimen collection site to provide a blood sample and giving written consent to participate, including use of blood samples for genetic and other research	systolic and diastolic blood pressure	0	0.3215663	0	
593	896	412	PK parameters and safety and tolerability	well tolerated	0	0.3319736	0	
325	534	864	response rates	response	1	0.766877	1	
548	1630	588	the frequency of fussing and crying of the infants	frequency of stooling	0	0.5072447	1	
162	233	1027	10 MCP Trans PDA	DAS28(CRP)	0	0.0	0	
291	1346	229	body mass index (BMI) percentile	percentage of obesity	0	0.3953342	0	
148	1205	328	Rate of change in [Na]	duration (average of 12 hours)	0	0.20768672	0	
604	1717	364	changes in absenteeism, school rule infractions and suspension days during the four-month pretest period prior to randomization compared with the four-month intervention period	suspension days due to behavior-related problems	0	0.6079926	1	
332	1418	260	FEV 1 (% predicted) in the two groups at 1, 5, 15, 30, 60 min after administration of the study drug	the % predicted FEV1	1	0.59588605	1	
616	1723	511	response rate, survey response bias, item non-response, and cost	rate of item non-response	0	0.5425037	1	
455	709	38	perinatal mortality (stillbirth or death during the first seven days after birth)	perinatal mortality	1	0.47392696	1	
596	913	246	initiation of breastfeeding	episiotomy	0	0.3987969	0	
582	1671	182	the GSRS subscores for abdominal pain	the GSRS abdominal distension subscore	0	0.7744825	1	
36	53	24	HSV-2 seroconversion during the study period	the unintended pregnancy rate	0	0.5857763	1	
420	1493	204	response rate	took part in the Link-Up Study	1	0.2056256	0	
184	277	0	change in score	understanding of the relationship between control and complications	0	0.3724422	0	
452	1512	1053	more frequently interrupted MARS sessions without anticoagulation	treatment efficacy	0	0.32470486	0	
502	1571	190	HSCL-25	the severity of symptoms of depression	0	0.0	0	
97	141	193	coma recovery time; time to sit unsupported, begin oral intake; duration of hospitalization; death and adverse effects	the mortality	0	0.48532268	1	
157	1257	560	RDQ	Average total costs	0	0.28590903	0	
176	1241	147	the duration of severe neutropenia (DSN) in cycle 1	Toxicities	0	0.38898933	0	
372	607	578	HRQL	mental HRQL	1	0.8042642	1	
619	1731	252	change from baseline in fasting serum total cholesterol	triglycerides	0	0.48983905	1	
314	1372	821	myocardial infarction	cardiac death	0	0.5224701	1	
163	1227	685	the ratio of expiratory time to reach PTEF to the total expiratory time	the ratio of the tidal expiratory flow at 25% of the remaining tidal volume to PTEF (25/PT)	0	0.8091439	1	
241	406	265	a dichotomous measure (occurrence of low back pain)	race/ethnicity	0	0.0	0	
135	200	463	the change in serum methylmalonic acid (MMA) levels after one month of treatment	MMA levels	1	0.3417956	0	
591	1701	529	intra-operative pain	intra-operative complications	0	0.33740163	0	
604	1717	364	suspension days during the four-month pretest period prior to randomization compared with the four-month intervention period	suspension days due to behavior-related problems	1	0.57225055	1	
719	1862	928	pain severity	the necessary ROM for discharge	0	0.25098363	0	
453	1518	540	pain catastrophising	global PC	1	0.092943594	0	
390	632	215	Total scores	Role Physical	0	0.19688758	0	
473	736	515	incidence of low back pain resulting in the seeking of health care	low back incidence resulting in the seeking of health care	1	0.97946537	1	
586	891	500	improved PFS for the maintenance phase	well-tolerated	0	0.0	0	
572	881	369	the overall discomfort reported during WC versus SC pH-metry	throat, chest, or overall discomfort during placement	1	0.7168592	1	
127	190	188	all-cause mortality over 3 years	The rates of adverse events	0	0.3420882	0	
350	1429	734	the performance of the trial according to the revised CONSORT statement	Recruitment	0	0.07636211	0	
111	210	856	glycated hemoglobin A1c	SBP levels	0	0.34258637	0	
390	632	215	Total scores	Body Pain	0	0.11338765	0	
7	3	249	prescription data of a three-year period (one year before and 2 years after guideline dissemination) and proportion of change according to recommendations	one recommendation: mupirocin	0	0.36326355	0	
384	1463	263	the differences in the levels of iFGF23 and iPTH after each treatment period	the iPTH level	0	0.75868046	1	
570	1656	1017	change in this composite from baseline at four months post-randomization	adherence	0	0.07748812	0	
307	513	195	Early Treatment Failure (ETF); Late Clinical Failure (LCF); Late Parasitological Failure (LPF); Adequate Clinical and Parasitological Response (ACPR) 18	the fever clearance time	0	0.13122562	0	
66	108	801	force platform variables PVF and impulse, the HCPI and rescue NSAIDs	the veterinary assessment variables	0	0.5435275	1	
421	1493	205	response rate	participation rate ratio	0	0.67066705	1	
60	1078	408	the rate of response to PRGF	a clinical improvement	0	0.2820819	0	
139	206	521	OMAS	muscle strength in the plantar flexors (p = 0.029) and dorsiflexors	0	0.20806086	0	
223	389	472	comparison of the change from baseline to end of 12 weeks between simvastatin and fenofibrate	LDL	0	0.2637963	0	
596	913	246	postpartum haemorrhage	breastfeeding initiation	0	0.44234234	1	
401	645	543	the temperature difference between the CRPS affected and the contralateral limbs	the number of short walking periods	0	0.64449483	1	
173	252	330	objective functional capacity, assessed using a 25 m walk test, a repeated chair rise test, and a stair climb test	Adherence	0	0.21929994	0	
4	1001	387	the average efficacy over Seasons 1 and 2 for the prevention of culture-confirmed influenza illness due to influenza A or B virus strains antigenically matching those in the vaccine (ie vaccine-matched, culture-confirmed influenza; VMCCI)	attack rates	0	0.30162153	0	
594	897	564	the SF-36 quality of life score	SF-36 score	1	0.5670094	1	
390	632	215	Total scores	Social Functioning domains	0	0.23617204	0	
383	627	316	the ovicidal effect of the treatments, defined as no nymphal lice emerging from eggs between treatments	any newly emerged louse nymphs	0	0.58399874	1	
732	1886	166	a sub-microscopic parasite carriage of ≥ 30% 28	Parasite prevalence by molecular detection methods	0	0.37037754	0	
529	813	302	the 11-point NRS in patients' daily pain diaries	NC	0	0.07353967	0	
48	1808	335	the mean change in self-reported symptoms of depression as measured on the BDI	the median time (IQR) to complete all eight CCBT sessions	0	0.6258695	1	
254	437	1078	comet assay	the DNA tail length	0	0.23402463	0	
349	1429	733	the performance of the trial according to the revised CONSORT statement	cost	0	0.18604851	0	
625	1731	258	change from baseline in fasting serum total cholesterol	insulin resistance	0	0.38622853	0	
65	108	800	rescue NSAIDs	PVF	0	-0.0052563325	0	
582	1671	182	distension	GSRS abdominal pain subscore	0	0.59250516	1	
141	1198	917	health care costs and utilization rates	utilization (89.7% of patients) with COPD visits	0	0.57715523	1	
479	742	231	the duration of fluid fast prior to induction of anaesthesia	fluid or food fasting times	1	0.5702601	1	
93	137	62	≥ Grade 2 (G2) toxicity incidence	volumes receiving ≥ 50 Gy (V50) and 70 Gy (V70)	0	0.611784	1	
487	1542	18	PVF	MA duration	0	0.10172138	0	
96	141	192	coma recovery time	sit unsupported	0	0.122527085	0	
95	137	64	≥ Grade 2 (G2) toxicity incidence	An α/β ratio for late rectal toxicity	0	0.48390076	1	
594	897	564	improvement of GHbA 1c	GHbA 1c	1	0.7348043	1	
173	1239	760	the change in test scores for residents and faculty (pre-test vs. post-test), and the difference in score improvement between the residents randomized to undergo proctored ultrasound examinations compared to those who were not	test scores (out of a 24 point test)	0	0.5948776	1	
393	1476	612	whether the GP had provided patients with a written asthma action plan (WAAP yes/no)	to manage acute asthma attack	0	0.45898512	1	
460	1519	661	PASI-75	the SF-36	0	0.0	0	
483	763	1060	success at quitting (expired CO ≤ 9 ppm), the dose of NRT used, and the rating of withdrawal symptoms using the Mood and Symptoms Scale	reporting of ratings of withdrawal symptom scores	0	0.5463814	1	
361	626	295	the intra-individual change in the total score of the Hamilton Rating Scale for Depression (HAM-D, 17-item version) between baseline and the end of the 6-week acute phase	effective	0	0.17401415	0	
466	1536	395	number of post-CCRT hospital admission days	hospital admission days	1	0.90226835	1	
595	1707	535	CR	appetite loss evolution	0	0.05240313	0	
621	932	925	PDSS	cost effective with respect to therapist time	0	0.13669695	0	
230	389	479	comparison of the change from baseline to end of 12 weeks between simvastatin and fenofibrate	size	0	0.26152688	0	
636	954	621	the serum phosphorus at 12 weeks	The albumin-adjusted serum calcium concentration	0	0.5742417	1	
761	1938	547	reduction in duration of severe pneumonia and pneumonia	hospital stay	0	0.4295394	1	
446	695	675	an ASAS40	various infections	0	-0.059169296	0	
96	141	192	coma recovery time; time to sit unsupported, begin oral intake; duration of hospitalization; death and adverse effects	time to start oral intake	0	0.6567363	1	
596	913	246	initiation of breastfeeding	caesarean birth	0	0.4128929	1	
47	82	1055	change in SBP and change in HOMA index, from week 0 (pre-treatment) to week 6	HOMA index	0	0.32721743	0	
314	1372	821	cardiac death	TVR	0	0.14512953	0	
660	1787	249	the initial rate of temperature decrease, expressed as °C/h	Temperature decline	1	0.39592904	0	
588	896	407	PK parameters and safety and tolerability	median T max	0	0.23370494	0	
681	1812	681	duration of diarrhea (in hours) from onset and from admission until cessation of diarrhea (passage of soft/formed or no stools for two consecutive 8-hour periods), and the total stool weight in grams during hospitalization	the proportion of participants with diarrhea more than 7 days from onset	0	0.816337	1	
754	1936	56	Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating	total score	1	0.58689374	1	
605	1717	365	suspension days during the four-month pretest period prior to randomization compared with the four-month intervention period	absenteeism	0	0.16091153	0	
578	886	70	Major bleeding	rate of TEs	0	0.03886424	0	
19	420	1042	detection of bilateral aerated middle ears (confirmed with tympanometry) at two consecutive monthly visits	perforations	0	0.21846396	0	
343	1423	359	differences in screening interest and patient test preferences between versions of the decision aid	likely to choose colonoscopy	0	0.45279345	1	
435	978	487	response rate based on a 20% improvement in WOMAC pain scores	the safety profile	0	0.4053212	1	
518	808	489	time from induction to delivery and incidence of vaginal delivery within 12 and 24 hours	spontaneous rupture of the membranes occurred	0	0.48223814	1	
652	974	287	the percent of subjects meeting TR during the initial 30 minutes of treatment	likely to reach the physician-specified SBP target range within 30 minutes	0	0.6274912	1	
506	782	950	the mean time to onset of the first 24-h heartburn-free period after initial dosing	Tolerance	0	0.080786094	0	
49	102	823	pulmonary or cardiac toxicity	role- and social-functioning scores	0	0.12753768	0	
598	913	248	Apgar scores less than 8	intervention during labour and delivery	0	0.22669472	0	
148	1205	328	Rate of change in [Na]	the volume of additional isotonic fluids given	0	0.3558273	0	
79	1099	378	body weight	Dietary energy	0	0.22131279	0	
755	1936	57	Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating	irritability	0	0.2473864	0	
26	472	982	death from any cause, recurrent infarction and unstable angina within one year (per protocol and adjusted for 2 days PCI delay)	revascularization-procedures	0	0.0	0	
475	1601	397	costs per quality adjusted life years (cost/QALY)	Quality adjusted life years	0	0.81170666	1	
216	379	1052	day-28 failure rates (uncorrected and PCR corrected)	efficacious	0	0.19828156	0	
600	1712	276	safety, tolerability and level at which dose limiting toxicity occurred	Dose limiting toxicity	0	0.68052864	1	
539	826	504	the p27 antigen analysis of serum samples	negative for persistent antigenaemia	1	0.26804087	0	
580	886	72	Major bleeding	TE risk	0	0.19316652	0	
543	1630	582	the frequency of fussing and crying of the infants	bowel movements	0	0.25494805	0	
653	980	97	BMD	BMD at the femoral neck	1	0.470695	1	
423	1493	207	response rate	buffy coat	0	0.013799688	0	
348	569	92	diarrhoea	HIV infection	0	0.0	0	
169	1912	964	knowledge of labour analgesia, decisional conflict (uncertainty regarding analgesia decision) and anxiety	anxiety	0	0.59561336	1	
103	1128	944	time from the commencement of study drug to extubation	successfully extubated	1	0.44540367	1	
47	82	1055	change in HOMA index	HOMA index	1	0.7620042	1	
171	1912	966	knowledge of labour analgesia, decisional conflict (uncertainty regarding analgesia decision) and anxiety	analgesia use	0	0.49041906	1	
33	50	569	IES-R	ratings of the therapeutic alliance	0	0.0	0	
204	360	85	the prevalence of arm, shoulder and neck symptoms	sick leave	0	0.27109832	0	
518	808	489	time from induction to delivery and incidence of vaginal delivery within 12 and 24 hours	delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05)	0	0.54037815	1	
501	1569	894	change in summary lifestyle score (Prudence Score) and individual health behaviours at three months	salt intake	0	0.20826884	0	
237	1965	199	to test the effect of TA on the incidence of IR and VS in patients undergoing elective CPB	creatine-kinase levels	0	0.23552546	0	
16	420	1039	'success'	the proportion of children with i) perforation at the end of therapy (27% to 12% RD = -16% [-31,-1]), ii) recurrent perforation during therapy (18% to 4% RD = -14% [-25,-2])	0	0.0	0	
407	1483	189	the Premature Infant Pain Profile (PIPP ) 48 49	recovery time	0	0.18939064	0	
178	1243	322	the change relative to baseline in the multiple sclerosis functional composite score (MSFC)	The overall frequency of adverse events	0	0.5386687	1	
53	1074	836	the proportion of patients with plasma HIV-1 RNA levels <200 copies/mL at week 24	CD4+ count	0	0.240065	0	
756	1936	58	changes compared to baseline observed after 4 weeks (40 sessions) of treatment, in parallel groups, on (1) Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating, (2) Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating, and (3) Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	the ATEC	0	0.5411988	1	
557	859	963	blood pressure control	progressed to the higher dose of R or E	0	0.27968714	0	
185	277	1	change in score	Practice	0	0.106796026	0	
697	1924	792	the anatomical knowledge (MCQ)	the MC exam	1	0.49356094	1	
596	913	246	postpartum haemorrhage	induction	0	0.16905215	0	
598	913	248	initiation of breastfeeding	safe	0	0.13200796	0	
221	1284	691	the volume of blood loss between T1 and T4	PPH stopped after only uterotonics and PRBC transfusion	0	0.44564214	1	
483	763	1060	success at quitting (expired CO ≤ 9 ppm), the dose of NRT used, and the rating of withdrawal symptoms using the Mood and Symptoms Scale	Reporting of NRT consumption	0	0.39822948	0	
69	396	800	the validated HCPI	all three scores in the comparative questionnaire (locomotion, every-day situations, and skin & coat)	0	0.49702945	1	
209	368	838	the mean change in modified extrinsic tooth stain index (all sites) from baseline to week 6	stain reduction	1	0.44910288	1	
548	831	143	violent attitudes using the Total MVQ score	locus of control	0	0.23147315	0	
28	1051	158	incidence of malaria attacks over 8 weeks of follow up	malaria parasitaemia prevalence	0	0.4874628	1	
276	1337	65	cumulative survival without mechanical ventilation or oxygen dependency at 30 days; mortality at 30 days; therapy failure; crossover rate; and persisting pulmonary problems defined as oxygen dependency or still being on a ventilator at 30 days	crossover	0	0.1899973	0	
262	1329	347	the percentage of children who had ≤ 4 days with pain and no missed activities during the previous month 41	days of pain	0	0.5413781	1	
329	543	638	waist circumference (cm)	waist circumference	1	1.0	1	
386	1697	711	"the change in IOP from baseline to week 4 at 8 a.m. and 4 p.m. for the per protocol (PP) population using a ""worse eye"" analysis"	diagnosed with primary open-angle glaucoma	0	0.35666645	0	
304	512	626	the reduction in systolic blood pressure defined as the average of 3 office readings with the patient in the sitting position	systolic (-1.36 mm Hg) and diastolic (-0.97 mm Hg) office BPs	1	0.3723219	0	
40	1062	320	the comparison of the scores on the 12-Item Short-Form Health Survey (SF-12) and the Graded Chronic Pain Scale (GCPS) questionnaire for the two survey modes	comparability	0	0.1755884	0	
9	1016	104	blood pressure	education session participation	0	0.12159039	0	
362	1436	652	gastric emptying T half	the postprandial response to a high-fat test meal	0	0.36214423	0	
510	783	1096	the onset of relief of dyspnoea, expressed as the change in Borg score 1 minute after study drug administration	The median time to 50% recovery in Borg score after methacholine provocation	0	0.7633982	1	
470	1536	399	tube dependency at one-year and number of post-CCRT hospital admission days	the probability for PREP being cost-effectiv	0	0.43225577	1	
518	808	489	incidence of vaginal delivery within 12 and 24 hours	additional doses were required	0	0.40359917	1	
499	1567	558	retention on treatment at 1 year	effective	0	0.22536214	0	
755	1936	57	Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating	the ABC total score and subscales	1	0.7381651	1	
482	763	1059	success at quitting (expired CO ≤ 9 ppm), the dose of NRT used, and the rating of withdrawal symptoms using the Mood and Symptoms Scale	side effects	0	0.3349747	0	
542	1630	581	the frequency of fussing and crying of the infants	fed a median of eight times/day, 148 min/day	0	0.36576495	0	
41	1072	332	the recruitment rate	The recruitment rate, calculated as the proportion of those invited to fill in a screening questionnaire who were consented into the trial,	1	0.6714463	1	
65	108	800	the HCPI	PVF	0	0.12512691	0	
290	493	406	self-rated overall effect of treatment, measured once; on the day treatment was completed	likely to report feeling much better or very much better	0	0.50891167	1	
465	1532	30	 appropriate osteoporosis management based on the 2002 clinical practice guidelines for osteoporosis in Canada 16	management of osteoporosis	1	0.62464124	1	
390	632	215	Total scores	WOMAC Pain	0	0.23237312	0	
146	1200	2	Anthropometry at birth	stunting	0	0.12736659	0	
260	1826	268	DFS, defined as the time from randomization until the first event: relapse (local, regional, or metastatic), contralateral breast cancer, or death from any cause	Ki67-positivity	0	0.0	0	
215	1276	830	the number of clinical episodes of P. falciparum malaria	Malaria episodes	1	0.62103695	1	
274	467	451	reduction in systolic blood pressure, total cholesterol and estimated 10-year CVD risk	risk factor reductions	0	0.58759844	1	
664	1790	1023	severity of mental health symptoms measured using the Hospital Anxiety and Depression Scale (HADS) 23	Mean total costs	0	0.3280461	0	
417	655	101	attitudes, knowledge and skills in EBM	reported use of the Cochrane Library and secondary journals	0	0.39116892	0	
57	1129	938	post-operative morphine consumption in a 24 hour period	pain relief	0	0.27291033	0	
582	1671	182	the GSRS subscores for abdominal pain, distension, and flatus; and the SODA subscores for bloating and gas	the GSRS total score	0	0.5607258	1	
586	1683	108	the clinical and laboratory adverse event profile and the effect of ferroquine on the cardiovascular system	slightly elevated liver parameters	0	0.41406634	1	
596	913	246	induction of labour	episiotomy	0	0.20308822	0	
511	792	414	Involuntary termination of a woman's pregnancy (miscarriage) and other fetal loss (eg stillbirth),	multiple risks	0	0.33017352	0	
53	102	827	pulmonary or cardiac toxicity	recovery from fatigue	0	0.29003498	0	
330	1402	130	the patient assessment of spinal pain (100-mm VAS), patient global assessment of disease activity (100-mm VAS), and the Bath Ankylosing Spondylitis Functional Index (100-mm VAS)	Response rates	0	0.31382644	0	
556	1631	518	The proportion of recurrent parasitaemia's during the 4-week follow-up	effective	0	0.11382766	0	
228	389	477	comparison of the change from baseline to end of 12 weeks between simvastatin and fenofibrate	HDL particle number (HDLP)	0	0.32830602	0	
758	1936	60	changes compared to baseline observed after 4 weeks (40 sessions) of treatment, in parallel groups, on (1) Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating, (2) Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating, and (3) Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	eye contact	0	0.1909761	0	
390	632	215	WOMAC Pain	hamstring strength in both legs	0	0.25138506	0	
26	1039	155	intestinal volume	harmful influences on the human body	0	0.23636556	0	
405	1483	187	the Premature Infant Pain Profile (PIPP ) 48 49	heart rate	0	0.2676733	0	
213	1274	1040	the incidence of predefined GI AEs	GI safety profile	1	0.4848839	1	
637	1762	8	time to azoospermia	adverse events	0	0.25887352	0	
343	941	305	the Gastrointestinal Symptom Rating Scale-IBS version (GSRS-IBS) 42	GSRS-IBS	1	0.0	0	
66	108	801	force platform variables PVF and impulse, the HCPI and rescue NSAIDs	force platform impulse	0	0.5503547	1	
311	513	200	Early Treatment Failure (ETF); Late Clinical Failure (LCF); Late Parasitological Failure (LPF); Adequate Clinical and Parasitological Response (ACPR) 18	cost	0	0.092598446	0	
428	1821	207	participation in the Link-Up Study, through attendance at a biospecimen collection site to provide a blood sample and giving written consent to participate, including use of blood samples for genetic and other research	measures of height	0	0.22139648	0	
423	1493	207	response rate	weight	0	0.0832068	0	
366	1441	236	time needed to perform the motor task	independent performance (EG1+2)	0	0.29605368	0	
598	913	248	relative risk	safe	0	0.27247104	0	
759	1938	545	reduction in duration of severe pneumonia and pneumonia	wheeze	0	0.23330499	0	
514	796	616	the proportion of children achieving a well clinical response	a 'Well' clinical response	1	0.6081962	1	
10	10	977	whether or not participants have abstained from smoking (self-reported three months prolonged abstinence)	likely to provide outcome data	0	0.486595	1	
586	891	500	improved PFS for the maintenance phase	similar proportion of patients in each arm experienced at least 1 grade 3/4 TEAE	0	0.53614527	1	
363	1440	656	healing at 3 months	3-month healing rates	1	0.48103955	1	
708	1843	665	Weight-for-age Z-score	pain experience	0	0.0	0	
6	0	1012	the horizontal VAS according to Jensen	ICERs	0	0.0	0	
611	1721	806	the incidence of adverse events	adverse event profile	1	0.71635824	1	
192	302	211	u-AQP2 CR	U-AQP2 CR	1	1.0000001	1	
264	1329	349	no missed activities during the previous month 41	days with missed activities	1	0.7442564	1	
224	1288	968	mortality	risk of mortality	1	0.82834566	1	
349	569	93	diarrhoea	Helicobacter pylori	0	0.0	0	
699	1924	795	the anatomical knowledge (MCQ)	advantage concerning anatomical skills	0	0.66246504	1	
190	288	365	the number of hospital days after surgery	probability of being cost-effective	0	0.3334842	0	
661	987	986	CRF as measured by the BFI	fatigue as measured by the BFI	1	0.9087896	1	
541	1618	589	crying	stooling	0	0.28921068	0	
488	1542	19	PVF	technical validity	0	0.082412496	0	
30	45	554	the proportion with peak flow compared to best/predicted	the objective assessment of attacks	0	0.4848461	1	
19	420	1042	'success'	normal ears	0	0.0	0	
65	108	800	the HCPI	NSAID use	0	0.08651406	0	
390	632	215	WOMAC Pain, Physical Function and Total scores	WOMAC Pain	0	0.6203354	1	
323	1391	212	the proportion of delivered compressions within target depth compared over a 2-minute period within the groups and between the groups	median values for proportion of delivered compressions within target depth	1	0.7666142	1	
182	1250	293	The frequency of acute exacerbation	symptoms	0	0.34298	0	
52	1074	835	the proportion of patients with plasma HIV-1 RNA levels <200 copies/mL at week 24	HIV-1 RNA	0	0.34951094	0	
626	1731	259	change from baseline in fasting serum total cholesterol	simplifies treatment	0	0.28796214	0	
712	1846	614	physical activity	physical activity	1	1.0000001	1	
596	913	246	instrumental birth	episiotomy	0	0.28249308	0	
390	632	215	WOMAC Pain	Role Physical	0	0.30914712	0	
392	1476	611	whether the GP had provided patients with a written asthma action plan (WAAP yes/no)	score higher on the asthma knowledge questionnaire	0	0.626129	1	
276	1337	65	cumulative survival without mechanical ventilation or oxygen dependency at 30 days; mortality at 30 days; therapy failure; crossover rate; and persisting pulmonary problems defined as oxygen dependency or still being on a ventilator at 30 days	therapy failure	0	0.49598736	1	
18	1035	1075	the parasite clearance rate constant K	The proportions of patients with a parasite clearance time of >72 hours	0	0.61757463	1	
97	1122	89	days alive and off assisted breathing	FVC	0	0.04977281	0	
615	1723	510	survey response bias	the characteristics of online respondents	0	0.4450633	1	
423	1493	207	response rate	measures of height	0	0.2838855	0	
428	1821	207	participation in the Link-Up Study, through attendance at a biospecimen collection site to provide a blood sample and giving written consent to participate, including use of blood samples for genetic and other research	weight	0	0.19811307	0	
485	1542	16	PVF	the MA intensity	0	0.061577216	0	
428	1821	207	participation in the Link-Up Study, through attendance at a biospecimen collection site to provide a blood sample and giving written consent to participate, including use of blood samples for genetic and other research	the median number of aliquots of plasma	0	0.5903479	1	
336	1458	751	a significant difference in mean birth weight	an infant with low birthweight	0	0.5019672	1	
327	543	636	body weight (kg)	weight loss	1	0.63361657	1	
381	1454	35	the incidence of oxygen desaturations defined as a decrease in oxygen saturation ≥ 5%, assessed by continuous pulse oxymetry, at any time between the start of the induction sequence and two minutes after the completion of the intubation	severe oxygen desaturations	0	0.42844808	1	
570	1656	1017	change in this composite from baseline at four months post-randomization	levels of participation	0	0.26033646	0	
766	1979	933	an injury surveillance with a missed match injury definition	primary lower limb muscle strains	0	0.376047	0	
725	1873	672	change in Treatment Satisfaction (Tables 5 and 6 ), change in Perceived Hyperglycaemia (Tables 7 and 8 ) and change in Perceived Hypoglycaemia (Tables 9 and 10 )	Questionnaire effects	0	0.24128255	0	
754	1936	56	Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating	hyperactivity	0	0.23572676	0	
760	1938	546	reduction in duration of severe pneumonia and pneumonia	time taken for resolution of severe pneumonia	1	0.7149087	1	
449	706	137	serum markers of bone resorption and formation	physical domains of quality of life	0	0.27442297	0	
19	420	1042	'success'	pneumococcal carriage	0	0.0	0	
429	1821	208	participation in the Link-Up Study, through attendance at a biospecimen collection site to provide a blood sample and giving written consent to participate, including use of blood samples for genetic and other research	data quality	0	0.39615637	0	
230	1291	241	antimalarial drug prescription	antibiotic prescriptions	0	0.7703585	1	
273	1506	344	The observed change on the RDQ	pain intensity	0	0.22938713	0	
185	277	1	change in score	Attitudes toward seriousness	0	0.26344392	0	
418	1492	998	the differences between groups in changes over time in perceived stress, as measured by the Perceived Stress Scale (PSS) 11	perceived stress	1	0.5470028	1	
448	706	136	changes between baseline and nine months of bone mineral density (BMD) of the proximal femur and lumbar spine (dual-energy X-ray absorptiometry) and serum markers of bone resorption and formation	femoral neck BMD changes	0	0.67296547	1	
596	913	246	instrumental birth	Apgar scores	0	0.110628664	0	
551	839	107	the comparison of sensitivity and specificity of perfusion-CMR to detect CAD on CXA vs SPECT based on a single-point threshold reading	MVD	0	0.12724204	0	
218	1284	688	the volume of blood loss between T1 and T4	Blood loss between enrolment and 6 hours later	1	0.63156706	1	
596	913	246	initiation of breastfeeding	postpartum haemorrhage	0	0.44234234	1	
145	215	50	The PCR-corrected ACPR rate at follow-up on day 28 after the first malaria episode	haemoglobin	0	0.0	0	
391	632	216	WOMAC Pain, Physical Function and Total scores	pain	0	0.18064535	0	
609	1721	804	the incidence of adverse events	frequently reported adverse event	1	0.7124903	1	
139	1198	915	health care costs and utilization rates	COPD-related costs	0	0.6740088	1	
270	464	974	a change in the serum ALT activity or the INR	safe	0	0.18187922	0	
687	1833	1069	depression (Edinburgh Postnatal Depression Scale EPDS)	proportions of women with CAS scores ≥7	0	0.253939	0	
673	999	1032	Chlamydia screening rates	logged on	0	0.04109493	0	
415	652	944	systemic haemodynamics	the subjective tolerance	0	0.3076505	0	
39	62	582	weight gain after eight weeks	hemoglobin levels	0	0.18256873	0	
369	607	575	log HbA 1c and HRQL	HbA 1c	0	0.8206735	1	
735	1887	972	decisional conflict 42 47	Decisional conflict	1	0.7840271	1	
306	512	628	the reduction in systolic blood pressure defined as the average of 3 office readings with the patient in the sitting position	BP	0	0.15992557	0	
451	706	139	changes between baseline and nine months of bone mineral density (BMD) of the proximal femur and lumbar spine (dual-energy X-ray absorptiometry) and serum markers of bone resorption and formation	Clinical measures of balance	0	0.39656273	0	
632	945	778	the proportion of children aged 9-23 months completely vaccinated	the proportion of children completely vaccinated	1	0.91627795	1	
2	0	1008	the horizontal VAS according to Jensen	mean total health care costs	0	0.30121028	0	
620	932	924	PDSS	cost-effectiveness ratios	0	0.16414535	0	
754	1936	56	changes compared to baseline observed after 4 weeks (40 sessions) of treatment, in parallel groups, on (1) Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating, (2) Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating, and (3) Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	irritability	0	0.23389086	0	
67	108	802	force platform variables PVF and impulse, the HCPI and rescue NSAIDs	veterinary assessment	0	0.24197777	0	
34	1052	15	Correlation between VPW measurements from the portable chest radiograph with the PAOP	VPW correlates with PAOP	1	0.6024929	1	
378	884	261	ACR 50 improvement	Functional Assessment of Chronic Illness Therapy-Fatigue	0	0.22708046	0	
93	137	62	≥ Grade 2 (G2) toxicity incidence	V54	0	0.0	0	
46	1808	332	the mean change in self-reported symptoms of depression as measured on the BDI	The recruitment rate, calculated as the proportion of those invited to fill in a screening questionnaire who were consented into the trial,	0	0.74620885	1	
672	1802	1021	The throughput times length of ED stay (LOS) and time to first physician 1	times	0	0.5294772	1	
395	636	467	28-day all-cause mortality	The 28-day mortality rate	1	0.68453604	1	
337	547	57	pain visual analogue scores	pain relief	1	0.46374044	1	
261	455	436	the generic instrument EuroQol-5D (EQ5D)	self-perceived health	0	0.10139491	0	
760	1938	546	reduction in duration of severe pneumonia and pneumonia	intravenous fluid	0	0.28276044	0	
731	1886	165	a sub-microscopic parasite carriage of ≥ 30% 28	The coverage rate	0	0.20361577	0	
534	1618	581	crying	fed a median of eight times/day, 148 min/day	0	0.18107428	0	
661	1787	250	the initial rate of temperature decrease, expressed as °C/h and the percentage of time the temperature was out of range during the first 24 hours of treatment (defined as more than 0.2°C above or below target temperature)	the target temperature	0	0.7674295	1	
166	237	611	Aberrant Behaviour Checklist-Community (ABC-C)	the VAS	0	0.087678626	0	
0	0	1006	the horizontal VAS according to Jensen	effectiveness at one year follow-up	0	0.40248153	1	
108	161	856	HbA1c	glycated hemoglobin A1c	1	0.72531396	1	
687	1833	1069	IPV (Composite Abuse Scale CAS)	mental wellbeing mean scores (MCS-SF36	0	0.2559724	0	
65	108	800	PVF	NSAID use	0	0.03825498	0	
331	721	637	change in body weight	weight loss	1	0.582372	1	
120	179	453	the proportion of pregnant women who attended ANC with their partners at the subsequent antenatal visit	the percentage of trial participants who attended the antenatal clinic with their partners	1	0.89891213	1	
314	1372	821	target vessel revascularization (TVR)	myocardial infarction	0	0.5037815	1	
767	1986	1042	daily physical activities (measured by a validated tri-axial accelerometer)	walking time	0	0.21539934	0	
398	1479	602	safety climate, measured using the Safety Climate Survey	the safety climate attitudes	1	0.6819412	1	
596	913	246	Apgar scores less than 8	Apgar scores	1	0.63680243	1	
341	549	592	patient reported pain	intrusive	0	0.11785582	0	
526	1598	954	to assess the efficacy of sodium butyrate enema in improving clinical, endoscopic and histological features of shigellosis	Stool concentration of LL-37	0	0.29203287	0	
65	108	800	rescue NSAIDs	Quality of life VAS	0	0.12457153	0	
329	543	638	body weight (kg) and waist circumference (cm)	waist circumference	0	0.8462952	1	
632	1760	678	Biopsy proven acute rejection (BPAR) at 24 weeks	Efficacy	0	0.28153276	0	
59	1078	407	the rate of response to PRGF	post-injective pain reaction	0	0.31200007	0	
43	1072	335	the recruitment rate	the median time (IQR) to complete all eight CCBT sessions	0	0.5162923	1	
710	1843	667	Weight-for-age Z-score	free of clinical dental sepsis	0	0.0	0	
554	1631	515	The proportion of recurrent parasitaemia's during the 4-week follow-up	response	0	0.22490175	0	
42	77	793	VC	Risk reductions	0	0.02794324	0	
666	1790	1025	severity of mental health symptoms measured using the Hospital Anxiety and Depression Scale (HADS) 23	indirect costs	0	0.20196201	0	
151	1219	669	disease-free survival (DFS)	LDL levels	0	0.19637671	0	
117	170	133	duration	frequency	0	0.38847622	0	
149	221	534	a difference of ≥ 20% in the microvascular flow index of small vessels among groups	a MAP	0	0.21321404	0	
251	424	548	The Insomnia Severity Index (ISI) 32	cost	0	0.095110506	0	
326	1395	1006	the time to first SRE, including pathologic fracture, spinal cord compression, and the requirement for surgery or radiation therapy to bone	skeletal-related events (SREs)	0	0.2275221	0	
431	672	487	response rate to treatment	the safety profile	0	0.23172839	0	
645	1782	880	Trough FEV 1 after 12 weeks of treatment	LSM (± SEM)	0	0.08745474	0	
444	695	673	an ASAS40	parents' global assessment of subject's overall well-being	0	0.13823889	0	
314	1372	821	major adverse cardiac events (MACE) defined as a composite endpoint of cardiac death, myocardial infarction, and target vessel revascularization (TVR)	target lesion revascularization	0	0.67244095	1	
280	1337	70	cumulative survival without mechanical ventilation or oxygen dependency at 30 days; mortality at 30 days; therapy failure; crossover rate; and persisting pulmonary problems defined as oxygen dependency or still being on a ventilator at 30 days	baseline OI	0	0.18876666	0	
209	368	838	the mean change in modified extrinsic tooth stain index (all sites) from baseline to week 6	shade lightening	0	0.27237627	0	
437	1852	630	(1) anti-malarial consumption recorded from routine statistics in ledger books of all HF before and after intervention; (2) anti-malarial prescription recorded during observed consultations in cross-sectional surveys conducted in all HF before and 18 months after m RDT implementation	the amount of artemether-lumefantrine blisters	0	0.48710784	1	
552	1628	376	'TQ total score'	investigated biomarkers for oxidative stress	0	0.19861959	0	
596	913	246	initiation of breastfeeding	instrumental birth	0	0.3008549	0	
234	399	1099	biochemically verified 7-day point prevalence smoking abstinence defined as no cigarettes (not even a puff) in the previous 7 days at Week 26, validated using salivary cotinine collected at Week 26	smoked an average of 8.0 cigarettes per day	0	0.59685856	1	
480	1541	593	ETDRS visual acuity recorded in the laboratory, supplemented with a number of secondary lab-based visual function measures	visual acuity (VA) at normal illumination level	1	0.70192015	1	
546	830	223	the change in morning peak expiratory flow (PEF) rate from baseline to the end of the treatment period (mean of weeks 23–24)	lung function	0	0.24737816	0	
485	1542	16	PVF	the CSOM	0	0.043618537	0	
80	126	835	changes in disc height as measured on CT scans	pain	0	0.24292287	0	
334	546	556	the proportion of patients in each group with cardiovascular risk ≥ 10% over five-years at 12 months follow up	systolic (adjusted difference 0.97 mmHg, 95%CI -2.34 mmHg to 4.29 mmHg) or diastolic (adjusted difference 0.70 mmHg, 95%CI -1.05 mmHg to 2.45 mmHg) blood pressure	0	0.4777343	1	
394	634	513	patient intention to visit a psychosocial counselor	patient satisfaction	0	0.5592252	1	
574	1659	312	response rate	the response rate	1	0.87246144	1	
89	136	790	the hands-on time during the first three minutes of the cardiac arrest	leadership statements	0	0.23885584	0	
35	1059	1008	1) the population reached (usefulness), 2) the self-reported benefit or achievement (usefulness), 3) experienced barriers and potential solutions the (usefulness), 4) the extent to which the intervention was performed according to protocol (acceptability), 5) participants’ exposure to and engagement in the training (acceptability), and 6) the opinion about the training (acceptability)	experienced benefits of the cane	0	0.707415	1	
230	389	479	comparison of the change from baseline to end of 12 weeks between simvastatin and fenofibrate	LDLP	0	0.0	0	
524	813	297	the 11-point NRS in patients' daily pain diaries	Mean durations	0	0.19595812	0	
485	765	689	The Shoulder Pain and Disability Index (SPADI) at 1 year follow-up	SPADI score at 1 year	1	0.6466116	1	
111	210	856	blood pressure	SBP levels	1	0.2804564	0	
418	655	102	attitudes, knowledge and skills in EBM	attitude scores	0	0.2692202	0	
314	1372	821	cardiac death	target lesion revascularization	0	0.36201197	0	
116	166	352	the percentage of patients who reached 25(OH)D levels of 30 ng/ml or above on day 7	adverse effects	0	0.20837434	0	
409	651	682	the PHQ-9	attendance at sessions	0	0.31748727	0	
509	1583	979	an overall response that integrated clinical, bacteriological and radiological results, at the end of treatment (month 6) and after 12 additional months of follow-up (month 18)	rapid complete response	1	0.5697116	1	
601	1713	238	the Team Check-up Tool (TCT)	measurement reliability	0	0.1930238	0	
90	1107	77	treatment preference	symptoms in subjects with IBS	0	0.3357767	0	
293	501	309	disease-free survival (DFS) at three years	the five-year OS probability	0	0.35948107	0	
228	1289	861	the rate of success	the post-LP syndromes	0	0.5068022	1	
759	1938	545	reduction in duration of severe pneumonia and pneumonia	nasal flaring	0	0.30899373	0	
89	1107	76	treatment preference	the number needed to harm	0	0.28387743	0	
617	932	919	PDSS	the main outcome measure, the Panic Disorder Severity Scale (PDSS) after treatment	1	0.34994942	0	
666	990	955	the mean number of oocytes retrieved	efficacy in controlled ovarian hyperstimulation	0	0.4570542	1	
462	1528	340	the Patient Reported Physician Cultural Competency (PRPCC) Scale	visits to the study physician	0	0.45872134	1	
2	0	1008	the horizontal VAS according to Jensen	productivity costs	0	0.18213329	0	
597	913	247	induction of labour	augmentation of labour	0	0.28150812	0	
456	709	39	perinatal mortality (stillbirth or death during the first seven days after birth)	early neonatal mortality	0	0.588614	1	
61	1078	410	the rate of response to PRGF	clinical improvement	0	0.2820819	0	
424	1493	208	response rate	response rates	1	0.9346842	1	
572	1659	310	response rate	responded	1	0.36482942	0	
554	859	960	blood pressure control	the proportions of women (53.6%) and treatment naïve patients	0	0.2964721	0	
298	503	444	sustained remission, defined as freedom from relapse at the 6 months follow-up visit	The median time to relapse	0	0.6038459	1	
65	108	800	the HCPI	HCPI	1	0.7108269	1	
748	1931	636	 attitudes towards EBM; personal application and current use of EBM; EBM knowledge; future use of EBM	imparting knowledge	0	0.35686496	0	
110	1988	941	time to extubation	median time to extubation	1	0.8601271	1	
272	467	449	reduction in systolic blood pressure, total cholesterol and estimated 10-year CVD risk	acceptability of the Polypill to patients and physicians	0	0.51900995	1	
623	935	55	the impact of the headache using the Headache Impact Test (HIT-6)	positive influences on headache complaints	0	0.5241215	1	
158	224	1067	foot function	foot pain	0	0.5809594	1	
48	82	1056	change in SBP and change in HOMA index, from week 0 (pre-treatment) to week 6	low-density lipoprotein/high-density lipoprotein ratio	0	0.19113488	0	
289	493	405	self-rated overall effect of treatment, measured once; on the day treatment was completed	EQ-5D utility score	0	0.2642303	0	
638	954	623	the serum phosphorus at 12 weeks	serum phosphorus	1	0.6245485	1	
359	1436	649	gastric emptying T half	postprandial triacylglycerol	0	0.33898467	0	
188	288	363	the number of hospital days after surgery	The median pre-operative fluid loading volume	0	0.34501898	0	
125	190	186	all-cause mortality over 3 years	health status	0	0.21892036	0	
597	913	247	initiation of breastfeeding	augmentation of labour	0	0.24803972	0	
653	1962	879	trough FEV 1 after 12 weeks of treatment (average of the 23 h 10 min and 23 h 45 min post-dose values assessed on the morning of Day 85)	peak FEV 1	1	0.5628255	1	
470	728	397	Mobilization status as assessed by the 4-item abbreviation of the Barthel index, focusing on lower extremity motoric function	Evaluation of the intensity of pain with a visual analogue scale (VAS)	0	0.65162486	1	
69	396	800	PVF	HCPI	0	0.20679583	0	
359	1436	649	gastric emptying T half	glucose concentrations	0	0.25454018	0	
658	1962	884	trough FEV 1 after 12 weeks of treatment (average of the 23 h 10 min and 23 h 45 min post-dose values assessed on the morning of Day 85)	Serum potassium	0	0.24715263	0	
297	503	443	sustained remission, defined as freedom from relapse at the 6 months follow-up visit	sustained remission	1	0.4584306	1	
240	406	264	a dichotomous measure (occurrence of low back pain)	reservist military status	0	0.14994584	0	
158	224	1067	'first-step' pain (measured on a 100 mm Visual Analogue Scale)	foot function	0	0.31258518	0	
96	141	192	coma recovery time; time to sit unsupported, begin oral intake; duration of hospitalization; death and adverse effects	sit unsupported	0	0.3681017	0	
642	1782	877	Trough FEV 1 after 12 weeks of treatment	Trough FEV 1 (LSM ± SEM)	1	0.6719172	1	
329	1402	129	the patient assessment of spinal pain (100-mm VAS)	pain	1	0.6248335	1	
92	1845	755	the effect on markers of bone turnover at 24 weeks	PINP	0	0.0	0	
293	501	309	disease-free survival (DFS) at three years	The probability of overall survival (OS) at three years	0	0.852719	1	
229	1289	862	the rate of success	pain	0	0.17624684	0	
171	1912	966	knowledge of labour analgesia, decisional conflict (uncertainty regarding analgesia decision) and anxiety	poor follow through between antenatal analgesia intentions and use	0	0.5113313	1	
151	223	829	change in weight from randomization (0-M) to 12 months post randomization	mean BMI	0	0.3294817	0	
347	1428	537	pedometer step counts (Omron HJ-109E Step-O-Meter)	mood	0	0.08454339	0	
64	108	799	force platform variables PVF and impulse, the HCPI and rescue NSAIDs	guessing what group their dogs had been in	0	0.38654977	0	
641	965	28	lung function	Asthma Quality of Life Questionnaire mean difference	0	0.22303148	0	
109	210	854	blood pressure	Glycated hemoglobin A1c	0	0.36037487	0	
331	721	637	change in body weight and waist circumference	weight loss	0	0.548317	1	
127	1161	824	The mean decrease in HAM-D score from baseline	effective	0	0.16368791	0	
713	1862	922	pain severity and knee range of motion (ROM)	Verbal Rating Scale for pain (VRS)	0	0.47517532	1	
105	159	67	the mean change from pre-dose FEV 1 at 12 hours post dose	change from pre-dose FEV 1 at 12 hours	1	0.8876273	1	
264	1329	349	the percentage of children who had ≤ 4 days with pain and no missed activities during the previous month 41	days with missed activities	0	0.759171	1	
234	1291	245	antimalarial drug prescription	The overall sensitivity	0	0.10583114	0	
299	507	869	the change from baseline to 52 weeks of carotid arterial wall volume, reflecting plaque burden, as measured by carotid cardiovascular magnetic resonance	glycemic control	0	0.35421973	0	
301	1361	697	i) cognitive functioning, as measured by the ADAS-Cog, a 0–70 point scale with a higher score indicating worse cognition; and ii) quality of life, rated by the participant and their nominated carer, as measured by the QOL-AD, both 13-item scales, scoring between 13 and 52 points with a higher score indicating better quality of life	carer quality of life	0	0.39105257	0	
169	1912	964	anxiety	decisional conflict scores	0	0.34020936	0	
250	424	547	The Insomnia Severity Index (ISI) 32	remission rate	0	0.23181818	0	
143	1198	920	health care costs	treatment costs	1	0.6761531	1	
57	273	1002	Treatment Alliance Scale (TAS) 40 and Client Satisfaction Questionnaire (CSQ) 44 	satisfaction	0	0.36245382	0	
670	1802	1019	The throughput times length of ED stay (LOS) and time to first physician 1	patient inflow	0	0.34804094	0	
120	1150	618	BP	target BP control	1	0.5823182	1	
616	931	928	combined renal parameters	LPS-binding protein	0	0.23163866	0	
541	830	218	the change in morning peak expiratory flow (PEF) rate from baseline to the end of the treatment period (mean of weeks 23–24)	The PEF values	1	0.32127112	0	
557	859	963	blood pressure control	α-methyldopa added	0	0.12613365	0	
164	233	1029	10 MCP Trans PDA	the registration of significant treatment effects	0	0.10973008	0	
414	652	943	systemic haemodynamics	PR	0	0.057940785	0	
20	420	1043	detection of bilateral aerated middle ears (confirmed with tympanometry) at two consecutive monthly visits	NCHi	0	0.0	0	
167	1233	86	the maximum % fall in FEV 1 7 hours after the first AMP challenge	protective effect against inhaled AMP-induced bronchoconstriction	0	0.32889038	0	
621	932	925	PDSS	effective	0	0.15466738	0	
277	1337	66	cumulative survival without mechanical ventilation or oxygen dependency at 30 days	mortality	0	0.29947564	0	
117	1145	1055	the number of additional donors deferred by the HQ	deferred due to risks identified by the HQ but not by the DHAQ	1	0.8157263	1	
558	859	966	blood pressure control	blood pressure control	1	0.99999994	1	
552	1628	376	'TQ total score'	general quality of life areas (SF-36)	0	0.14480919	0	
513	792	416	Involuntary termination of a woman's pregnancy (miscarriage) and other fetal loss (eg stillbirth),	sessions were fully completed	0	0.20626248	0	
339	1421	162	the rate of acute gastrointestinal complications	the rate of acute gastrointestinal complications	1	0.9999999	1	
194	304	121	the mean RTDI overall	a shorter TTDP	0	0.27001643	0	
423	1493	207	response rate	systolic and diastolic blood pressure	0	0.1670653	0	
619	1731	252	change from baseline in fasting serum total cholesterol	low density lipoprotein (LDL)-cholesterol	0	0.42513	1	
67	108	802	force platform variables PVF and impulse, the HCPI and rescue NSAIDs	the HCPI	0	0.612774	1	
705	1839	1031	1) defecation frequency > 3/week; 2) normalization of stool consistency; 3) no more painful defecation; 4) absence of abdominal or rectal palpable mass at physical examination	stool consistency	0	0.41274303	1	
20	420	1043	'success'	NCHi	0	0.0	0	
535	1618	582	crying	the frequency of stooling	0	0.20920087	0	
547	1630	587	the frequency of fussing and crying of the infants	colic	0	0.27033055	0	
509	1583	979	an overall response that integrated clinical, bacteriological and radiological results, at the end of treatment (month 6) and after 12 additional months of follow-up (month 18)	respiratory symptoms	0	0.28301772	0	
390	632	215	Total scores	the SF-36 Physical Function	0	0.2575566	0	
39	1062	319	the comparison of the scores on the 12-Item Short-Form Health Survey (SF-12) and the Graded Chronic Pain Scale (GCPS) questionnaire for the two survey modes	cost	0	0.23411243	0	
106	161	854	HbA1c	SBP	0	0.17971948	0	
86	128	657	good clinical and biological tolerability	effective	0	0.26695645	0	
210	378	273	the duration of the weaning process	age	0	0.19474377	0	
136	1883	194	number of oocytes	local tolerability	0	0.23674875	0	
158	224	1067	foot function	'first-step' pain	0	0.18101415	0	
146	221	531	a difference of ≥ 20% in the microvascular flow index of small vessels among groups	oxygen transport	0	0.29251614	0	
1	1001	383	the average efficacy over Seasons 1 and 2 for the prevention of culture-confirmed influenza illness due to influenza A or B virus strains antigenically matching those in the vaccine (ie vaccine-matched, culture-confirmed influenza; VMCCI)	The VMCCI attack rates	0	0.42067525	1	
65	108	800	force platform variables PVF and impulse, the HCPI and rescue NSAIDs	PVF	0	0.34729776	0	
623	1731	256	change from baseline in fasting serum total cholesterol	adjusted mean change from baseline in CD4+ cell count	0	0.7571144	1	
504	1573	888	the clinical and virological effects of zidovudine in combination with lamivudine	gait	0	0.19537342	0	
412	652	941	systemic haemodynamics	stroke volume	0	0.11176425	0	
680	1812	680	duration of diarrhea (in hours) from onset and from admission until cessation of diarrhea (passage of soft/formed or no stools for two consecutive 8-hour periods)	the mean stool weight during hospital stay	0	0.6409483	1	
300	1361	696	cognitive functioning, as measured by the ADAS-Cog, a 0–70 point scale with a higher score indicating worse cognition	the ADAS-Cog score	1	0.623308	1	
430	672	486	response rate to treatment	Rescue medication use	0	0.402748	1	
179	262	840	the determination of the perioperative concentration of IL-1β in the patient's peritoneal fluid	The median follow-up	0	0.36896694	0	
409	1486	202	'total number of sand flies per trap per night' before and 5 months after intervention	sand fly density	1	0.40397424	1	
685	1816	853	pain and disability	bodily pain	0	0.7043953	1	
373	1445	807	The AIMS2 walking and bending sub-scale	The clinical and quality of life outcomes	0	0.26405802	0	
654	1962	880	trough FEV 1 after 12 weeks of treatment (average of the 23 h 10 min and 23 h 45 min post-dose values assessed on the morning of Day 85)	LSM (± SEM)	0	0.12366877	0	
676	999	1036	Chlamydia screening rates	effective in engaging community-based physicians to complete the intervention	0	0.23841555	0	
169	244	154	a composite endpoint of all-cause mortality or all-cause hospitalization	The mean age of screened patients	0	0.49193397	1	
7	1016	101	blood pressure	retained	0	0.06933366	0	
576	1659	315	response rate	the sampling frame	0	0.23096652	0	
83	1103	957	global quality of life change at 6-weeks, measured by EORTC QLQ-C30	stomatitis	0	0.16200651	0	
677	1811	504	the overall between-patient variability around the mean time to neurological assessment	facilitating assessment of neurological function	0	0.5121963	1	
180	262	841	the determination of the perioperative concentration of IL-1β in the patient's peritoneal fluid	The overall mortality rate	0	0.5027032	1	
714	1862	923	pain severity	cumulative treatment effect	0	0.47142506	1	
429	672	485	response rate to treatment	WOMAC	0	0.25030568	0	
0	1001	381	the average efficacy over Seasons 1 and 2 for the prevention of culture-confirmed influenza illness due to influenza A or B virus strains antigenically matching those in the vaccine (ie vaccine-matched, culture-confirmed influenza; VMCCI)	the point estimate for efficacy in the prevention of all laboratory-confirmed influenza	0	0.82904434	1	
623	935	55	global perceived effect (GPE) and the impact of the headache using the Headache Impact Test (HIT-6)	positive influences on headache complaints	0	0.5591809	1	
134	1883	191	number of oocytes	the mean number of collected oocytes (primary endpoint)	1	0.69526905	1	
605	1717	365	suspension days during the four-month pretest period prior to randomization compared with the four-month intervention period	rule infractions	0	0.32906654	0	
261	1826	269	DFS, defined as the time from randomization until the first event: relapse (local, regional, or metastatic), contralateral breast cancer, or death from any cause	the relapse risk	0	0.6813032	1	
16	420	1039	detection of bilateral aerated middle ears (confirmed with tympanometry) at two consecutive monthly visits	the proportion of examinations with a diagnosis of perforation during therapy	0	0.6181743	1	
422	660	859	clinical response at the test-of-cure visit (14–35 days after therapy) for the m-mITT and ME populations	clinical cure rates at TOC	0	0.5215766	1	
649	1782	884	Trough FEV 1 after 12 weeks of treatment	Serum potassium	0	0.23416999	0	
266	461	327	10-year CVD risk	absolute CVD risk reduction	1	0.79804355	1	
560	861	933	changes in lifestyle according to established goals	lifestyle behaviours	1	0.43060777	1	
84	1103	958	global quality of life change at 6-weeks, measured by EORTC QLQ-C30	death	0	0.18216448	0	
191	288	366	the number of hospital days after surgery	likely to be cost-effective	0	0.3412319	0	
203	1273	124	the percentage of patients who had a CSTE	the percentages of patients who received platelet transfusions	0	0.7936603	1	
76	1092	767	malaria incidence during the study period	preventing clinical episodes of malaria	1	0.49755767	1	
704	1839	1029	absence of abdominal or rectal palpable mass at physical examination	the presence of an abdominal or rectal mass	1	0.78353226	1	
301	1361	697	quality of life, rated by the participant and their nominated carer, as measured by the QOL-AD, both 13-item scales, scoring between 13 and 52 points with a higher score indicating better quality of life	carer quality of life	1	0.43742862	1	
310	513	198	Early Treatment Failure (ETF); Late Clinical Failure (LCF); Late Parasitological Failure (LPF); Adequate Clinical and Parasitological Response (ACPR) 18	tolerance	0	0.099142276	0	
481	1541	594	ETDRS visual acuity recorded in the laboratory, supplemented with a number of secondary lab-based visual function measures	normal (100%), low (4%), and very low (0.1%) illumination log CS	0	0.47472173	1	
314	522	433	the QTcF interval (QT interval corrected for heart rate using Fridericia's formula, QT/RR 0.33 )	maximal time-matched QTcF prolongation	1	0.5870389	1	
36	53	24	HSV-2 seroconversion during the study period	HSV-2 seroincidence	1	0.0	0	
630	1760	676	Biopsy proven acute rejection (BPAR) at 24 weeks	Biopsy proven acute rejection (BPAR) at 24 weeks, the primary study endpoint,	1	0.83012533	1	
663	1790	1022	severity of mental health symptoms measured using the Hospital Anxiety and Depression Scale (HADS) 23	clinical outcomes	0	0.41717404	1	
596	913	246	initiation of breastfeeding	breastfeeding initiation	1	0.99999994	1	
538	826	503	the p27 antigen analysis of serum samples	the required level of persistent antigenaemia	1	0.37545684	0	
85	128	656	absence of parasites and clinical signs on days 14 and 28, and good clinical and biological tolerability	No serious side-effect requiring premature termination of treatment	0	0.46571007	1	
331	1402	131	the patient assessment of spinal pain (100-mm VAS), patient global assessment of disease activity (100-mm VAS), and the Bath Ankylosing Spondylitis Functional Index (100-mm VAS)	spine pain	0	0.5225569	1	
176	257	1082	participation	Participation	1	0.6728859	1	
358	626	291	the intra-individual change in the total score of the Hamilton Rating Scale for Depression (HAM-D, 17-item version) between baseline and the end of the 6-week acute phase	treatment response	0	0.24996066	0	
192	1983	79	nutrition knowledge	Mean total nutrition knowledge score	1	0.64805424	1	
718	1862	927	pain severity and knee range of motion (ROM)	fared significantly better clinically	0	0.31620866	0	
268	1333	354	sexual activity	bothered by the impact of kidney disease on their sex life	0	0.38730952	0	
433	1494	47	Number of headache days over a 12 week period (item A MIDAS questionnaire)	the number of migraine like headaches at 4 weeks	1	0.6406136	1	
636	1762	7	time to azoospermia	the number of vasectomy failures	0	0.412026	1	
714	1862	923	pain severity and knee range of motion (ROM)	cumulative treatment effect	0	0.4211805	1	
128	1161	826	The mean decrease in HAM-D score from baseline	anticholinergic effects	0	0.19987598	0	
661	1787	250	the initial rate of temperature decrease, expressed as °C/h and the percentage of time the temperature was out of range during the first 24 hours of treatment (defined as more than 0.2°C above or below target temperature)	out of range	0	0.5335836	1	
593	1701	531	intra-operative pain	surgeon satisfaction	0	0.36896625	0	
94	1121	781	the patient's death or institutionalization	no personal contact	0	0.39106262	0	
374	1445	808	The AIMS2 walking and bending sub-scale	clinical outcomes	0	0.034161184	0	
240	406	264	a dichotomous measure (occurrence of low back pain)	have received individualized attention via the physical/USI examination	0	0.285626	0	
17	1035	1074	the parasite clearance rate constant K	The median parasite-reduction ratio	1	0.38249087	0	
445	1502	1099	sUA < 6.0 mg/dL at final visit	Efficacy rates	0	0.23538463	0	
38	62	581	weight gain after eight weeks	weight gain	1	0.65706354	1	
177	257	1083	adherence and participation	able to comply with resistance exercise	0	0.3081462	0	
726	1873	673	change in Treatment Satisfaction (Tables 5 and 6 ), change in Perceived Hyperglycaemia (Tables 7 and 8 ) and change in Perceived Hypoglycaemia (Tables 9 and 10 )	a Treatment × Questionnaire interaction	0	0.32030538	0	
183	265	272	the precision of the final result set selected to answer the clinical question	precision	1	0.3368757	0	
560	1646	745	the proportion of subjects who achieved targets for compression depth and compression rate	the quality of the initial assessment algorithm	0	0.61316866	1	
339	1421	162	the rate of renal involvement at one year and the rate of acute gastrointestinal complications	the rate of acute gastrointestinal complications	0	0.87577647	1	
244	408	77	the recovery rate, defined as the percentage of patients who had an adequate clinical and parasitological response (ACPR) after follow-up for 28 days	The recovery rate at D14	1	0.60080695	1	
627	1745	1090	the cost of therapy per delivered baby, estimated according to a cost-minimization analysis	The overall FSH dose needed to achieve ovulation	0	0.43162027	1	
278	485	843	time to catheter association blood stream infection	Observed catheter days	0	0.47257966	1	
556	1631	518	The proportion of recurrent parasitaemia's during the 4-week follow-up	efficacy	0	0.16290501	0	
74	112	1073	claim duration (in days) during 12 months follow-up	claim duration	1	0.7899632	1	
596	913	246	postpartum haemorrhage	instrumental birth	0	0.27564168	0	
17	420	1040	'success'	the proportion of examinations with penicillin non-susceptible (MIC > 0.1 microg/ml) pneumococci	0	0.0	0	
340	1421	163	the rate of renal involvement at one year and the rate of acute gastrointestinal complications	intussusceptions	0	0.0	0	
656	981	179	the proportion of patients relapse-free at Week 26	the most common AEs (influenza-like symptoms, headache, injection-site reactions)	0	0.5346075	1	
747	1925	248	glycemic variability, represented as SD (Glu SD ), glucose lability index ([∑(Glu n - Glu n+1 (mmol/L)) 2 *(h n+1 - h n ) -1 )*(number of readings) -1 or mean daily delta (difference between minimum and maximum) glucose	a loss of complexity	0	0.24939288	0	
435	978	487	response rate based on a 20% improvement in WOMAC pain scores	rescue medication use	0	0.3429077	0	
613	929	227	the percentage of days on which the prescribed dose of medication was taken, measured objectively over 12 weeks with an electronic medication-monitoring device (TrackCap, Aardex, Switzerland)	functional status	0	0.2885595	0	
655	981	177	the proportion of patients relapse-free at Week 26	The proportion of patients who remained relapse-free at Week 26	1	0.8559775	1	
117	1145	1055	the number of additional donors deferred by the HQ	deferred by the DHAQ	0	0.82872224	1	
591	896	410	PK parameters and safety and tolerability	fatigue	0	0.2694846	0	
28	472	985	death from any cause, recurrent infarction and unstable angina within one year (per protocol and adjusted for 2 days PCI delay)	risk of recurrent ischemia	0	0.57012945	1	
660	984	321	improvement in oxygenation (improvement of PaO 2 /FiO 2 (PF) ratio)	stay in the intensive care unit	0	0.47413772	1	
44	77	796	VC	generally severe impairment	0	0.037237696	0	
463	1528	341	the Patient Reported Physician Cultural Competency (PRPCC) Scale	satisfaction	0	0.21781029	0	
571	880	258	retention in treatment, which was defined as the number of weeks that patients remained in the study before being discharged	the drug side effects	0	0.56463695	1	
62	1082	390	the extent to which the Internet affected the participants' confidence in dealing with their LTC	had used discussion forums for their LTC	0	0.63980263	1	
474	1601	396	costs per quality adjusted life years (cost/QALY)	Total costs	0	0.5341747	1	
415	652	944	systemic haemodynamics	dialysis efficiency	0	0.16175596	0	
610	1721	805	the incidence of adverse events	frequently reported related adverse events	1	0.76115507	1	
583	1678	639	the time course of the corrected colonisation index	Candida colonisation	0	0.024974741	0	
390	632	215	Total scores	hamstring strength in both legs	0	0.23188223	0	
416	654	118	SHBG and sex hormones [ie, testosterone, estradiol, dehydroepiandrosterone sulfate]	SHBG	0	0.7794	1	
618	1723	513	response rate, survey response bias, item non-response, and cost	The cost	0	0.43418497	1	
3	1001	386	the average efficacy over Seasons 1 and 2 for the prevention of culture-confirmed influenza illness due to influenza A or B virus strains antigenically matching those in the vaccine (ie vaccine-matched, culture-confirmed influenza; VMCCI)	efficacy over two influenza seasons against laboratory-confirmed influenza	0	0.7307742	1	
81	128	652	absence of parasites and clinical signs on days 14 and 28, and good clinical and biological tolerability	efficacy	0	0.52118146	1	
223	1284	693	the volume of blood loss between T1 and T4	maternal morbidity	0	0.19888191	0	
725	1873	672	change in Treatment Satisfaction (Tables 5 and 6 ), change in Perceived Hyperglycaemia (Tables 7 and 8 ) and change in Perceived Hypoglycaemia (Tables 9 and 10 )	DTSQs scores at/near ceiling	0	0.19700673	0	
377	884	260	ACR 50 improvement	the percentage of responders according to American College of Rheumatology 50 criteria (the primary endpoint, based on a 28-joint count)	1	0.29024705	0	
255	437	1079	comet assay	catalase activities	0	0.20590214	0	
160	1394	629	the cure-markedly effective rate	the treatment of FD of spleen-deficiency and qi-stagnation syndrome	0	0.4511275	1	
390	632	215	WOMAC Pain, Physical Function and Total scores	Role Physical	0	0.55113924	1	
220	1284	690	the volume of blood loss between T1 and T4	Invasive procedures	0	0.17022306	0	
575	881	372	the overall discomfort reported during WC versus SC pH-metry	the failure rate	0	0.535416	1	
466	1536	395	tube dependency at one-year	tube dependency	1	0.8312272	1	
337	1458	752	a significant difference in mean birth weight	infants with a birth weight <2000 g	0	0.5775877	1	
211	1274	1038	the incidence of predefined GI AEs	disease activity	0	0.35124	0	
276	1337	65	mortality at 30 days	therapy failure	0	0.25310922	0	
179	1243	323	the change relative to baseline in the multiple sclerosis functional composite score (MSFC)	MS-related impairment	0	0.2217605	0	
406	650	168	trough forced expiratory volume in one second (FEV 1 ) at 24 h post-dose after 14 days	the mean FEV 1	1	0.63212085	1	
62	317	1003	the ORS scale	motivation for treatment	0	0.2721239	0	
460	712	380	change in urinary HRQOL at 3 months	biopsy-proven local failure	0	0.2037061	0	
403	646	209	PCS	PCS	1	1.0	1	
275	1506	346	The observed change on the RDQ	effective	0	0.18604138	0	
590	1701	528	intra-operative pain	intra-operative corneal clarity	0	0.19854541	0	
311	513	200	Early Treatment Failure (ETF); Late Clinical Failure (LCF); Late Parasitological Failure (LPF); Adequate Clinical and Parasitological Response (ACPR) 18	efficacy	0	0.2410394	0	
758	1936	60	changes compared to baseline observed after 4 weeks (40 sessions) of treatment, in parallel groups, on (1) Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating, (2) Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating, and (3) Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	sensory/cognitive awareness	0	0.20777082	0	
553	854	333	time to achieve haemostasis at the suture line	mean blood loss during the operation	0	0.5872189	1	
596	1712	272	safety, tolerability and level at which dose limiting toxicity occurred	dose limiting toxicity	0	0.7755016	1	
136	1883	194	incidence of adverse effects	retrieved oocytes	0	0.09282568	0	
577	1660	641	The number of destroyed alveolar attachments, expressed as a percentage over the total number of alveolar attachments,	the total wall area	0	0.67023486	1	
79	1099	378	body weight	%saturated fat	0	0.4794757	1	
188	288	363	the number of hospital days after surgery	days in hospital after surgery	1	0.9108352	1	
283	1339	858	improvement compared to baseline	symptom improvement	0	0.6410359	1	
78	126	833	changes in pain as measured on a verbal rating scale from 0 to 10 during a flexion-extension range of motion evaluation and changes in disc height as measured on CT scans	body mass index	0	0.41459846	1	
672	1802	1021	The throughput times length of ED stay (LOS) and time to first physician 1	These throughput times	0	0.560457	1	
338	1421	161	the rate of renal involvement at one year and the rate of acute gastrointestinal complications	the rate of renal involvement	0	0.8554412	1	
113	1988	944	time to extubation	reintubated	0	0.0	0	
374	624	260	the percentage of responders according to American College of Rheumatology 50 criteria	the percentage of responders according to American College of Rheumatology 50 criteria (the primary endpoint, based on a 28-joint count)	1	0.9265628	1	
117	1145	1055	the number of additional donors deferred by the HQ	deferred	0	0.41314328	1	
147	221	532	a difference of ≥ 20% in the microvascular flow index of small vessels among groups	The proportions of perfused vessels	0	0.5527878	1	
240	1313	563	the primary process outcome	ACQ score	0	0.15098795	0	
469	1536	398	tube dependency at one-year and number of post-CCRT hospital admission days	the willingness to pay threshold for 1 additional QALY	0	0.45190933	1	
658	984	319	improvement in oxygenation (improvement of PaO 2 /FiO 2 (PF) ratio)	Initial oxygenation	1	0.42326254	1	
168	237	613	the ABC Irritability subtest score	functional benefits	0	0.20124717	0	
654	980	99	BMD	two major determinants of bone fractures	0	0.30519179	0	
595	1707	535	CR	insomnia	0	0.063580826	0	
249	1619	952	sucrose/pacifier effect on pain reduction	easy to use	0	0.21720736	0	
69	396	800	force platform variables PVF and impulse, the validated HCPI and the use of rescue NSAIDs	Quality of life VAS	0	0.27673566	0	
128	190	189	all-cause mortality over 3 years	incidence of pneumonia	0	0.36459926	0	
574	881	371	the overall discomfort reported during WC versus SC pH-metry	Per patient costs ($Canadian)	0	0.3245631	0	
613	1723	508	response rate	response rate	1	0.99999994	1	
532	814	647	to decrease reintubation rates, defined by the necessity of mechanical positive-pressure ventilation through orotracheal intubation in the first 48 hours after extubation, in the treatment group	used NIV	0	0.22849108	0	
713	1862	922	pain severity	the pain scores	1	0.6074271	1	
719	1862	928	pain severity and knee range of motion (ROM)	the necessary ROM for discharge	0	0.3405446	0	
284	1341	743	shoulder mobility, shoulder and arm function and pain	shoulder mobility	0	0.7868223	1	
390	632	215	Total scores	Physical Function	0	0.21477792	0	
71	1085	866	the levels of inflammatory cells (neutrophils, eosinophils, macrophages, and lymphocytes) and epithelial cells in induced sputum	PEF	0	0.07093273	0	
55	105	788	a well-validated outcome measure for upper limb function and disability	patient satisfaction	0	0.35501307	0	
402	646	208	the EPDS (a 10-item scale developed for use in the postnatal period, in which a score ≥ 13 identifies probable depression 33 , and the physical and mental component scores (PCS and MCS) of the Short Form 36 (SF-36), a widely used general health status measure 34	Women's mental health scores	0	0.49877977	1	
82	1103	956	global quality of life change at 6-weeks, measured by EORTC QLQ-C30	Global quality of life	1	0.6436629	1	
634	1762	5	time to azoospermia	time to azoospermia	1	1.0	1	
106	161	854	HbA1c	systolic blood pressure (SBP) levels	0	0.4805294	1	
571	1659	308	response rate	dentist response rates	1	0.79094017	1	
276	1337	65	therapy failure	crossover	0	0.14673923	0	
561	861	934	changes in lifestyle according to established goals	their aerobic capacity	0	0.31304613	0	
182	1250	293	The frequency of acute exacerbation	psychological domain	0	0.28086326	0	
700	1924	796	the anatomical knowledge (MCQ)	difficult to learn	0	0.33450815	0	
566	1652	171	the proportion of subjects achieving PASI-75, defined as ≥ 75% improvement in PASI score from baseline,	construct validity	0	0.19062808	0	
550	1628	374	'TQ total score'	efficacy	0	0.03931117	0	
660	984	321	improvement in oxygenation (improvement of PaO 2 /FiO 2 (PF) ratio)	The duration of use of paralysing or sedative agents	0	0.29993862	0	
96	141	192	begin oral intake	sit unsupported	0	0.2308261	0	
602	1717	362	changes in absenteeism	absentee periods	1	0.36354452	0	
275	475	662	the shortened version of the Chedoke Arm & Hand Activity Inventory (CAHAI-7)	the CMSA motor impairment stage of the affected arm	0	0.5652763	1	
495	770	540	the time until shock reversal	levels of VCAM	0	0.14567088	0	
311	1770	96	knee-specific patient-reported WOMAC scores	knee-specific results	1	0.3054943	0	
410	1489	1058	PCR-corrected adequate clinical and parasitological response (ACPR) on day 28	early treatment failures	0	0.48588872	1	
615	931	927	combined renal parameters	endogenous creatinine clearance (baseline to Day 28)	0	0.3680021	0	
227	1288	971	mortality	application of evidence-based key interventions and of diagnostic and therapeutic procedures	0	0.24902286	0	
555	1631	517	The proportion of recurrent parasitaemia's during the 4-week follow-up	fever	0	0.14648111	0	
396	1479	600	safety climate, measured using the Safety Climate Survey	safety climate scores	1	0.565046	1	
597	913	247	relative risk	augmentation of labour	0	0.1197774	0	
140	1198	916	health care costs and utilization rates	non-study COPD medication costs	0	0.62805504	1	
596	913	246	caesarean birth	Apgar scores	0	0.11821425	0	
129	190	190	all-cause mortality over 3 years	moderate-to-severe exacerbations	0	0.14539674	0	
652	974	287	the percent of subjects meeting TR during the initial 30 minutes of treatment	likely in TR	1	0.57397	1	
80	126	835	changes in pain as measured on a verbal rating scale from 0 to 10 during a flexion-extension range of motion evaluation	pain	1	0.34370935	0	
748	1931	636	EBM knowledge	imparting knowledge	1	0.6605311	1	
543	830	220	the change in morning peak expiratory flow (PEF) rate from baseline to the end of the treatment period (mean of weeks 23–24)	the symptom scores	0	0.64268434	1	
75	1092	766	malaria incidence during the study period	Coverage with IPTc	0	0.31801647	0	
47	1808	333	the mean change in self-reported symptoms of depression as measured on the BDI	Recruitment	0	0.09434584	0	
246	408	79	the recovery rate, defined as the percentage of patients who had an adequate clinical and parasitological response (ACPR) after follow-up for 28 days	apyrexial	0	0.0	0	
260	1826	268	DFS, defined as the time from randomization until the first event: relapse (local, regional, or metastatic), contralateral breast cancer, or death from any cause	DFS improvement	1	0.19606864	0	
337	1458	752	a significant difference in mean birth weight	births <32 weeks)	0	0.33125445	0	
443	695	672	an ASAS40	the Bath Ankylosing Spondylitis Disease activity spinal inflammation score	0	0.19657716	0	
344	941	306	the Gastrointestinal Symptom Rating Scale-IBS version (GSRS-IBS) 42	IBS-related fear	0	0.09675384	0	
390	632	215	WOMAC Pain, Physical Function and Total scores	Social Functioning domains	0	0.42430383	1	
69	396	800	force platform variables PVF and impulse, the validated HCPI and the use of rescue NSAIDs	all three scores in the comparative questionnaire (locomotion, every-day situations, and skin & coat)	0	0.54512084	1	
67	1083	53	changes in the HDRS, ATYP and the SIGH-SAD-SR over the 8-week study period	response to treatment	0	0.21856086	0	
108	161	856	blood pressure	the compliance in all the control criteria, except for LDL cholesterol	0	0.3534314	0	
38	1062	318	the comparison of the scores on the 12-Item Short-Form Health Survey (SF-12) and the Graded Chronic Pain Scale (GCPS) questionnaire for the two survey modes	mental health	0	0.29236454	0	
678	1811	505	the overall between-patient variability around the mean time to neurological assessment	awakening for neurological assessment	0	0.6044379	1	
624	1731	257	change from baseline in fasting serum total cholesterol	Two possible abacavir-related hypersensitivity reactions	0	0.35026085	0	
117	170	133	The frequency	severity	0	0.32905695	0	
517	808	488	time from induction to delivery	The induction-delivery interval	1	0.23704782	0	
389	632	214	WOMAC Pain, Physical Function and Total scores	the proportion of MCIIs	0	0.21795428	0	
43	77	794	VC	the PFS times	0	0.080526695	0	
92	137	61	≥ Grade 2 (G2) toxicity incidence	The crude incidence of late rectal toxicity ≥ G2	1	0.70698094	1	
766	1979	933	an injury surveillance with a missed match injury definition	limb injury prevention	0	0.5546599	1	
706	1839	1032	normalization of stool consistency	softer stools	1	0.46187833	1	
222	1284	692	the volume of blood loss between T1 and T4	Mild, transient adverse manifestations	0	0.27207282	0	
629	1745	1092	the cost of therapy per delivered baby, estimated according to a cost-minimization analysis	number of vials/patient	0	0.24973352	0	
263	461	324	10-year CVD risk	smoking	0	0.25208423	0	
443	1502	1097	sUA < 6.0 mg/dL at final visit	efficacy	0	0.2172118	0	
618	1723	513	cost	The cost	1	0.73449546	1	
435	1496	908	sickness absence	the QQ index	0	0.1458454	0	
14	1034	38	changes in ADHD symptoms following treatment	ADHD symptoms	1	0.6678434	1	
583	891	497	improved PFS for the maintenance phase	PFS	1	0.48282346	1	
642	965	31	lung function	symptoms	0	0.3083032	0	
107	161	855	BMI after 24 months of follow-up	BMI	1	0.52619284	1	
402	646	208	MCS	EPDS ≥ 13 ('probable depression')	0	0.21229644	0	
698	1924	794	the anatomical knowledge (MCQ)	overall performances	0	0.18002878	0	
495	770	540	the time until shock reversal	plasma CoQ10 levels	0	0.21063387	0	
596	1712	272	level at which dose limiting toxicity occurred	dose limiting toxicity	1	0.7278293	1	
543	1630	582	the frequency of fussing and crying of the infants	the frequency of stooling	0	0.75674367	1	
182	1250	293	The frequency of acute exacerbation	physical domain	0	0.24862856	0	
383	1454	37	the incidence of oxygen desaturations defined as a decrease in oxygen saturation ≥ 5%, assessed by continuous pulse oxymetry, at any time between the start of the induction sequence and two minutes after the completion of the intubation	Intubation conditions	0	0.32278994	0	
529	813	302	the 11-point NRS in patients' daily pain diaries	pain	1	0.49122018	1	
24	33	985	composite death, reinfarction, stroke, or new myocardial ischemia	risk of recurrent ischemia	0	0.5891527	1	
130	1878	826	the 17-item HAM-D	dry mouth	0	0.151382	0	
119	173	182	the 15th percentile point	all densitometric indices	0	0.38606533	0	
394	1479	598	safety climate, measured using the Safety Climate Survey	the mean safety climate scores for nurses	1	0.61548215	1	
631	1760	677	Biopsy proven acute rejection (BPAR) at 24 weeks	BPAR	1	0.31919256	0	
548	831	143	violent attitudes using the Total MVQ score	violent attitudes	1	0.56145513	1	
161	226	931	the total MET minutes of moderate and vigorous physical activity accrued over the past 7 days	cost-effective	0	0.0	0	
86	128	657	good clinical and biological tolerability	well-tolerated	1	0.0	0	
625	1731	258	change from baseline in fasting serum total cholesterol	glucose	0	0.421683	1	
739	1896	638	The plaque scores	inhibiting effect on the plaque regrowth	0	0.43655333	1	
615	1723	510	response rate, survey response bias, item non-response, and cost	the characteristics of online respondents	0	0.4435268	1	
402	646	208	the EPDS (a 10-item scale developed for use in the postnatal period, in which a score ≥ 13 identifies probable depression 33 , and the physical and mental component scores (PCS and MCS) of the Short Form 36 (SF-36), a widely used general health status measure 34	EPDS score	0	0.46932593	1	
3	0	1009	the horizontal VAS according to Jensen	Mean societal costs after one year	0	0.40080935	1	
564	1647	178	serum metal ion concentration	periprosthetic bone density loss	0	0.44203764	1	
511	1583	981	an overall response that integrated clinical, bacteriological and radiological results, at the end of treatment (month 6) and after 12 additional months of follow-up (month 18)	their globular sedimentation rate values	0	0.34708545	0	
706	1839	1032	1) defecation frequency > 3/week; 2) normalization of stool consistency; 3) no more painful defecation; 4) absence of abdominal or rectal palpable mass at physical examination	defecation frequency	0	0.5263353	1	
639	1773	707	changes in the mean FEV 1 , PEF, and ACT scores	ACT score	0	0.5399982	1	
606	924	822	unexpected ocular or systemic findings, adverse event rate, and temporary and permanent discontinuation	VA	0	0.12466304	0	
748	1931	636	EBM knowledge	effective	0	0.13233694	0	
281	1337	72	cumulative survival without mechanical ventilation or oxygen dependency at 30 days; mortality at 30 days; therapy failure; crossover rate; and persisting pulmonary problems defined as oxygen dependency or still being on a ventilator at 30 days	OI	0	0.069191575	0	
314	1372	821	myocardial infarction	target lesion revascularization	0	0.5920269	1	
745	1925	246	glycemic variability, represented as SD (Glu SD ), glucose lability index ([∑(Glu n - Glu n+1 (mmol/L)) 2 *(h n+1 - h n ) -1 )*(number of readings) -1 or mean daily delta (difference between minimum and maximum) glucose	Glycemic variability measures	0	0.42407408	1	
345	941	307	the Gastrointestinal Symptom Rating Scale-IBS version (GSRS-IBS) 42	societal costs	0	0.16266923	0	
577	1660	641	The number of destroyed alveolar attachments, expressed as a percentage over the total number of alveolar attachments,	The bronchodilatory effect of deep inspiration	0	0.49050885	1	
515	1584	645	whether or not the ulcer was completely healed within 8 weeks	Complete healing of stage I ulcers	0	0.50700307	1	
235	399	1100	biochemically verified 7-day point prevalence smoking abstinence defined as no cigarettes (not even a puff) in the previous 7 days at Week 26, validated using salivary cotinine collected at Week 26	The mean Fagerström Test for Nicotine Dependence	0	0.5304448	1	
605	1717	365	school rule infractions	suspension rates	0	0.33792537	0	
158	224	1067	general foot health	general foot health	1	1.0000001	1	
432	1494	46	Number of headache days over a 12 week period (item A MIDAS questionnaire)	The disability	0	0.30358362	0	
172	1912	967	knowledge of labour analgesia, decisional conflict (uncertainty regarding analgesia decision) and anxiety	informed of labour analgesia options	0	0.5268655	1	
129	190	190	all-cause mortality over 3 years	FEV 1	0	0.41203856	1	
625	937	816	cure and severity of IAD	healed	0	0.26498774	0	
29	45	552	the proportion with peak flow compared to best/predicted	our primary outcome measure (the proportion with peak flow compared to best/predicted)	1	0.86619115	1	
752	1936	54	Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	mean physician CGI scores	1	0.44127688	1	
255	437	1079	comet assay	tail moment	0	0.18467309	0	
96	141	192	coma recovery time; time to sit unsupported, begin oral intake; duration of hospitalization; death and adverse effects	total coma duration	0	0.59232444	1	
620	1731	253	change from baseline in fasting serum total cholesterol	Mean CD4+ cell counts	0	0.35506532	0	
54	1074	837	the proportion of patients with plasma HIV-1 RNA levels <200 copies/mL at week 24	HIV-1 RNA <200 copies/mL at week 24	1	0.6714006	1	
598	913	248	Apgar scores less than 8	safe	0	0.13106813	0	
160	226	930	the total MET minutes of moderate and vigorous physical activity accrued over the past 7 days	systolic blood pressure	0	0.26693335	0	
475	736	517	incidence of low back pain resulting in the seeking of health care	incidence of low back pain resulting in the seeking of health care	1	0.99999994	1	
674	1811	501	the overall between-patient variability around the mean time to neurological assessment	between-patient variability around the time of neurological assessment	1	0.93811244	1	
106	161	854	HbA1c	baseline glycated hemoglobin A1c	1	0.72790015	1	
229	1289	862	the rate of success	satisfied	0	0.18494056	0	
65	108	800	force platform variables PVF and impulse, the HCPI and rescue NSAIDs	all three scores in the comparative questionnaire (locomotion, every-day situations, and skin & coat)	0	0.4320772	1	
382	1454	36	the incidence of oxygen desaturations defined as a decrease in oxygen saturation ≥ 5%, assessed by continuous pulse oxymetry, at any time between the start of the induction sequence and two minutes after the completion of the intubation	The duration of the intubation sequence	0	0.7482684	1	
181	262	842	the determination of the perioperative concentration of IL-1β in the patient's peritoneal fluid	cytokine levels	0	0.2984061	0	
504	1573	888	the clinical and virological effects of zidovudine in combination with lamivudine	markers of T-cell activation or proliferation	0	0.4299408	1	
596	913	246	relative risk	episiotomy	0	0.16448827	0	
463	1528	341	the Patient Reported Physician Cultural Competency (PRPCC) Scale	weight	0	0.08666622	0	
616	931	928	combined renal parameters	the systemic markers C-reactive protein	0	0.42708197	1	
456	1518	543	pain catastrophising	depression	0	0.44271526	1	
16	1035	1073	the parasite clearance rate constant K	The median parasite clearance half-lives	0	0.61550355	1	
13	26	341	the Sum of Pain Intensity Differences (SPID) of the CSTP Intensity scale by the child	Global evaluation of efficacy	0	0.30827492	0	
596	913	246	postpartum haemorrhage	episiotomy	0	0.5026568	1	
710	1843	667	Weight-for-age Z-score	sepsis	0	0.0	0	
86	128	657	absence of parasites and clinical signs on days 14 and 28, and good clinical and biological tolerability	effective	0	0.2702299	0	
655	1962	881	trough FEV 1 after 12 weeks of treatment (average of the 23 h 10 min and 23 h 45 min post-dose values assessed on the morning of Day 85)	use of rescue medication	0	0.27351162	0	
404	1483	186	the Premature Infant Pain Profile (PIPP ) 48 49	Time to recovery	0	0.29499298	0	
746	1925	247	glycemic variability, represented as SD (Glu SD ), glucose lability index ([∑(Glu n - Glu n+1 (mmol/L)) 2 *(h n+1 - h n ) -1 )*(number of readings) -1 or mean daily delta (difference between minimum and maximum) glucose	Glucose complexity	0	0.3760182	0	
567	1652	172	the proportion of subjects achieving PASI-75, defined as ≥ 75% improvement in PASI score from baseline,	responsiveness to change in underlying clinical status of the patients	0	0.67336684	1	
680	1812	680	duration of diarrhea (in hours) from onset and from admission until cessation of diarrhea (passage of soft/formed or no stools for two consecutive 8-hour periods), and the total stool weight in grams during hospitalization	the mean stool weight during hospital stay	0	0.765008	1	
435	1496	908	1) physical activity, 2) work productivity, and 3) sickness absence	SA days	0	0.16677676	0	
567	880	254	retention in treatment, which was defined as the number of weeks that patients remained in the study before being discharged	Treatment retention	1	0.33511615	0	
650	1782	886	Trough FEV 1 after 12 weeks of treatment	a safety and tolerability profile	0	0.20539103	0	
460	1519	661	PASI-75	itching VAS	0	0.0	0	
141	1198	917	utilization rates	outpatient costs	0	0.4439855	1	
381	1454	35	the incidence of oxygen desaturations defined as a decrease in oxygen saturation ≥ 5%, assessed by continuous pulse oxymetry, at any time between the start of the induction sequence and two minutes after the completion of the intubation	oxygen desaturations	1	0.3451228	0	
39	1062	319	the comparison of the scores on the 12-Item Short-Form Health Survey (SF-12) and the Graded Chronic Pain Scale (GCPS) questionnaire for the two survey modes	completeness of data	0	0.24907325	0	
687	1833	1069	IPV (Composite Abuse Scale CAS) and depression (Edinburgh Postnatal Depression Scale EPDS)	physical wellbeing mean scores (PCS-SF36	0	0.35959524	0	
158	224	1067	foot function	foot function	1	0.9999999	1	
552	1628	376	'TQ total score'	objective audiometric examinations	0	0.17925863	0	
203	360	84	the prevalence of arm, shoulder and neck symptoms	risk indicators for work posture and movement	0	0.44662207	1	
644	1782	879	Trough FEV 1 after 12 weeks of treatment	peak FEV 1	1	0.6099585	1	
597	913	247	instrumental birth	likely to have continuous electronic fetal monitoring	0	0.1934886	0	
347	569	91	diarrhoea	Hypochlorhydria (fasting gastric pH > 4.0)	0	0.0	0	
